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Abbreviations. 
 
 
AA: amino acid 
AIDS: acquired immunodeficiency 
syndrome 
ALT: alanine aminotransferase 
BVDB: bovine viral diarrhea virus 
cccDNA: covalently closed circular DNA 
CEA: carcinoembryonic antigen 
CK: cytokeratin 
COFRADIC: combined fractional diagonal 
chromatography 
CTL: cytotoxic T lymphocyte 
DC-SIGN: dendritic cell-specific ICAM3 
grabbing nonintegrin 
DHBV: duck hepatitis B virus 
DNA:  deoxyribonucleic acid 
ELISA: enzyme linked immunosorbent 
assay 
ER: endoplasmatic reticulum 
FCH: fibrosing cholestatic hepatitis 
FDA: food and drug administration 
H&E: hematoxylin and eosin 
HBcAg: hepatitis B core antigen 
HBeAg: hepatitis B e antigen 
HBsAg: hepatitis B surface antigen 
HBV: hepatitis B virus 
HCC: hepatocellular carcinoma 
HCV: hepatitis C virus 
HDL: high-density lipoprotein 
HIV: human immunodeficiency virus 
HLA: human leukocyte antigen 
HPCs: hepatic progenitor cells 
HVR: hypervariable region 
IFN: interferon 
Ig: immunoglobulin 
IRES: internal ribosome entry site 
IU: international units 
kb: kilo base 
kDa: kilo Dalton 
LDL: low-density lipoprotein 
L-SIGN: liver/lymph node specific ICAM3 
grabbing nonintegrin 
MHC: major histocompatibility complex 
mRNA: messenger RNA 
NANBH: non-A non-B hepatitis 
NCR: non coding region 
nm: nanometer 
NS: non-structural 
OAS: oligoadenylate synthetase 
ORF: open reading frame 
ORO: oil red O 
PAS: periodic-acid-Schiff 
PCR: polymerase chain reaction 
PEG: polyethylene glycol 
pgRNA: pregenomic RNA 
RdRp: RNA dependent RNA polymerase 
RNA: ribonucleic acid 
sCD14: soluble CD14 
SCID: severe combined immune deficient 
SPF: specific pathogen free 
SR-B1: scavenger receptor B1 
uPA: urokinase-type plasminogen 
activator 
VLDL: very low-density lipoprotein 
WHV: woodchuck hepatitis virus 
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Summary. 
 
 
A small, non-primate animal model 
for the study of HBV and HCV infections 
would be of great benefit to the scientific 
community. These viral pathogens can only 
be studied in chimpanzees, which is a highly 
expensive experimental approach that 
raises a lot of ethical concerns. 
 
By backcrossing uPA-transgenic 
mice with SCID mice, we have generated 
uPA-transgenic SCID mice. These mice 
suffer from a severe liver disease caused by 
the overexpression of uPA and a severe 
immune deficiency, derived from the SCID 
background. Hepatocytes of human origin 
are therefore not rejected by these mice. 
The severe and chronic liver disease allows 
the human hepatocytes to repopulate the 
mouse liver in their attempt to restore 
normal liver function. Because only mice 
homozygous for the uPA transgene turn out 
to be ideal acceptors for xenogeneic 
hepatocyte transplantation and because the 
uPA+/+-SCID mice must be transplanted 
within two weeks after birth to achieve 
optimal liver regeneration, we have 
designed a one day screening method that 
allows for the unambiguous discrimination 
between negative, heterozygous and 
homozygous uPA-SCID mice. This assay 
consists of a multiplex PCR that is based on 
the presence of the uPA transgene and the 
absence of a small part of the mouse 
genome that was deleted at the site where 
the uPA transgene cassette had integrated. 
 
We transplanted homozygous uPA-
SCID mice with primary human hepatocytes 
and analyzed the mouse plasma and liver 
architecture at selected time points. 
Immunohistochemical analysis of the liver 
demonstrated that the repopulation process 
occurred in a progressive and organized 
fashion, until up to 87% of liver parenchyma 
was repopulated by human hepatocytes. 
The human hepatocytes formed functional 
bile canaliculi that connected to the mouse 
biliary system. The functionality of the 
human hepatocytes was corroborated by a 
proteomic analysis of the mouse plasma 
that showed the presence of at least 21 
proteins of human origin in addition to 
human albumin. The concentration of the 
latter protein in the mouse plasma was 
measured using an in-house ELISA and 
used as an in vivo marker of liver cell 
expansion and function.  
A remarkable observation was that, besides 
mature human hepatocytes, human hepatic 
progenitor cells also contributed to the liver 
regeneration process. 
 
HBV infections could be easily 
achieved in successfully transplanted 
animals. Interestingly, infection with HBV 
resulted in severe hepatocellular damage 
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that ultimately led to the premature death 
of the infected animals. HBV is generally 
considered to be a non-cytopathic virus, but 
in our immune deficient animal model it 
replicated in an unrestrained fashion and 
became cytopathic for the infected cell. The 
pathology observed in HBV infected 
animals closely resembled that of chronic 
HBV patients that suffer from fibrosing 
cholestatic hepatitis. This frequently fatal 
syndrome occasionally occurs in HBV 
patients undergoing severe immune 
suppression, for example in the context of 
organ transplantation. 
 
uPA mice harboring a human 
hepatocyte graft could also be infected with 
HCV. Although we have never been able to 
directly visualize the virus in the infected 
liver cells, infection and active replication of 
HCV in chimeric mice is beyond any doubt 
based on the convincing increase of viral 
load in the plasma of infected mice and the 
fact that minute amounts of infected mouse 
plasma sufficed to transmit infection to an 
uninfected chimeric recipient. 
 
Chronic HBV and HCV patients have 
increased levels of soluble CD14 (sCD14) in 
their plasma. We wanted to investigate what 
the source of this sCD14 could be and if the 
increased levels are a direct result from the 
viral infection. Using our chimeric animal 
model we demonstrated that hepatocytes 
are a major source of sCD14. The secretion 
of this protein was not elevated in HBV or 
HCV infected mice, suggesting that these 
infections do not directly stimulate the 
sCD14 production by hepatocytes. We 
assume that in patients with chronic HBV 
or HCV infections other, indirect factors 
determine the plasma sCD14 levels. 
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Samenvatting. 
 
 
De studie van het hepatitis B virus 
(HBV) en het hepatitis C virus (HCV) wordt 
momenteel bemoeilijkt door het ontbreken 
van een klein en doeltreffend 
proefdiermodel. De chimpansee was tot op 
heden de enige diersoort die succesvol 
geïnfecteerd kon worden met HBV en HCV. 
Het gebruik van chimpansees is om ethische 
redenen echter zeer omstreden en 
bovendien zeer duur. 
 
Daarom hebben we de uPA-SCID 
muis ontwikkeld. Deze muis is een kruising 
van een uPA (urokinase type plasminogeen 
activator) transgene muis met de SCID 
(severe combined immune deficient) muis. 
De uPA-transgene muis lijdt aan een 
chronische leverziekte als gevolg van 
leverspecifieke overexpressie van het uPA 
gen. Daardoor ontstaat er een chronische 
leverinsufficiëntie die kan gecorrigeerd 
worden door transplantatie met gezonde 
levercellen. De SCID mutatie zorgt ervoor 
dat de uPA-SCID muis bovendien een niet-
functioneel adaptief immuun systeem heeft, 
waardoor levercellen van humane 
oorsprong getransplanteerd kunnen worden 
zonder risico op afstoting. 
Enkel uPA-SCID muizen die homozygoot 
zijn voor het uPA-transgen kunnen met 
succes getransplanteerd worden met 
humane hepatocyten. Bovendien moeten 
deze dieren zo vlug mogelijk, liefst binnen 
twee weken na de geboorte, 
getransplanteerd worden. Het is daarom 
van cruciaal belang dat we kunnen 
beschikken over een vlugge en betrouwbare 
methode om het onderscheid te maken 
tussen uPA-negatieve, heterozygote en 
homozygote muisjes. We hebben hiervoor 
een multiplex PCR methode ontwikkeld die 
ons op één dag het antwoord brengt. Deze 
test is gebaseerd is op de aanwezigheid van 
het uPA-gen en de afwezigheid van een 
fragment muis DNA dat gedeleteerd werd 
tijdens de integratie van het transgen-
construct in het muisgenoom. 
 
Op verschillende tijdstippen na de 
transplantatie met humane hepatocyten 
hebben we de lever en het plasma van 
homozygote uPA-SCID muizen onderzocht. 
Immunohistochemische analyse toonde aan 
dat de humane hepatocyten de zieke 
muislever op een georganiseerde en 
progressieve manier innemen. Tot 87% van 
het muislever-parenchym werd vervangen 
door gezonde hepatocyten van humane 
oorsprong. De humane levercellen vormden 
functionele galcanuliculi die verbindingen 
aangingen met galcanaliculi gevormd door 
muishepatocyten. Bovendien werden ook 
chimere canaliculi aangetroffen. 
Analyse van het muisplasma toonde 
duidelijk aan dat de getransplanteerde 
humane hepatocyten goed functioneerden. 
Een proteoom-analyse leerde ons dat er, 
naast humaan albumine, nog 21 andere 
  8
humane eiwitten in het muizenbloed 
voorkwamen. De concentratie van humaan 
albumine in het muisplasma is bovendien 
een merker voor de hoeveelheid humane 
hepatocyten aanwezig in de muislever. 
Interessant was de vaststelling dat er, naast 
mature hepatocyten, ook humane 
leverstamcellen deelnamen aan het 
regeneratieproces. 
 
Succesvol getransplanteerde uPA-
SCID muizen konden we infecteren met 
HBV. Deze infectie veroorzaakte echter 
ernstige schade aan de menselijke 
levercellen die uiteindelijk leidde tot de 
vroegtijdige dood van de geïnfecteerde 
muizen. Dit is opmerkelijk aangezien HBV 
doorgaans wordt beschouwd als een niet-
pathogeen virus. Een belangrijk aspect is 
dat de geïnfecteerde muizen 
immuundeficiënt zijn waardoor de 
replicatie van het virus niet onderdrukt 
wordt. De pathologie die we observeerden 
in de HBV-geïnfecteerde muizen kan 
worden vergeleken met ‘fibroserende 
cholestatische hepatitis’. Dit syndroom kan 
optreden bij chronische HBV patiënten die 
een immuunonderdrukkende therapie 
krijgen, meestal in het kader van 
orgaantransplantaties. ‘Fibroserende 
cholestatische hepatitis’ staat bekend als 
een ernstige, dikwijls dodelijke aandoening. 
 
Succesvol getransplanteerde muizen 
konden eveneens geïnfecteerd worden met 
HCV. Na injectie van het virus vonden we 
wekenlang hoge aantallen virusdeeltjes in 
het muisplasma terug. 
Immunohistochemische kleuring voor het 
virale E2 eiwit toonde duidelijk de 
geïnfecteerde humane hepatocyten aan. Met 
de elektronenmicroscoop konden we echter 
geen virale partikels detecteren. 
Injectie van een kleine hoeveelheid plasma 
van een geïnfecteerde muis in een nieuwe, 
chimere muis resulteerde opnieuw in een 
‘chronische’ HCV infectie. De stijgende 
virale titers in de geïnfecteerde muizen en 
de overdraagbaarheid van de infectie naar 
nieuwe muizen zijn echter voldoende 
bewijzen voor een actieve virale infectie. 
 
In het plasma van chronische HBV 
en HCV patiënten worden verhoogde 
concentraties sCD14 gedetecteerd. Wij 
hebben in onze uPA-SCID muis onderzocht 
wat de oorzaak kan zijn van deze verhoging 
en of deze een direct gevolg is van de virale 
infectie. Ons onderzoek toonde aan dat bij 
de mens de lever, meer bepaald de 
hepatocyten zelf, een belangrijke bron is van 
sCD14. HBV of HCV infectie had echter 
geen invloed op de hoeveelheid sCD14 die 
geproduceerd werd. Aangezien humane 
hepatocyten de enige bron van sCD14 zijn in 
ons muismodel moet de verhoging van 
sCD14 bij patiënten verklaard worden door 
een ander mechanisme. De activatie van 
monocyten/macrofagen is één 
mogelijkheid. 
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Résumé. 
 
 
Un petit modèle animal, qui ne soit 
pas un primate, et qui permettrait l’étude 
des infections dues au virus de l’hépatite B 
(VHB) et C (VHC) serait d’un grand intérêt 
pour la communauté scientifique. Seul le 
chimpanzé permet l’étude de ces agents 
pathogènes, mais ce modèle expérimental 
est très coûteux et pose des problèmes 
d’éthique. 
 
En croisant des souris transgéniques 
pour la molécule uPA avec des souris SCID, 
nous avons généré des souris SCID-uPA 
transgéniques. Ces souris souffrent d’une 
atteinte hépatique sévère due à la 
surexpression de l’uPA ainsi que d’une 
déficience immunitaire sévère due au fond 
SCID. Dans ces souris, des hépatocytes 
humains greffés ne sont donc pas rejetés. 
L’atteinte hépatique chronique sévère 
permet aux hépatocytes humains, dans leur 
effort de restaurer des fonctions hépatiques 
normales, de  coloniser le foie de la souris. 
Seules les souris homozygotes pour le 
transgène uPA se sont avérées des 
réceptrices idéales de transplantation 
hépatique xénogènique. Par ailleurs, les 
souris uPA+/+-SCID doivent être 
transplantées dans un délai de 2 semaines 
après la naissance pour permettre une 
transplantation hépatique optimale. Ainsi, 
nous avons développé une méthode de 
criblage qui permette en 24 heurs de 
discriminer sans ambiguïté entre des souris 
uPA-SCID négatives, hétérozygote et 
homozygotes. Cette méthode repose sur un 
test de PCR multiplex basé sur la présence 
du transgène uPA et l’absence d’une petite 
portion du génome murin qui a été délaité 
du site ou la cassette du transgène uPA a été 
intégré. 
 
Nous avons transplanté des souris 
homozygotes uPA-SCID avec des 
hépatocytes humains primaires et analysé le 
plasma des souris et l’architecture du foie 
en des temps différents. Des analyses 
immuno-histochimiques du foie de telles 
souris démontrent que la repopulation a 
lieu de façon progressive et organisée, 
jusqu’à que 87% du parenchyme soit 
colonisé par des hépatocytes humains. Les 
hépatocytes humains forment des canicules 
biliaires fonctionnelles qui se connectent au 
système biliaire de la souris. La 
fonctionnalité des hépatocytes humains est 
corroborée avec une analyse protéomique 
du plasma murin qui a montré la présence 
d’au moins 21 protéines d’origine humaine 
en plus de l’albumine humaine. La 
concentration de cette dernière protéine 
dans le plasma murin a été mesurée avec un 
ELISA maison et utilisée comme marqueur 
in vivo de l’expansion et la fonction de 
cellules hépatiques.  
 Une observation remarquable a été 
que, en plus d’hépatocytes humains 
matures, des cellules progénitrices d’origine 
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hépatique d’origine humaine ont aussi 
contribué au processus de régénération du 
foie. 
  
Des infections par le VHB ont pu 
être facilement obtenues dans les animaux 
transplantés. De façon intéressante, 
l’infection par le VHB a résulté en une 
atteinte hépatique sévère conduisant en 
final à la mort prématurée des animaux 
infectés. Le VHB est typiquement considéré 
comme un virus non cytopathique, mais 
dans notre modèle murin présentant une 
déficience immunitaire, il se réplique de 
façon non contrôlée et devient cytopathique 
pour les cellules infectées. La pathologie 
observée dans les animaux infectés par le 
VHB ressemble fortement à celle observée 
chez des patients chroniquement infectés 
qui souffrent de fibrose hépatique 
cholestatique. Ce syndrome fréquemment 
fatal est souvent trouvé chez des sujets 
porteurs du VHB soumis à une déficience 
immunitaire sévère, par exemple dans le 
contexte d’une transplantation d’organe.  
  
Les souris uPA portant une greffe 
d’hépatocytes humains ont également pu 
être infectées par le VHC. Bien que nous 
 
n’ayons jamais réussi à visualiser le virus 
dans les cellules infectées, l’infection et la 
réplication active du virus dans les souris 
chimériques ne fait aucun doute notamment 
de part l’augmentation évidente du titre 
viral dans le plasma des souris  infectées et 
le fait que des quantités infimes de plasma 
de souris infectées permettent le transfert 
de l’infection à de nouvelles souris. 
 
 Les patients chroniquement infectés 
par le VHB et le VHC ont des taux élevés de 
CD14 solubles dans leur plasma. Nous 
avons voulu rechercher quelle était la source 
de ce CD14 soluble et si l’augmentation des 
titres est une signature de la réplication 
vitale. En utilisant notre modèle chimérique 
nous avons montré que les hépatocytes sont 
une source majeure de CD14 soluble. La 
sécrétion de cette protéine n’est élevée ni 
dans les souris infectées par le VHB ni dans 
celles  infectées par le VHC suggérant que 
ces infections ne stimulent pas directement 
la sécrétion du CD14 soluble par les 
hépatocytes. Ainsi, notre hypothèse est que 
dans les infections naturelles dues au VHB 
ou au VHC, d’autres facteurs indirects sont 
responsables des taux plasmatiques du 
CD14 soluble.  
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Chapter 1: Introduction. 
 
 
The Hepatitis B Virus. 
 
 
 The Hepatitis B Virus (HBV) is the 
causative agent of a major global health 
problem. Worldwide, more than two billion 
people show evidence of past or current 
infection. An estimated 360 million people 
suffer from a chronic infection, of which 
about 25% will die due to liver cirrhosis 
and/or hepatocellular carcinoma. Each 
year, the hepatitis B virus is responsible for 
more than 1 million deaths (1). 
 Despite these high numbers, the risk 
of getting chronically infected with HBV is 
quite low. Only 5 to 10% of adults become 
persistent carriers of the virus after 
infection. However, the rate of chronicity 
after infection is significantly higher in 
infants and neonates, 30 - 50% and 90% 
respectively. 
 
Classification. 
The Hepatitis B Virus (HBV) is a 
small partially double-stranded DNA virus 
belonging to the family of the 
Hepadnaviridae. This family contains two 
genera: the Orthohepadnaviridae and the 
Avihepadnaviridae. The members of the 
first genus are viruses that can infect 
mammals like humans (HBV), woodchucks 
(Woodchuck Hepatitis Virus, WHV), 
squirrels and primates. The latter genus 
includes viruses that can infect birds such as 
ducks (Duck Hepatitis B virus, DHBV). 
Genomic organization and viral 
proteins. 
The infectious HBV particle has a 3.2 
kb long circular DNA genome that is only 
partially double stranded. While the minus 
(-)-strand is complete, the plus (+)-strand is 
always incomplete and variable in length. 
Despite this small genome, the virus is able 
to produce a remarkable variety of proteins. 
This is achieved by combining overlapping 
open reading frames (ORFs) with the use of 
different translation start sites within one 
ORF, thus producing several related gene 
products from one specific ORF. The HBV 
genome contains four ORFs: the S-, the C, 
the P- and the X-ORF (Fig. 1). 
The S region encodes the three viral 
envelope proteins by differential initiation 
of translation at three in-frame initiation 
codons with one stop codon. Of these three 
proteins the S protein is the most abundant. 
This 24 kDa protein is also known as the 
hepatitis B s antigen (HBsAg) and shares its 
sequence (226 AA) with the two other 
proteins derived from the S gene. The 
middle (M) protein is identical to the S 
protein but contains an extra 55 amino 
acids, known as the PreS2 sequence, at the 
amino-terminal side. S and M are translated 
from two distinct 2.1 kb mRNAs (preS2/S 
mRNA) produced by a common promoter 
with heterogeneous start sites around the
 12
initiation codon at the 5’ end of preS2. The 
L protein, which besides the preS2 sequence 
also contains the 128 AA preS1 sequence, is 
translated from a 2.4 kb mRNA (preS1 
mRNA) starting upstream of preS1 of the 
envelope ORF. This protein is considered to 
interact with the receptor on the host cell (2, 
3) and plays an important role in the 
assembly of the virion and its release from 
the cell (4). 
The C region encodes for two 
proteins: the core and precore protein. The 
latter being the precursor of the soluble 
hepatitis B e antigen (HBeAg) while the core 
protein constitutes the nucleocapsid. The 
function of the HBeAg is somewhat unclear, 
however experiments in mice suggest that 
this protein may induce tolerance to the 
virus (5, 6). The precore, core and 
polymerase (P ORF) proteins are produced 
from the largest mRNA, the pregenome 
RNA (3.5 kb). The precore and core proteins 
are translated from distinct mRNA’s with 
heterogeneous 5’ ends (7), while the 
polymerase translation is initiated from a 
more downstream, less efficient, internal 
promoter in a different reading frame. The 
polymerase protein contains two main 
domains linked by a spacer region. The 
amino terminal domain plays a vital role in 
the priming of transcription and packaging 
while the carboxy terminal domain contains 
the reversed transcriptase and RNase H 
activity. 
The last ORF, X, encodes for the 
Orthohepadnaviridae unique X protein. 
The function of this protein is still unclear. 
It is however necessary for in vivo infection 
(8, 9) and can activate the transcription of 
host (10-12) as well as viral genes (13, 14) 
 
 
 
 
Figure 1:  Genomic organization of the hepatitis B 
virus.  The inner circles depict the relaxed circular DNA 
with the reversed transcriptase attached to the 5’ end of the 
complete minus-strand DNA (solid sphere) and a capped 
RNA oligomer attached to the 5’ end of the incomplete plus-
strand DNA (solid half sphere). The outer circles represent 
the Core or pregenomic RNA (3.5 kb), the PreS1 RNA (2.4 
kb) and the PreS2/S mRNA (2.1 kb). The precore mRNA 
from which HBeAg is translated is not shown. The coding 
regions for the precore, core, polymerase, Pre-S1, Pre-S2 
and S proteins are shown between the inner and outer 
circles. The open reading frame (ORF) of the envelope 
proteins overlap with the polymerase ORF. (Adapted from 
Seeger C. and Mason W., Micr. Mol. Biol. Reviews 2000; 
64(1):51-68) 
 
 
The virion. 
The infectious HBV particle, also 
known as the Dane particle, has a diameter 
of 42 nm (15) (Fig. 2). It consists of an outer 
phospholipid membrane composed of 
primarily HBsAg. The L and M envelope 
proteins are present in roughly the same 
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concentrations, while the S protein is three 
times as abundant. Although antibodies 
directed against the S protein are protective 
against infection, the preS1 domain is 
thought to be the ligand for the, still 
unidentified, human receptor (3). Inside the 
envelope, the icosahedral nucleocapsid 
encloses the viral DNA and polymerase. 
 
 
 
Figure 2:  Viral and subviral particles found in 
plasma.  Complete HBV virions with a size of 42 nm 
(white arrows) and 20 nm spherical particles (arrowheads) 
as well as filamentous structures of up to 200 nm long 
(black arrow), both composed of HBsAg, can be detected in 
the plasma of chronic HBV patients. (Adapted from Ganem 
D. and Prince A., NEJM 2004; 35:1118-29) 
 
 
The capsid is composed of 120 core dimers 
and has a diameter of 37 nm (16). As 
mentioned above, the viral DNA is only 
partially double stranded and maintains a 
relaxed circular DNA structure. While the 
minus strand is complete, the plus strand is 
always incomplete and variable in length. 
The viral DNA polymerase is covalently 
linked to the 5’ end of the minus strand and 
the 5’ end of the plus strand is preceded by a 
17 bp RNA sequence. 
Besides the Dane particle, other sub-
viral HBV particles are present in the 
circulation of patients with acute or chronic 
HBV infection. These can be formed by the 
S protein alone, or in combination with the 
other HBs proteins. Two different forms of 
these non-infectious particles can be 
identified: a 22 nm large spherical particle 
(Fig. 2) and filamentous structures of 20 nm 
in diameter and up to 200 nm long (Fig. 2). 
These particles are more than 100 times 
more abundant in the plasma of infected 
individuals than the virions, and do not 
contain any DNA. 
 
Replication cycle. 
The virion attaches to the hepatocyte 
membrane through interaction of the preS1 
sequence with the yet unidentified receptor. 
Recently it was shown that also a domain 
within the S protein may facilitate this 
interaction (17). After membrane fusion, the 
core particle is translocated to the nucleus 
where the shorter positive DNA strand is 
completed and the nick in the minus DNA 
strand is repaired after removal of the 
covalently attached viral polymerase (Fig. 
3). This generates a fully double-stranded 
covalently closed circular genome (cccDNA) 
(18) that forms a supercoil and serves as the 
template for the transcription of viral 
mRNAs by the host RNA polymerase II (19). 
All RNA’s have a common 3’-termination 
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site and use the same polyadenylation site. 
These mRNA’s are transcribed from four 
different promoters (core/precore, preS1, 
preS2/S and X) and are regulated by two 
enhancers upstream the core/precore and X 
promoters. These enhancers and promoters 
are subsequently regulated by general and 
liver-specific transcription factors. This 
explains the liver tropism of HBV. 
The largest mRNA, the pregenomic 
RNA, which besides containing the code for 
the core/precore and polymerase also serves 
as template for the synthesis of the minus 
DNA strand (20). 
The first step in the replication cycle 
involves the binding of a newly synthesized 
viral polymerase to a secondary RNA 
structure at the 5’ end of the pgRNA, called  
 
 
 
 
Figure 3:  The replication cycle of HBV.  After attachment to the, still unidentified, receptor the HBV virions are 
internalized. The viral core particles migrate to the nucleus of the hepatocytes where the viral genome is repaired to form a 
covalently closed circular DNA (cccDNA) that serves as the template for mRNA transcription. The viral mRNA is translated in 
the cytoplasm to produce the viral proteins. The progeny viral capsids assemble and incorporate the viral pregenomic RNA 
(pgRNA). This pgRNA is then reverse transcribed into viral DNA. The core particles can then either bud into the 
endoplasmatic reticulum to be enveloped and secreted into the plasma or they can recycle to the nucleus to be converted to 
cccDNA. (Adapted from Ganem D. and Prince A., NEJM 2004; 35:1118-29) 
 15
epsilon (ε). This triggers encapsidation of 
the complex by the core protein. The bulge 
of the ε structure acts as a template for a 3-4 
nucleotide long DNA primer that is 
covalently attached to the polymerase. The 
polymerase–primer complex then 
translocates to the 3’ end of the pgRNA 
where the 4 bases can anneal with a 
complementary sequence. During 
elongation of the minus DNA strand 
towards the 5’ end of the pregenome, all but 
the final 17-18 ribonucleotides are degraded 
by the RNase H activity. The remaining 
fragment translocates to the 5’ end of the 
newly synthesized (-)-strand where it 
anneals to the homologous DR2 region and 
then serves as primer for the (+)-strand 
synthesis. 
In about 10% of all replication cycli, 
the translocation of the RNA primer does 
not occur and the (+)-strand synthesis 
occurs through an in situ priming reaction 
(21). This results in an infectious particle 
with a double stranded linear genome that 
can form cccDNA through illegitimate 
recombination (22). 
All the replication events occur in a 
closed capsid that allows the entry of 
nucleotides through pores. However, once 
the capsid buds through the endoplasmatic 
reticulum (ER) it acquires an envelope that 
is impermeable. Once the nucleotide pool 
inside the capsid is depleted it cannot be 
replenished explaining the variable length 
and incomplete nature of the (+)-strand. 
Besides budding through the ER and 
subsequent export from the cell, intact 
capsids can also recycle to the nucleus 
where their genome can be converted to 
cccDNA to maintain a stable intranuclear 
pool of transcriptional templates (18). 
 
Serotypes and genotypes. 
Mutations in the HBV genome can 
arise during two steps in the HBV 
replication cycle (23). First, during the RNA 
pregenome synthesis by the host-derived 
RNA polymerase II and second, during the 
reverse transcription of the viral polymerase 
which lacks a proof-reading function. 
Genome analysis shows that all HBV 
isolates have a sequence homology of about 
85%. 
 
 
 
Figure 4:  Geographic distribution of the hepatitis 
B virus genotypes.  (Adapted from Schaefer S., JVH 
2005; 12:111-124) 
 
 
This variability is reflected in the 
presence of distinct HBV serotypes. 
Serologic analysis with subtype-specific 
antibodies against the HBsAg showed that 
all serotypes contain the ‘a’ determinant in 
combination with two pairs of mutually 
exclusive subdeterminants (d or y and w or 
r). The resulting nine major HBV serotypes 
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(ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, 
adrq+ and adrq-) can also be deduced from 
the amino acid composition at positions 122 
(K for d and R for y), 160 (K for w and R for 
r) and 127 (P for w1/2, T for w3 and L for 
w4) (24, 25). 
Based on the complete genetic 
diversity, different HBV strains can be 
classified into 8 genotypes, A to H, with an 
inter-genotype divergence of at least 8%. 
These genotypes have a more or less well 
defined geographic distribution (Fig. 4). 
Genotype A (serotypes adw2 and ayw1) is 
most prevalent in the United States (26, 27), 
north-west Europe and South Africa (28). 
Genotypes B and C (serotypes adw2, adr 
and ayr) predominate in Asia (29), while 
genotype D (serotypes ayw2 and ayw3) is 
found in the Mediterranean region as well 
as in the Middle East. Genotype E (serotype 
ayw4) is confined to western Africa (30-34). 
Genotype F (serotype adw4) is mainly 
present in South and Central America (25, 
35-37). Genotype G (serotype adw2) has 
been reported recently in France (38) and 
the USA (39). Genotype H (serotype adw4) 
is restricted to Central and South America 
(40, 41). The geographic distribution 
should, however, not strictly be interpreted 
and can change due to the migration of 
chronically infected individuals (42). 
The knowledge about the clinical 
significance of these genotypes has been 
rather limited. Several studies, conducted 
primarily in Asia, showed that genotype B, 
in contrast to genotype C, is associated with 
spontaneous HBeAg seroconversion, less 
pronounced liver disease, a slower 
progression to liver cirrhosis and a less 
frequent progression to hepatocellular 
carcinoma (HCC) (43-48). Interferon-α 
therapy is more successful in patients 
chronically infected with HBV of genotype A 
and B compared to genotype C and D (49-
51). This was recently confirmed for 
treatment with pegylated interferon (52). 
Several studies were undertaken to find a 
correlation between genotype and response 
to lamivudine and adefovir treatment. 
Although no correlation could be 
demonstrated (53, 54), lamivudine resistant 
mutations arose more rapidly in patients 
infected with genotype A compared to 
genotype D (55).  
 
Transmission routes. 
HBV can be transmitted by mucous 
and percutaneous membrane exposures to 
infectious blood, serum, semen and saliva. 
The presence of HBeAg in serum correlates 
with higher titers of HBV DNA and greater 
infectivity. 
Mucous membrane exposures to 
infectious blood or body fluids through 
sexual and perinatal contact are extremely 
efficient modes of HBV transmission. No 
infections have been reported through oral 
exposure to HBsAg-positive saliva. Sexual 
contact is the predominant transmission 
route in adults. 
Percutaneous exposures leading to 
transmission include transfusion of blood or 
blood products from infected donors, 
therapeutic injections with contaminated 
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equipment, intravenous drug use, cosmetic 
related procedures like tattooing and 
traditional shaving, and injuries with 
contaminated sharp instruments. The 
impact of contaminated blood products are 
nowadays limited in the industrialized 
world due to routine screening with 
sensitive methods. In addition, the hepatitis 
B virus is an extremely stable virus (more 
than 7 days at room temperature and 
resistant to drying, simple detergents and 
alcohol), thus increasing the risk of 
infection from contaminated environmental 
surfaces. 
 
Natural history. 
Once a person is infected with HBV, 
the infection can be characterized by three 
successive phases. The first, 
immunotolerant or viral replicative phase is 
characterized by the presence of HBsAg, 
HBeAg and high levels of HBV DNA in the 
plasma. In adults, this phase generally lasts 
about 2-4 weeks, while in perinatal acquired 
infections it often last for decades. At this 
point an immune response is generally 
absent or weak, resulting in the absence of 
symptoms, normal or slightly elevated 
transaminases and only minimal 
hepatocellular damage and infiltration. 
Immunostaining shows a predominant 
nuclear localization of HBcAg (56), while 
HBsAg is found in the cytoplasm of some 
hepatocytes and near the membrane of 
numerous cells forming a honeycomb-like 
pattern (57). A strong cytoplasmic HBeAg 
expression can be observed and is a marker 
for a high viral replication (56, 58). 
The second, immunoreactive or viral 
clearance phase is associated with a 
decrease of HBV DNA, an increase of serum 
transaminases and ultimately 
seroconversion of HBeAg to anti-HBe (59). 
Liver histopathology consists of more severe 
lesions, like confluent necrosis of variable 
extent (60). Immunostaining reveals 
nuclear, cytoplasmic and membranous 
HBcAg, while HBsAg shows a membranous 
staining pattern and sometimes a weak 
cytoplasmic positivity (61). In an acute HBV 
infection, clinical symptoms and jaundice 
now appear and usually last for 3-4 weeks. 
At this point, more than 95% of acute 
infected adults will mount an HBV specific 
immune response of sufficient magnitude 
and complexity, and will recover 
spontaneously from the viral infection 
(acute self-limited hepatitis B). In less than 
5% of adults, the anti-viral immune 
response is not adequate enough to 
suppress the viral replication and to 
eliminate HBV from most infected 
hepatocytes. Here the immunoreactive 
phase may last for decades, resulting in 
chronic hepatitis B. 
The majority of chronically infected 
HBV patients who seroconvert to anti-HBe 
remain HBeAg negative and anti-HBe 
positive with normal transaminase levels 
and minimal to no necroinflammation on 
liver biopsy. The seroconversion is usually 
preceded with a decrease of HBV DNA 
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levels to below 105 copies/ml. This phase 
has been referred to as the low or non-
replicative phase. At this point integration 
of the virus in the host genome is not 
uncommon (viral integration phase) and 
HBsAg remains detectable in the serum. 
HBsAg accumulates in clusters of 
hepatocytes, while HBcAg is usually 
undetectable. Mild inflammation might 
persist for some time without substantial 
necroinflammation. This inactive carrier 
state may last for lifetime and if the damage 
during the viral clearance phase was not too 
severe, the liver may recover with only 
minimal abnormalities. Up to 20% of 
inactive carriers, however, experience 
exacerbations of hepatitis, as determined by 
ALT elevations exceeding 5 to 10 times the 
upper limit of the normal value. This HBV 
reactivation can occur with or without 
seroconversion of anti-HBe to HBeAg. 
Repeated flare-ups generally result in 
progressive fibrosis and eventually 
cirrhosis. 
Some patients suffer from ongoing 
liver disease, even after HBeAg 
seroconversion. This particular disease 
course is frequently associated with the 
occurrence of a precore HBV mutant that is 
unable to produce HBeAg (62-66). 
 
HBV in immune suppressed patients. 
In immune competent subjects, a 
chronic HBV infection may induce a varying 
degree of liver damage depending on the 
vigour of the host’s immune response 
towards the virus. This immune response 
also suppresses the viral replication and 
maintains the viral load in the circulation 
between undetectable levels with 
unamplified assays (<105 copies/ml) and 1 
or 2 log higher (106-107 copies/ml). 
However, when a state of severe immune 
deficiency occurs, e.g. by medical immune 
suppression or by progressive immune 
failure in the context of acquired immune 
deficiencies (e.g. HIV/AIDS), the viral load 
of HBV carriers increases dramatically (> 
108 copies/ml) and even reactivation of 
seemingly recovered or silent HBV 
infections can occur (67-69). In a minority 
of HBV carriers who undergo an 
immunosuppressive therapy for an auto-
immune disorder (70) or after liver (71, 72), 
renal (73, 74) or bone marrow (75-77) 
transplantation or who are treated with 
chemotherapy for non-Hodgkin lymphoma 
(78, 79), the clinical course may severely 
worsen and eventually the clinico-
pathophysiological picture of fibrosing 
cholestatic hepatitis (FCH) may arise. FCH 
is an aggressive and mostly fatal form of 
viral hepatitis associated with increased 
viral replication (80) and expression of 
intrahepatic viral proteins (81). Diffuse 
hepatocyte ballooning, the presence of 
ground-glass hepatocytes, cholestasis and 
periportal fibrosis are prominent 
histological features of FCH (74, 80-83). 
 
Prevention of HBV infection. 
The most important tool for the 
prevention of HBV infection is vaccination. 
The first vaccine was available in 1981, and 
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was derived from plasma from chronically 
infected HBV patients. Because of practical, 
financial and safety concerns, this plasma-
derived vaccine was gradually replaced from 
the mid 80’s by a safe and efficacious yeast-
derived recombinant vaccine. This vaccine 
is solely composed of HBsAg (20 µg) in 
combination with an aluminum adjuvant. 
Three doses of this vaccine, given at months 
0, 1 and 6, suffice to adequately protect the 
majority of vaccinated adults from HBV 
infection. However, 1 to 3% of neonates and 
up to 10% of healthy adults is unable to 
produce protective levels of anti-HBs 
antibodies. These non-responders do not 
suffer from a general immune deficiency, 
but their unresponsiveness is related to 
their HLA haplotypes (84). Although HBsAg 
non-responsiveness affects only a minority 
of the population, the search for more 
immunogenic vaccines is still going on.  
It is clear that due to massive 
vaccination programs, the amount of newly 
infected people will dramatically decrease, 
but the effects of vaccination on the 
incidence of HBV related HCC will only be 
visible within decades due to the long 
incubation period.  
 
Therapy. 
Although the hepatitis B virus has 
been discovered in the mid sixties (85), no 
successful therapy is currently available. At 
present, four therapeutic agents have been 
approved by the Food and Drug 
Administration (FDA) for the treatment of 
chronic hepatitis. The aims of treatment are 
the sustained suppression of HBV 
replication and remission of liver disease. 
To assess the response to therapy, the 
following criteria are evaluated at the end 
points of therapy: normalization in serum 
ALT levels, undetectable serum HBV DNA 
by an unamplified assay (i.e. <105 viral 
copies/ml), loss of HBeAg with or without 
the appearance of anti-HBe antibodies and 
the improvement of liver histology. 
 
a. Interferon. 
Interferons (IFN) have a dual mode 
of action. Besides a direct anti-viral effect 
they also have an immunomodulatory effect 
(86, 87). IFN-alpha has now already been 
used for more than 20 years for the 
treatment of chronic HBV patients. 
Nevertheless, the efficacy of this treatment 
is only limited to a small percentage of 
selected patients. In HBeAg-positive 
chronic HBV patients with persistent or 
intermittently elevated ALT levels, 37% of 
individuals responded to therapy (criteria 
described above) compared to 17% of 
controls (spontaneous improvement) (88). 
Therapy-induced HBeAg clearance appears 
to be durable in 80 to 90% of responders for 
at least 4 to 8 years (89, 90). Using sensitive 
PCR methods, HBV DNA remains 
detectable in the serum of these patients. 
High pre-treatment ALT and low serum 
HBV DNA level are the most important 
predictors of response to IFN-alpha therapy 
(91-93). In addition, IFN-α treatment 
reduces the risk of hepatocellular carcinoma 
in cirrhotic patients (94). 
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In HBeAg negative chronic HBV 
patients, the HBeAg seroconversion can not 
be used as an end-point to evaluate therapy. 
Therefore HBV DNA levels below 105 
copies/ml and the normalization of ALT 
levels are use as indicators of response. 
Results of four randomized trials showed 
that the end-of-treatment response ranged 
from 38% to 90% in treated patients 
compared with only 0% to 37% in controls. 
The 12 month sustained response rates 
varied from 10% to 47% (95-98). A major 
problem with the IFN-α treatment of 
HBeAg-negative chronic HBV patients is a 
high relapse after discontinuation 
(approximately 50% of responders). 
Although relapses can occur up to 5 years 
after therapy, 15% to 25% show a sustained 
response, while 15% to 30% of sustained 
responders cleared HBsAg (99). 
A major drawback to IFN therapy is 
the occurrence of adverse effects like flu-like 
symptoms, fatigue, myalgia, 
thrombocytopenia and depression that may 
result in the discontinuation of therapy. 
Many patients undergoing therapy 
experience an acute flare of liver injury, 
generally preceding the clearance of HBeAg. 
This probably reflects the 
immunomodulatory effect of IFN which up-
regulates MHC class I antigen presentation. 
Therefore, IFN-α therapy is generally 
contraindicated for patients with advanced 
cirrhosis and decompensated liver disease, 
since these flares of liver injury can result in 
total liver failure. 
b. Pegylated Interferon.  
Pegylated interferon α-2a is a 
modified form of conventional interferon. A 
large 40 kDa branched polyethylene glycol 
(PEG) molecule is attached to the base of 
the IFN molecule. This procedure results in 
a compound with a prolonged half-life, thus 
requiring only a weekly administration of 
the drug without high fluctuations in serum 
concentration (100). Two studies showed a 
superior efficacy to PEG-IFN therapy 
compared to conventional IFN α-a2 (36% 
vs. 25%) (52, 101). The frequency and 
severity of adverse effects are, however, 
comparable to conventional IFN therapy 
(101). 
 
c. Lamivudine.  
Lamivudine (Epivir-HBV, 3TC) is a 
cytidine analogue ((-)enantiomer of 2’-3’ 
dideoxy-3’-thiacytidine) that upon 
incorporation into the viral DNA strand 
leads to premature chain termination, thus 
inhibiting DNA synthesis. The anti-HBV 
potency of lamivudine was discovered when 
HIV patients, coinfected with HBV 
displayed a reduction in serum HBV DNA 
during treatment (102). This reduction in 
HBV viremia was also observed in chronic 
HBV patients without HIV infection (103, 
104). 
Virologic response after a one year 
lamivudine therapy ranges from 16 to 18% 
in HBeAg positive patients with elevated 
ALT levels compared to 4% to 6% in 
controls (104-106). In chronic HBV patients 
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with relatively normal or slightly elevated 
ALT levels, virologic response was lower 
than 10% (107). In HBeAg negative patients, 
a virologic response was achieved in 63% of 
patients treated for 24 weeks (placebo 6%) 
(108). The same rate of response was also 
observed after 12 months of therapy (109, 
110), but 90% of individuals relapsed after 
cessation of therapy.  
Combination therapy of Lamivudine with 
PEG-IFN is not superior to PEG-IFN 
monotherapy (52). 
A major advantage of lamivudine is 
that it is usually well tolerated. It has no 
immunomodulatory effect and therefore can 
be used to treat HBV patients with 
decompensated cirrhosis (111). 
The main drawback of lamivudine is 
the appearance of resistant mutants during 
treatment. The most frequent mutation 
affects the YMDD motif of the viral 
polymerase (112, 113). Lamivudine resistant 
viruses appear in 15 to 20%, 40% and even 
in 67% of patients after one, two and four 
years of treatment respectively (104-106, 
114, 115), resulting in the reappearance of 
HBV DNA in the serum using unamplified 
assays. Most patients who continue 
treatment still have lower HBV DNA and 
ALT levels than before treatment due to the 
impaired replication of the mutant virus 
variants (116, 117). 
 
d. Adefovir dipivoxil.  
Adefovir is an adenosine 
monophosphate analogue that acts as an 
inhibitor of both the viral reversed 
transcriptase and DNA polymerase activity. 
A 48 week treatment of HBeAg positive 
chronic HBV patients with adefovir showed 
normalization of ALT levels in 48% of 
treated patients versus 16% in the placebo 
group (118). Twelve and 21% of treated 
patients experienced HBeAg seroconversion 
and a decrease of serum HBV DNA to below 
400 copies/ml respectively (placebo 6 and 
0%) (118). HBeAg negative chronic HBV 
patients showed a normalization of serum 
ALT levels in 72% of cases (placebo 29% 
and a reduction of viral DNA in the serum 
to below 400 copies/ml in 51% of treated 
patients (placebo 0%) (119). The safety 
profile in all adefovir treated chronic HBV 
patients was similar to the placebo group, 
while a 3 to 4 log median reduction of 
viremia and a histologic improvement of 
liver abnormalities was evident (118, 119).  
A major advantage of adefovir 
dipivoxil is that it can be successfully 
applied to treat patients with lamivudine-
resistant HBV mutants (120, 121). To date, 
the emergence of adefovir-resistant HBV 
mutants has not been reported after the first 
year of treatment (118, 119, 122, 123). 
However, a drug-resistant mutation 
(N236T) downstream the YMDD motif of 
the polymerase has been reported during 
the second year of therapy in 2 of 79 (2.5%) 
HBeAg negative chronic HBV patients 
(124). Patients harboring this mutant virus 
can be successfully treated with lamivudine 
(124). 
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e. Entecavir.  
Entecavir (Baraclude™) is a 
guanosine nucleoside analogue with activity 
against the HBV polymerase. After initial 
testing in two animal models for HBV (125-
127), entecavir was successfully used for the 
treatment of chronic HBV in nucleoside-
naïve patients infected with wild-type HBV 
(128). Treatment for 22 weeks with 
entecavir reduced HBV DNA levels 4.7 log10-
fold and was shown to be superior to 
lamivudine treatment (128). A dose-ranging 
efficacy and safety study in chronic HBV 
patients who were considered to be 
lamivudine refractory showed an up to 5.06 
log10-fold reduction in viremia after 48 
weeks of treatment with 1.0 mg entecavir 
(129). In addition, 68% of patients achieved  
normalization of alanine aminotransferase 
levels. 
 
f. Other antiviral compounds.  
It is clear that there still is need for 
improvements in the current therapies. 
Therefore, the search for more affordable 
and effective antiviral compounds that 
induce fewer side-effects is essential. 
Several candidates, like tenofovir (130-132), 
emtricitabine (133), clevudine (134) and 
several other compounds and compound 
combinations are currently in (pre)clinical 
phase for evaluation, but although the 
initial results from in vitro and in vivo 
experiments are promising, the promotion 
to approved standard therapy is still far 
away. 
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The Hepatitis C Virus. 
 
 
In the mid-1970s, several patients 
were diagnosed with a transfusion-
associated form of hepatitis that could not 
be attributed to an infection with hepatitis A 
virus, hepatitis B virus, Epstein-Barr virus, 
cytomegalovirus and other viruses known to 
cause liver inflammation (135, 136). 
Therefore these cases were termed non-A, 
non-B hepatitis (NANBH). It was only in 
1989 that Choo et al. (137) were able to 
identify the causative agent of NANBH by 
molecular techniques. They isolated a cDNA 
clone from the plasma of a chimpanzee 
experimentally infected with NANBH, that 
encoded for an antigen specifically 
associated with NANBH infections. The 
etiologic agent of NANBH was designated 
hepatitis C virus (HCV). Screening of 
plasma of patients diagnosed with NANBH 
showed that the majority of these patients 
were infected with HCV (138, 139). 
According to the World Health 
Organization, approximately 170 million 
people are chronically infected with HCV 
worldwide. Each year an additional 3 to 4 
million people become newly infected.  
 
 
Classification. 
The hepatitis C virus belongs to the 
genus Hepacivirus (140), a member of the 
family of the Flaviviridae. This family also 
includes two other genera: the Pestivirus 
and the Flavivirus. 
The Pestivirus contains viruses like 
the bovine viral diarrhea virus (BVDV) and 
the classical swine fever virus, while yellow 
fever virus, Dengue virus, Tick-borne 
encephalitis virus and Japanese encephalitis 
virus are members of the Flavivirus genus. 
Although the sequence homology 
between HCV and the other members of the 
Flaviviridae is rather low, their genomic 
organization is very similar. Therefore these 
viruses and in particular BVDV, are often 
used as a model system to elucidate the 
replication. 
 
Genomic organization and viral 
proteins. 
 
a. The HCV Genome. 
All members of the Flaviviridae are 
small-sized, enveloped viruses containing a 
(+)-sense single stranded RNA encoding a 
viral polyprotein. The HCV genome consists 
of about 9600 nucleotides and is composed 
of a 5’ noncoding region (5’NCR), a long 
open reading frame (ORF) that encodes for 
a polyprotein of 3010 to 3033 amino acids 
long, depending on the strain, and a 3’ non 
coding region (3’NCR) (Fig. 5). 
The highly conserved 5’NCR is 341 
nucleotides long and contains an internal 
ribosomal entry site (IRES) that is essential 
for cap-independent translation of the viral 
RNA (141, 142). The 3’NCR is approximately 
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230 nucleotides long and is composed of a 
short variable region, a poly(U) tract of 
heterogeneous length and a highly 
conserved 98 nucleotide sequence essential 
for replication (143-145).  
 
b. Viral proteins. 
Translation of the HCV ORF yields a 
polyprotein that is co- and post-
translationally processed by cellular and 
viral proteinases into ten distinct mature 
structural and non-structural proteins. The 
first three proteins from the polyprotein are 
the nucleocapsid C protein (21 kDa) and the 
two viral envelope glycoproteins E1 (37 
kDa) and E2 (61 kDa). The C protein is 
highly basic and binds the viral RNA. 
Overexpression of the core protein has an 
impact on several host cell functions, like 
gene transcription, cell proliferation, cell 
death and lipid metabolism (146-149). The 
two envelope proteins, E1 and E2, form 
noncovalent heterodimers (150), and are 
essential for the interaction between the 
virus and the host cell (151, 152). Within the 
E2 sequence, two hypervariable regions 
have been identified: HVR1 and HVR2. This 
hypervariability is driven by continuous 
antibody selection and immune-escape. 
HVR1 shows a sequence variability of up to 
80% between the HCV genotypes and 
contains the only in vivo HCV 
neutralization epitope thus far discovered 
(153). 
The remaining seven proteins are 
non-structural proteins: p7, NS2, NS3, 
NS4A, NS4B, NS5A and NS5B. The p7 
protein is a small protein that can form an 
ion channel composed of p7-hexamers (154, 
155). These properties suggest that p7 
belongs to the viroporin family and 
therefore might be important for viral 
particle assembly and release. 
 
 
 
Figure 5:  HCV genes and gene products.  (a) The 
9600 nucleotide long HCV genome can be divided in a 
structural and non-structural region that are flanked by a 
5’ and 3’ non-coding region. The polyprotein is co- and 
post-translationally processed by cellular (circles) and viral 
(arrows) proteinases. The resulting viral proteins have a 
different topology with respect to the cellular membrane 
(b). (Adapted from Lindenbach B. and Rice C., Nature 
2005; 436:933-938) 
 
 
The NS2 is a metalloproteinase that, 
in collaboration with the N-terminal part of 
NS3, participates in the proteolytic cleavage 
of the polyprotein at the NS2-NS3 junction 
(156, 157). The NS3 protein comprises two 
domains: the N-terminal (189 AA-long) 
serine proteinase and the C-terminal (442 
AA-long) helicase-NTPase. The NS3 
protease domain associates with its co-
factor NS4A (54 AA-long) (158, 159) and 
this complex is responsible for the cleavage 
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of NS4A, 4B, 5A and 5B from the 
polyprotein (160). The NS3 helicase-
NTPase domain is responsible for RNA 
unwinding, a process driven by NTP 
hydrolysis (161-163). It was recently shown 
that NS4B can induce the formation of an 
ER-derived membranous web that is 
composed of all HCV structural and 
nonstructural proteins (164), and 
replicating RNA (165). It seems that the 
membranous web acts as a scaffold for the 
formation of the viral replication complex. 
The function of the NS5A protein remains 
inconclusive. It has been reported that a 
certain region within NS5A, termed the 
interferon sensitivity determining region, 
might play a role in the response to 
interferon alpha therapy (166, 167). In 
addition, the NS5A protein has been 
reported to interfere with the activity of the 
double-stranded-RNA-activated protein 
kinase (168). The NS5B protein plays a 
central role in the HCV replication cycle. 
Using the viral genome as a template, this 
RNA dependent RNA polymerase (RdRp) 
synthesizes a new viral (+)-strand RNA 
genome via an intermediate minus-strand 
RNA (169, 170). The RdRp can produce new 
RNA strands without the need of a primer, 
but it lacks a proofreading function. 
Recently, a new and alternate reading frame 
within the HCV core region was proposed 
(171). This reading frame is the result from a 
frame shift of the ribosome and generates a 
new protein called F (frame shift) or ARFP 
(alternate reading frame protein) (172, 173). 
Antibodies (174) and memory T-cell-
mediated immune (175) responses against 
this protein can be detected in the sera of 
chronically infected HCV patients, which 
indicates the expression of this protein 
during a natural infection. The function of 
this protein remains to be determined. 
 
The HCV virion. 
HCV particles are thought to have a 
diameter of about 56 to 60 nm (176-178). 
The virions have an outer double-layered, 
host-derived, lipid envelope in which E1-E2 
heterodimers are anchored. These viral 
envelope proteins are thought to form 
spikes on the virion surface (Fig 6). Inside 
the viral membrane an icosahedral 
nucleocapsid composed multimers of the 
viral core protein, encapsidates the viral 
RNA. Complete virions can only be rarely 
observed inside hepatocytes of HCV 
infected chimpanzees and humans (179). 
 
Viral infection and replication cycle. 
Although HCV RNA has been 
detected in several extrahepatic locations, 
like circulating lymphocytes, antigen 
presenting cells, bone marrow and even 
brain tissue (180-187), the hepatocyte is the 
primary target of the virus. Due to the lack 
of an efficient cell culture system the 
knowledge on viral attachment and host-cell 
entry was progressing slowly. However, 
since the development of infectious HCV 
pseudoparticles, new information on this 
subject is continuously being generated 
(151, 152). During the last decade, several 
candidate receptors were proposed. The 
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Figure 6:  HCV virions inside infected hepatocytes.  (a) A single virus-like particle composed of a relatively dense core 
and surrounded by a spiked envelope (arrow) can be seen inside a hepatocyte from a chronically infected chimpanzee. The 
peripheral cell membrane is indicated by a thick arrow. (b) A small group of HCV virus-like particles (arrows) can be noticed 
in a hepatocyte from a cirrhotic, HCV infected human liver. (Magnification x72,500; adapted from De Vos R. et al., J. 
Hepatology; 37:370-379) 
 
current consensus is that not one, but a 
combination of receptors, forming a 
receptor complex, are required to achieve 
infection.  
One of the first receptor candidates put 
forward was CD81. This was based on the 
observation that recombinant HCV E2 
could bind to the major extracellular loop of 
the CD81 molecule (188). A second receptor 
candidate was the low-density lipoprotein 
(LDL) receptor (189, 190). In serum 
obtained from chronically infected patients, 
HCV particles can be found associated with 
both LDL and VLDL (191-193). The LDL 
receptor was shown to facilitate the 
 
internalization of LDL-associated virions. 
Negative arguments for CD81 and the LDL-
R as a receptor for HCV are the broad tissue 
distribution of these proteins. 
Another putative receptor is the 
scavenger receptor class B type I (SR-BI), 
which is also able to bind the HCV E2 
protein via interaction of the HVR1 (194). 
SR-B1 is highly expressed on hepatocytes 
and is also known as the receptor that is 
responsible for the internalization of HDL 
(195). In addition, HDL has been shown to 
enhance the infectivity of HCV 
pseudoparticles in vitro, and to protect the 
virus from neutralizing antibodies (196). 
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The E2 HVR1 is essential in these processes. 
This is in accordance with the observed 
binding of recombinant HCV envelope 
proteins to HDL (197). While human and 
tupaia SR-B1 are able to bind HCV E2, this 
interaction is not observed with mouse SR-
B1 (198). This might explain why mouse 
hepatocytes are resistant to HCV infection 
in contrast to human and tupaia 
hepatocytes. 
HCV glycoproteins also interact with 
DC-SIGN and L-SIGN, two membrane-
associated C-type lectins that are expressed 
on dendritic cells and hepatic sinusoidal 
endothelial cells respectively (199, 200). 
These interaction might also contribute to 
the capture and delivery of the virus to the 
hepatocytes (201).  
 
After attachment of the hepatitis C 
virus to its receptor(s), the virus still has to 
enter the target cell (Fig. 7). Studies with 
the HCV pseudoparticle system showed that 
this entry is pH-dependent, strongly 
supporting a receptor-mediated endocytic 
route of entry (151, 202). After endocytosis, 
the viral glycoproteins probably undergo a 
low-pH induced conformational change that 
promotes fusion with the endosomal 
membrane. Once the viral RNA has entered 
the cytoplasm it is immediately translated 
near the rough endoplasmatic reticulum 
(ER). The ribosomal complex is directed by 
an IRES, and the produced polyproteins are 
co- and posttranslationally processed by 
host cell and viral proteinases (see above). 
 
The viral proteins, and probably also 
cellular proteins, form a replication complex 
which associates with the intracellular 
membranes. This replication complex is 
known as the membranous web (164, 165). 
The (+)-strand viral RNA is also used as 
template for the viral polymerase to 
produce new (+)-strand RNAs via 
intermediate (-)-strand RNAs. These 
progeny (+)-strand RNAs can be used either 
as new templates for translation, replication 
or for the assembly into new virions. The 
factors that regulate these processes are 
unknown. 
 
 
 
 
Figure 7:  HCV life cycle.  Enveloped viral particles 
interact with specific receptors on the surface of the 
hepatocyte. After fusion of the viral and cellular 
membranes the single stranded positive sense RNA genome 
is released in the cytoplasm. This RNA molecule can serve 
either as a mRNA for viral protein translation or as a 
template for viral replication, but it can also be packaged to 
form new infectious virions that are secreted into the 
circulation. (Adapted from Lindenbach B. and Rice C., 
Nature 2005; 436:933-938) 
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How a new virion is assembled is 
currently unknown. Probably, virion 
assembly is started by an interaction of the 
viral core protein with a (+)-strand RNA 
strand. The core proteins interact with a 
region in the 5’ UTR of the HCV genome 
(203), a process that also inhibits 
translation from the IRES (204). The HCV 
envelope proteins E1 and E2 are retained in 
the ER due to retention signals in their 
transmembrane domains (205, 206). This 
might indicate that the viral nucleocapsids 
acquire their envelope through budding into 
the ER. Thus, virus secretion can occur 
using the constitutive secretory pathway. 
Mathematical analysis of the viral 
decline in 23 chronically HCV infected 
patients during interferon-α-2b therapy 
showed that the virion half-life in serum 
was approximately 2.7 hours (207). Before 
treatment, 1012 new virions were produced 
on a daily basis, which means that an in 
infected hepatocyte produces 10 to 100 
virions daily. This calculation depends on 
the assumption that 5% to 50% of the 2x1011 
hepatocytes composing the human liver are 
infected. However, the actual amount of 
hepatocytes that are infected in a chronic 
HCV patient is difficult to determine since 
viral proteins are difficult to visualize on 
human liver biopsies. 
 
In vitro infection and replication of 
HCV. 
 Until recently, in vitro studies of 
HCV were limited to the subgenomic 
replicon system (208). However, these HCV 
replicons do not replicate efficiently without 
cell culture-adaptive mutations (209, 210). 
Full-length replicons with adaptive 
mutations replicate efficiently, but are 
unable to produce infectious particles (211, 
212) and are severely attenuated in vivo 
(213). This limits the use of the replicon 
system to the study of the replication and 
the evaluation of drugs with possible 
antiviral activity. 
Recently, a major breakthrough 
allowed the in vitro study of the complete 
viral life cycle. Three groups almost 
simultaneously described the production of 
infectious HCV in cell culture (214-216). 
The system was based on a subgenomic 
replicon derived from a Japanese patient 
suffering from a fulminant hepatitis (JFH1), 
which replicated efficiently without cell 
culture-adaptive mutations (217). 
Transfection of full-length JFH1 or chimeric 
J6/JFH1 into Huh7 or Huh-derived 
hepatoma cells resulted in high replication 
and the production and secretion of 
complete virions (HCVcc) into the culture 
medium. The culture supernatant could be 
used to infect naïve hepatoma cells (214-
216), and also induced a mild and transient 
HCV infection in a chimpanzee (216). 
We recently demonstrated that cell 
culture grown chimeric FL-J6/JFH could 
establish a long-term HCV infection in 
chimpanzees and chimeric human liver-
uPA/SCID mice (218). The animal-derived 
virus showed increased infectivity compared 
to the HCVcc, which correlated to a lower 
buoyant density of the virions. After re-
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culture in Huh7.5 cells the infectivity 
decreased again to levels of the initial cell 
culture virus. 
 
It is clear that the HCVcc system is a 
major step forward that will enable the 
scientific community to study all steps of 
the viral life-cycle in a very efficient way. 
The main drawbacks are that the HCVcc 
system is, thus far, limited to the JFH1 
strain or chimeric viruses that contain the 
JFH1 non-structural machinery. The fact 
that HCVcc are considerably less infectious 
than in vivo generated HCV indicates that 
cell culture conditions are not completely 
comparable to what happens in life 
situation. 
 
 
HCV Genotypes, subtypes and 
quasispecies. 
Based on sequence analysis, the 
different HCV strains can be classified 
within 6 major genotypes (1 to 6) 
comprising different subtypes (a, b and c). 
These genotypes have now been designated 
‘clades’. The new genotypes 7a, 8a, 9a and 
11a have been assigned to clade 6, while 
genotype 10a has been classified under 
clade 3 (140, 219). 
The divergence over the complete 
genome between different genotypes ranges 
between 30 and 35%. Higher variability can 
be noticed in the region comprising the 
envelope glycoproteins (>50%), whereas the 
nucleotide sequences of most of the 
nonstructural proteins are more conserved. 
The 5’UTR and the core region are highly 
conserved (220). The sequence difference 
between subtypes of the same genotype 
ranges from 20 to 25%.  
The most common genotypes in 
Western Europe and the US are genotype 1a 
and 1b (together these represent 70% with 
equal distribution), followed by genotype 2 
and 3. Genotype 1a and 3 are associated 
with intravenous drug abuse. In Europe, 
HCV prevalence ranges from 0,5% in 
northern countries to 2% in the 
Mediterranean and eastern regions. 
Genotype 4 is primarily found in Egypt, 
where about 22% of the population is 
infected with HCV, most likely as a 
consequence of unsafe parenteral 
antischistosomal therapy (221). Infections 
in western Africa are caused primarily by 
HCV genotype 2, whereas infections in 
central Africa are caused by genotypes 1 and 
4. Genotype 5 is most prevalent in South 
Africa, while genotype 6 is ubiquitous in 
Southeast Asia but also in Australia (Figure 
8). 
The determination of HCV genotype 
is definitely of clinical significance. 
Response to therapy varies among different 
genotypes. IFN monotherapy and 
IFN/ribavirin combination therapy are 
much more efficacious against genotype 2 
and 3 compared to genotype 1 (222). 
Infections with genotype 3 have a higher 
incidence of steatosis (223), probably due to 
virus-induced block in lipoprotein secretion 
(224). 
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Figure 8  HCV genotypes.  Evolutionary tree of the 
major HCV genotypes and their main epidemiological 
associations with specific risk groups. (Adapted from 
Simmonds P., J. Gen. Virology 2004; 85:3173-3188) 
 
 
Within a chronically infected 
patient, a pool of genetically distinct but 
closely related variants coexist as 
quasispecies (genomic diversity <10%). This 
phenomenon has several causes. First of all, 
HCV is an RNA virus and its replication is 
mediated by a polymerase without 
proofreading. Considering that RNA 
polymerases have a typical error rate 
between 10-4 and 10-5 substitutions per 
nucleotide copied (225), and that every day 
up to 1012 (207) new virions are produced in 
the liver, this degree of diversity is not 
surprising. The existence of the quasispecies 
might also be a strategy of the virus to evade 
the immune system and thus persist in the 
infected host. One target of the humoral 
immune system is the HVR1 of the E2 
protein. The existence of neutralizing 
antibodies to the envelope proteins and 
especially to this specific region (153, 226) 
might be the driving force to the variability 
of the HVR1. Studies in patients with 
agammaglobulinemia support this theory 
(227). In these patients, less mutants were 
observed compared to immune competent 
patients; probably because their occurrence 
does not represent any advantage in the 
absence of immunoglobulins. Additionally, 
the sequence diversity in the HCV 
population within the patient might also be 
a way to alter epitopes that are strongly 
recognized by the cellular immune system, 
or to avoid presentation by the MHC 
complex. 
 
Transmission routes. 
The main routes of HCV 
transmission are intravenous drug abuse 
and transfusions of blood or plasma-derived 
product. This latter mode of infection is 
nowadays rather limited in developed 
countries through the screening of blood 
products. People undergoing repeated 
medical interventions, like renal dialysis, 
also are at substantial risk of acquiring an 
HCV infection if the primary prevention 
strategies are not rigorously applied. 
Vertical transmission is limited, but 
rates of transmission of 5% have been 
reported in babies of otherwise healthy 
mothers and up to 30% in babies from HIV 
coinfected mothers. Transmission through 
sexual contact is still controversial but may 
occur at very low frequencies. 
The stability of HCV on 
environmental surfaces is relatively low 
compared to HBV. Nevertheless, in an 
experimental setting, viral transmission to 
chimpanzees still can occur 16 hours after 
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infectious plasma was dried in a vacuum 
chamber, but not after 4 days (228). 
 
Natural history. 
The majority of people acutely 
infected with HCV experience no or only 
mild symptoms, like jaundice, nausea, 
abdominal pain, fatigue and depression. 
Chronic HCV infections are also 
characterized by a prolonged period without 
specific symptoms. Therefore most HCV 
infections are not recognized before the 
onset of advanced or end stage liver disease, 
several decades later. 
Between 70% and 85% of the people 
infected with HCV evolve towards 
chronicity (229). Acute self-limited hepatitis 
is rare, but spontaneous elimination of the 
virus occurs in about 10 to 20%. About half 
of the chronically infected people have 
persistently normal ALT levels. Liver biopsy 
analysis reveals only minimal chronic 
hepatitis combined with mild fibrosis; 
cirrhosis is rare. The long-term outcome is 
generally favorable in this group. The other 
half of the chronically infected patients have 
intermittently or continuously elevated 
transaminase levels. Histological evaluation 
of liver biopsies shows marked 
necroinflammatory lesions and extensive 
fibrosis. In this group, cirrhosis will be 
diagnosed in more than 35% after 25 years 
of chronic infection. Overall, about 20% of 
chronically infected people will develop 
cirrhosis after 20 years. Once cirrhosis is 
established, the risk of developing 
hepatocellular carcinoma is approximately 
3% per year. 
Besides liver disease, HCV is also 
responsible for several extrahepatic 
diseases. About half of HCV infected people 
suffer from essential mixed 
cryoglobulinemia (type II). Cryoglobulins 
usually contain large amounts of HCV 
virions captured in antigen-antibody 
complexes (230). Type II cryoglobulinemia 
can induce purpura, arthritis, hypertension, 
vasculitis, peripheral neuropathy and in the 
most severe cases in membranous and 
membranoproliferative glomerulonephritis 
(in 5% of infected people). In about 5% of all 
cases, porphyria cutanea tarda can develop 
(231). Treatment consists of antiviral 
therapy or phlebotomy to deplete the excess 
of iron that can exacerbate the porphyria. 
Other extrahepatic manifestations 
possibly linked with HCV infections are 
lymphoproliferative disorders (5%-35%), 
autoimmune thrombocytopenia (10%-15%) 
and arthralgias and myalgias (20-30%). 
 
Immune evasion of HCV. 
 The hepatitis C virus generally 
induces a persistent infection, presumably 
because the virus has developed different 
strategies to evade the host’s immune 
system. 
 
a. Intracellular host defense. 
The hepatocyte, the prime target for 
HCV, has several defense mechanisms to 
protect itself against viral infections. Viral 
infections are usually detected through 
pathogen-associated molecular patterns 
(PAMP), which include viral proteins, 
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Figure 9: Overview of the intracellular events in the host response to HCV infection and possible points in 
this signaling cascade where the virus may interfere. (Adapted from Gale M.Jr. and Foy E.M., Nature 2005; 
436:939-945) 
 
single-stranded (ss) and double-stranded 
(ds) RNA and polyuridine structures (232-
234). Upon binding to PAMP-receptors, like 
Toll-like receptors (TLR) and nucleic acid 
binding proteins, a series of intracellular 
proteins become activated that lead to the 
induction and expression of several antiviral 
proteins. 
Two independent pathways become 
triggered once dsRNA is recognized: a TLR3 
pathway and a retinoid-acid-inducible gene 
I (RIG-I) pathway (Fig. 9). Both TLR3 and 
RIG-I can activate interferon regulatory 
factor (IRF)-3 which then migrates to the 
cell nucleus and activates the production of 
IFN-β (235-237). Activation of IRF-7 by 
TLR3 results in the production of IFN-α 
(238, 239). Both IFN-α and β are secreted 
by the activated hepatocyte, resulting in an 
autocrine and paracrine activation of the 
Jak-STAT pathway, which results in the 
transcription of IFN-stimulated genes (ISG) 
like IRF-7, OAS (2’,5’-oligo-adenylate 
synthetase), PKR (double stranded RNA-
activated protein kinase R), etc. (240). This 
increases the antiviral capacity of the 
infected hepatocyte, but also triggers nearby 
uninfected hepatocytes to prevent further 
spread of the virus. Besides inducing ISG 
expression, IFN-α also plays a role in the 
modulation of the adaptive immune 
response against the invading pathogen. 
In addition, RIG-I and TLR3 can activate 
NF-κB that activates the transcription of 
several chemokines and cytokines (232, 
241). 
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b. Evasion mechanisms. 
HCV has devised several ways to 
interfere in the intracellular signaling, thus 
preventing, or at least reducing, the 
antiviral potential of the hepatocyte.  
The NS3/4A protease can block IFN-
β production by inhibiting the activation of 
IRF-3 by RIG-I and by cleavage of TRIF 
(Toll-interleukin-1 receptor-domain-
containing adaptor inducing IFN-β), a TLR-
3 adaptor protein (242-244). Cleavage of 
TRIF also abolishes the activation of NF-κB 
(243). 
The HCV core protein has been 
shown to increase the expression of SOCS-3 
(suppressor of cytokine signaling-3) (245). 
SOCS proteins are inhibitors of the Jak-
STAT signaling pathway.(246). 
Both the envelope protein E2 and 
NS5A are inhibitors of PKR (168, 247, 248), 
but NS5A has also been implicated in the 
inhibition of 2’,5’ OAS (249). HCV of 
genotype 1 contains less OAS/RNaseL 
cleavage sites in its genome, which might be 
another way to be more resistant to this 
ribonuclease (250). 
 
Antiviral therapy. 
 
a. Evolution of therapy. 
At the time when HCV was still 
termed non-A, non-B hepatitis, interferon 
alpha therapy was initiated with limited 
success (251). Large randomized trials were 
started that showed the beneficial effect of 
IFN on serum alanine aminotransferase 
levels and liver histology, but most of the 
treated patients relapsed after cessation of 
therapy (252, 253). Depending on therapy 
duration, only 5 to 16% showed a sustained 
response defined as a normalization of 
serum aminotransferase levels. 
A major improvement in HCV 
therapy consisted of the combination of IFN 
with ribavirin. Combination therapy 
significantly increased the amount of 
patients with a sustained virologic response 
(HCV RNA negative) up to 40% after 48 
weeks of treatment (254, 255). Therapy was 
most successful in people infected with HCV 
genotype 2 and 3 (sustained response of 
65%). 
Recently, the treatment of HCV was 
largely improved by the replacement of 
‘traditional’ IFN by pegylated IFN. A 48 
week therapy with pegylated IFN alone, 
compared to ‘traditional’ IFN therapy, 
increased the sustained virologic response 
from 19% to 39% in non-cirrhotic patients 
(256) and from 8% to 30% in people with 
advanced liver disease (257). 
The current standard therapy 
consists of a 48 week combination therapy 
of pegylated IFN with ribavirin. The overall 
sustained virologic response rate is 55% 
(258, 259). People infected with HCV 
genotype 1 have a 40% to 50% sustained 
response rate, depending on the dose of 
ribavirin administered, while non-genotype 
1 infections can be cured in 75% of all cases 
(260). Treatment of chronic hepatitis of 
genotype 1 with PEG-IFN plus ribavirin will 
be discontinued after 12 weeks of therapy if 
a drop in HCV RNA titer of at least 2 log(10) 
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fold is not achieved (261). About 20% of 
treated patients do not meet this criterion 
and only have 1.6% chance of achieving a 
sustained virologic response. Therefore, the 
use of this early stopping rule prevents that 
20% of treated patients undergo the side 
effects associated with treatment without a 
significant chance of success. In addition 
the use of this early stopping rule reduces 
treatment costs by at least 19%. 
Desombere et al. recently showed 
that the decision to proceed or discontinue 
treatment could already be made after one 
week of therapy (personal communication). 
Chronic HCV patients who do not have 
antibodies against NS4A before start of 
therapy, and who still have a HCV RNA 
level exceeding 105 IU/ml have 0% chance 
of achieving a sustained virologic response. 
 
b. Active compounds. 
Interferon. The antiviral action of 
IFN is caused by two complementary 
mechanisms: a direct nonspecific antiviral 
effect and an immunomodulatory effect. In 
the first case, IFN induces the expression of 
2’-5’ oligoadenylate synthetase (2’-5’ OAS), 
Mx proteins and double-strand RNA-
dependent protein kinase (PKR). 2’-5’ OAS, 
which is also activated by double-stranded 
RNAs, in turn activates RNase L, a cellular 
endoribonuclease (262). RNase L degrades 
cellular and viral single-strand RNA. The 
Mx proteins directly inhibit viral 
polymerases, but are less important in HCV 
infections (263). PKR phosphorylates eIF-2 
which then inhibits nonspecifically all 
protein synthesis (264). The 
immunomodulatory effects of IFN-alpha 
comprise increased MHC class I expression, 
activation of macrophages, NK cells and 
cytotoxic T-cells and promotion of the type 1 
T-helper (Th1) pathway. 
Interferon therapy is associated with 
several side effects. Influenza-like 
symptoms, fatigue, fever, rigors, myalgia 
and thrombocytopenia are very common. 
Insomnia, lack of motivation, inability to 
concentrate, emotional instability and 
depression also occur frequently. 
 
Ribavirin. Ribavirin is a guanosine 
analogue with possibly four different 
antiviral characteristics (265). Ribavirin can 
directly inhibit the viral polymerase and can 
act as a competitive inhibitor of inosine 
monophosphate dehydrogenase. The latter 
functions results in a depletion of the 
cellular GTP pool, thus inhibiting viral RNA 
synthesis. In addition, ribavirin causes a 
shift towards Th1-type immune responses 
(266) and is an RNA mutagen (267). 
Ribavirin is much more tolerable 
than interferon, but nausea, anemia, 
pruritus and hemolysis are common adverse 
effects. 
 
Pegylated interferon. Pegylated 
interferon is conventional interferon that is 
covalently attached to a polyethylene glycol 
molecule. This increases the half-life of the 
IFN molecule from 4 to 6 hours to 96 hours, 
permitting a once-a-week dose regimen. 
Two forms of PEG IFN exist: IFN-α2b 
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linked to a 12 kDa polyethylene molecule 
(PEG-INTRON, Schering-Plough) and IFN-
α2a coupled to a 40 kDa branched 
polyethylene molecule (Pegasys, Roche). 
Pegasys has a longer half-life and is mainly 
cleared by the liver, while PEG-Intron is 
removed primarily by the kidney. 
The frequency and severity of 
adverse effects of pegylated interferon are 
comparable to those associated with 
standard interferon therapy. 
 
New antiviral compounds. 
Since currently approved therapies are not 
adequate enough to cure the majority of 
chronically infected patients, new antiviral 
compounds are designed that specifically 
inhibit the viral replication. Candidate 
targets are of course all viral proteins that 
are indispensable for viral replication, like 
the protease, helicase and polymerase. 
Since protease inhibitors have 
proven their effectiveness in HIV therapy, 
this strategy also became the most 
promising in anti-HCV drug design. One of 
the first promising protease inhibitors 
tested in humans was BILN 2061 
(Ciluprevir; Boehringer Ingelheim 
Pharmaceuticals Inc.) (268). This small 
organic molecule, originally based on a 
hexapeptide, was administered to ten 
patients chronically infected with HCV 
genotype 1. Ten patients were treated with 
200 mg BILN 2061, administered twice 
daily for two days. A dramatic 2 to 3 log10-
fold or greater reduction in viral load 
was observed in all treated patients 24 to 28 
hours after oral administration of the 
compound. This impressive viral decline 
was followed by a viral rebound in all 
treated persons with HCV RNA levels 
returning to pre-treatment levels within 6 to 
13 days after initiation of the treatment. 
Three other clinical trials, comprising in 
total 51 patients, confirmed the efficiency of 
the BILN 2061 compound (269). 
Unfortunately, this NS3-serine protease 
inhibitor has only minimal effect in patients 
chronically infected with HCV of genotypes 
2 and 3 (270). Nevertheless, additional and 
larger clinical studies are currently on hold 
due to cardiac toxicity of the compound in 
animals. 
Another viral protease inhibitor, VX-
950 (Vertex Pharmaceuticals Inc.), already 
proved its effectiveness in a Phase Ib study. 
Patients treated with this compound 
achieved a median 4.4 log10-fold reduction 
of HCV RNA at the end of 14 days of 
treatment (271). These results definitely 
encourage the start of a Phase II trial. 
Another potential target for antiviral 
therapy is the viral polymerase NS5B. Two 
compounds are currently in Phase II clinical 
trials: NM283 (Valopicitabine; Idenex 
Pharmaceuticals/Novartis) and JTK-003 
(Japan Tabacco). The former compound is a 
chain-terminating cytidine analogue while 
the latter is a non-nucleoside allosteric 
inhibitor. Another non-nucleoside allosteric 
inhibitor HCV-796 (ViroPharma/Weyth) is 
currently in a Phase Ia trial. 
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Animal models for the study of HBV and HCV. 
 
 
It is clear that current therapies 
against HBV and HCV need to be improved. 
Still a majority of people chronically 
infected with one of these hepatotropic 
viruses cannot be cured. New antiviral 
compounds are continuously being 
designed and even existing compounds that 
are effective against other viruses, like HIV, 
are evaluated for the treatment of HBV and 
HCV. Therefore suitable in vitro and in vivo 
models should be available. This has been a 
major problem for a long time due to the 
lack of a simple and robust cell culture 
system (208). Chimpanzees were the first, 
and probably the best model animals for the 
study of HBV and HCV. However, ethical, 
practical and financial constraints have 
hampered the use of these primates. 
Alternative animal models were sought and 
used, some with more success than others. 
Here we give an overview of the different 
animals and in vivo strategies applied for 
the study HBV and HCV infections. 
 
The chimpanzee. 
The chimpanzee genome (Pan 
Troglodytes) has a 98.77% sequence 
homology with the human genome (272). 
Therefore the chimpanzee has been 
routinely used for the study of human 
diseases. Despite this high genomic 
homology, some important immunological 
differences are present. Humans and 
chimpanzees do not share any HLA class I 
alleles (273); HLA-A2 alleles are absent in 
chimps (274) but they have more sequence 
diversity in the MHC region (274, 275). In 
addition there are also considerable 
differences in the MHC class II region (276-
278). These and other differences make that 
the disease pattern and outcome in 
chimpanzees are not necessarily the same as 
in humans. 
 
a. Hepatitis B infection in the chimpanzee. 
The first indications that the 
chimpanzee could be a useful animal for the 
study of hepatitis B virus infections came 
when HBsAg appeared to be present in the 
serum of a considerable amount of animals 
caught in the wild (279). In 1972, Robert 
Purcell’s group was the first to demonstrate 
successful de novo infection of chimpanzees 
with HBV (280). They inoculated two 
chimpanzees with plasma from HBV 
infected humans and these resulted in a 
transient appearance of HBsAg in the blood 
which was followed by anti-HBs 
seroconversion. In 1977, the chimpanzee 
played a major role in the identification of 
the infectious virion (281). 
Like humans, chimpanzees can 
experience the two known types of HBV 
infection: acute self-limited hepatitis and 
chronic hepatitis (282). In the acute phase, 
chimpanzees mount a cellular immune 
 38
response similar to what is observed in 
acutely infected humans (283), which 
indicates that the chimpanzee is a valuable 
and adequate animal to study immune 
responses towards HBV and to evaluate the 
efficacy of vaccines. However, the absence 
of any overt chronic liver disease prevents 
the study of liver cirrhosis and 
hepatocellular carcinoma. It is however 
useful to study the early events after viral 
infection. In humans, such studies are 
nearly impossible since the acute phase in 
HBV infection is generally asymptomatic 
(284). 
During the eighties, large numbers 
of chimpanzees were not only used to asses 
the immunogenicity and protective 
effectiveness of HBV vaccines, but also to 
evaluate the safety of plasma derived 
vaccines. All new batches from different 
manufacturers needed to be injected in 
more than 100 chimps without causing 
infection, before these could be approved 
for human use (283). The safety of blood 
derived products, such as coagulation 
factors, and new sterilization protocols for 
the inactivation of virions, without loss of 
the biological activity of these derivatives, 
were also evaluated in these highly evolved 
primates (285). 
Since the availability of a safe and 
efficacious recombinant yeast-derived 
vaccine and the accessibility of very 
sensitive methods to detect minute amounts 
of viral particles in blood products, the use 
of chimpanzees for the study of HBV has 
been drastically reduced. 
b. Hepatitis C infection in the chimpanzee. 
The chimpanzee also played a crucial 
role in the discovery of HCV. In 1978, 
chimps were found to suffer from non-A, 
non-B hepatitis (286-288). This was only 
three years after this disease was first 
observed (136). Non-A, non-B hepatitis was 
called HCV after the causative agent was 
partially cloned in 1989 (137).  
The cloning of the virus was a major 
breakthrough in the molecular 
characterization of HCV. This consequently 
led to the development of molecular clones 
that have been used as well defined 
infectious agents. Direct intrahepatic 
injection of in vitro synthesized RNA 
transcripts (289-292) results in acute 
hepatitis. In contrast to virus isolated from 
acute and chronic plasma samples, 
molecular clones have the advantage that 
the resulting infection is caused by a single, 
well characterized HCV sequence instead of 
different quasispecies. Molecular clones 
with artificially introduced mutations or 
deletions are excellent tools for the 
functional analysis of the HCV genome 
(293, 294), and to define the  impact of 
naturally occurring mutations. 
As with HBV infections, the initial 
phase after HCV infection is very difficult to 
study since the infection will only be 
recognized at the onset of acute hepatitis, 6 
to 8 weeks after infection. Because acute 
HCV infection in humans is generally 
asymptomatic, chimpanzees are the only 
tool to study the events early after infection. 
In chimpanzees it is easier to repeatedly 
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take blood and liver biopsies, thus providing 
a detailed overview of the events during 
HCV infection. This way it was discovered 
that only three days after inoculation of the 
virus, viremia became detectable in the 
serum. Three days later, viral proteins could 
be discerned in the cytoplasm of the 
infected hepatocytes. ALT values were 
elevated from two weeks after exposure, 
while antibodies to structural and non-
structural proteins appear after at least 10 
weeks (295-299). The amount of viral 
particles present in the serum ranges 
between 105 and 107 genome equivalents per 
milliliter. The study of cellular responses 
showed that an early, strong and 
multispecific intrahepatic T cell response is 
indicative for acute resolving hepatitis 
(300-302). 
The disease progression of HCV in 
chimpanzees closely resembles that 
observed in humans. The chronicity rate of 
HCV infections in humans is estimated 
between 70 and 85% (229). In chimpanzees 
this is only 39% according to some (303), 
and 60% according to others (296, 299, 
304). The liver disease in chimpanzees is 
significantly milder than in humans. 
Fibrosis and cirrhosis have never been 
observed, and the development of 
hepatocellular carcinoma has only been 
detected in one animal (305). 
The chimpanzee was and is still 
being used to evaluate several HCV 
inactivation protocols  (306-309). The 
animal is still instrumental for the 
development of prophylactic and 
therapeutic vaccines against HCV (310-314). 
Besides humans and chimpanzees, 
several other primates like cynomolgus 
monkeys, green monkeys, rhesus monkeys, 
Japanese monkeys and the doguera baboon 
have been inoculated with HCV. However, 
none of these species were susceptible to 
HCV infection (315). 
 
Although the chimpanzee is still the 
best available animal model for the study of 
viral hepatitis, the use of these animals has 
been hindered by several aspects. Due to 
large-scale hunting and the intensification 
of agriculture in their main habitats, the 
wild chimpanzee has been listed as an 
endangered species since 1988. The use of 
chimpanzees as laboratory animals is also 
very expensive as the result of strict 
regulations during (caging requirements, 
maintenance …) and after (retirement in 
semi-wild sanctuaries) experimentation. In 
addition, their high similarity to humans 
undoubtedly raises serious ethical concerns. 
To circumvent these obstacles, 
alternative animal models were sought that 
were smaller, cheaper, easier to handle, 
raised less ethical questions and, of course, 
that allowed infections with HBV and HCV. 
 
Tree shrews. 
Tree shrews are small non-rodent 
mammals, originally considered to be lower 
non-human primates, but later classified 
into a separate order Scandentia (316). The 
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family Tupaiidae is divided in two 
subfamilies: the diurnal Tupaiinae that 
contains the genera Anathana, Dendrogale, 
Lyonogale, Tupaia and Urogale, and the 
nocturnal Ptilocercinae that contains 
Ptilocercus as the sole genus. Tree shrews 
are geographically distributed in an area 
extending from India to the Philippines and 
from Southern China to Java, Borneo, 
Sumatra and Bali (316). 
Yan et al. were the first to report in 
vivo infection of Tupaia belangeri chinensis 
with human HBV (317). Animals captured 
in the wild can be infected with HBV and 
approximately 55% of those inoculated with 
HBV show signs of infection for more than 
41 weeks. Successive infections from one 
tree shrew to another were effective in 94% 
of cases, indicating adaptation of the virus 
to the new host. However, administration of 
a hepatitis B vaccine to the tree shrews 
prevented the successful establishment of 
an experimental HBV infection with a 
protection rate of 89%.  
These researchers were also able to 
demonstrate a synergistic role of exposure 
to HBV and aflatoxin B1 (AFB1) in the 
development of hepatocellular carcinoma 
(HCC) (318). Tree shrews infected with 
HBV and exposed to AFB1 suffered from an 
increased incidence of HCC (52.94%) 
compared to animals solely infected with 
HBV (11.11%) or exposed to AFB1 (12.50%) 
(318), supporting an etiological relationship 
between HBV, AFB1 and HCC. 
Almost simultaneously Walter et al. 
confirmed the results of Yan and colleagues. 
They showed that newborn tupaias could be 
easily and reproducibly infected with HBV, 
resulting in a serologic course typical of 
acute self-limited HBV infection. Two to 4 
weeks after inoculation, HBsAg could be 
detected in the serum, followed by the 
appearance of antibodies against HBcAg, 
HBeAg and HBsAg (319). By contrast, 
infection of adult animals resulted in a very 
short, transient production of viral antigens 
and a rapid seroconversion to anti-HBc, 
anti-HBe and anti-HBs antibodies after 2 to 
4 weeks. While immunosuppressive 
treatment prior to inoculation augmented 
the infection, still only 0.1 to 1% of 
hepatocytes in the liver showed a positive 
nuclear staining for HBcAg while HBsAg 
could never be detected 
immunohistochemically, demonstrating the 
weakness of the generated infection. 
The tree shrew has recently been 
used to evaluate the protective capacity of a 
new DNA vaccine (320). 
 
The logical next step after HBV 
infection was, of course, to examine HCV 
infections of tupaias. This was successfully 
accomplished in 1998 by Xie et al. (321). In 
34.8% of Tupaia belangeri chinensis 
inoculated with genotype 1b, HCV RNA 
could be detected in serum. Viremia was 
transient (25%) or intermittent (75%) in a 
period of 2 to 47 weeks post inoculation. In 
only 37.5% of HCV RNA positive animals 
HCV-specific antibodies could be detected, 
while in 15% of all animals HCV-specific 
antibodies could be detected in the absence 
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of viral RNA. In a second study from the 
same group only 20% of tupaias, inoculated 
with a mixture of genotypes 1a, 1b and 3, 
became infected. Total body irradiation 
(750 cGy) augmented the infection rate to 
50%, viremia was prolonged and the 
antibody response was augmented. 
Nonetheless, viral titers were on the low 
side, equal to or below 104 to 3.5x105 viral 
copies per ml serum. 
Tupaias may become a useful 
alternative for chimpanzees in the study of 
hepatitis B and C. These small animals, 
which have the size of a small rat, adapt 
easily to the environment in animal 
facilities and retain a high reproducibility in 
captivity. This results in lower costs and 
overcomes the problem that wild tupaias 
are frequently already infected with viruses, 
such as the tree shrew herpes virus which 
may cause spontaneous hepatitis (322). 
 
Surrogate models for HBV. 
 
a. The woodchuck. 
Infection of woodchucks (Marmota 
monax) with the woodchuck hepatitis virus 
(WHV) was first described by Summers et 
al. (323). In a colony of woodchucks high 
rates of chronic hepatitis and even 
hepatocellular carcinoma were observed. 
Viral particles with properties similar to 
those of HBV were observed in the serum of 
these animals. 
The WHV is a member of the 
Orthohepadnavirus genus, and has a 
genetic organization and replicative cycle 
similar to HBV. The disease progression in 
woodchucks with a natural chronic WHV 
infection resembles that in humans infected 
with HBV. Chronic, active hepatitis with 
portal mononuclear cell infiltration, bile 
duct proliferation, hepatic neoplasms 
consisting of well-differentiated HCC’s, and 
even fibrosis are observed (324, 325). 
Woodchucks with a natural chronic 
WHV infection were soon replaced by 
animals wherein the infection was 
introduced experimentally. That way the 
duration of infection was well known and 
any influence of unknown nutritional and 
environmental factors on the disease 
progression was avoided. In addition, 
hepatic lesions caused by other pathogens, 
like certain nematode species, were 
common in wild woodchucks (326), 
complicating the interpretation of 
experimental results. 
Experimental WHV infection in 
adult animals routinely results in an acute 
self-limited infection (327-329). Unless the 
animals are undergoing an 
immunosuppressive regimen, the WHV 
infection rarely evolves towards a chronic 
infection (330, 331). A broad and robust 
humoral and cellular immune response is 
responsible for the clearance of the virus 
from the infected hepatocytes (332-334). 
This is really impressive since virtually all 
the hepatocytes become infected (335). 
Because a chronic WHV infection 
was difficult to induce in adult animals, 
newborn woodchucks were inoculated with 
virus. The rate of chronicity in these 
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neonates was higher than 60% (336-338). 
Interestingly, all animals that suffered from 
a chronic WHV infection developed HCC, 
resulting in a reduced life expectancy (336, 
339). While HCC was not observed in 
uninfected control animals, 17% of 
woodchucks with a resolved WHV infection 
still developed HCC (339). These data 
provided the first experimental evidence of 
the carcinogenesis of mammalian 
hepadnaviruses. 
Since the pathology and severity of 
disease of a chronic WHV infection 
correlated very well with the disease pattern 
of HBV, the woodchuck became one of the 
most attractive animal models. It was 
extensively used to study the development 
of HCCs and to elucidate the impact of 
WHV gene expression, viral DNA 
integration into the host genome and 
certain environmental factors (340). In 
addition, it also proved to be a valuable tool 
in the preclinical evaluation of new antiviral 
drugs like lamivudine (341-343), 
famciclovir (343), emtricitabine (344), 
entecavir (126, 345), clevudine (346, 347), 
telbivudine (348, 349) and tenofovir (350) 
 
b. The duck. 
Another practical surrogate model 
for the study of HBV is the Peking duck, 
which can be infected with the duck 
hepatitis B virus (DHBV). Congenital 
infection or infection at early age usually 
results in a chronic infection, but is not 
associated with severe liver disease and 
HCC (351-354). Like the WHV, infection of 
adult ducks results in infection of almost all 
the hepatocytes but resolves rapidly 
thereafter without substantial 
hepatocellular damage (355). 
The DHBV model has been very 
important in the study of hepadnaviral 
replication. The first functional description 
and further characterization of cccDNA in 
the viral life cycle was done in this model 
(18, 356-358). Of course, the duck also has 
been used to evaluate the efficacy of new 
antiviral compounds (127, 359-365). A 
serious disadvantage is that Peking ducks 
are less sensitive to toxic effects of chemical 
compounds, thus preventing the prediction 
of potential severe side effects in humans 
(366, 367). 
 
Surrogate models for HCV. 
 
a. The tamarin. 
In the eighties, several reports 
described successful HCV infection in two 
tamarin species: Sanguinus mystax and S. 
labiatus (368-371). However, the infection 
rate in these small New World primates was 
disappointingly low and the experimental 
results were rather inconsistent. Later, 
another tamarin species, Sanguinus 
Oedipus Oedipus proved resistant to an 
experimental HCV infection (372). 
Although tamarins cannot be 
infected with HCV, they can be infected 
with the hepatitis GB virus B (GBV-B) (373, 
374). The GB virus was discovered after 
injection of sera from patients suffering 
from hepatitis into tamarins. One sample, 
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isolated from a surgeon with initials G.B., 
caused an acute hepatitis in these animals 
and could be passaged to new tamarins. 
Whether the GB virus was indeed present in 
the original serum sample from that patient 
or whether it was already present in the 
animals used remains unclear. 
GBV-B belongs to the Flaviviridae 
family and is phylogenetically the closest 
related virus to HCV: it has a similar 
genomic organization and the viral 
polyprotein has a 27% sequence homology 
(375). GBV-B causes an acute infection in 
tamarins characterized by increased ALT 
levels and transient high viremia (>109 
genome equivalent/mL). Ultimately, the 
viral infection is cleared between 10 to 26 
weeks (373, 374). The duration of viremia 
can be prolonged to 46 weeks if the animals 
are undergoing an immunosuppressive 
therapy at the moment of GBV-B infection 
(376). Eighteen weeks after the end of 
immunosuppressive therapy the tamarins 
cleared the virus. During clearance there 
was no increase in ALT levels in the plasma, 
indicating a non-cytolytic mechanism. 
Marmosets (Callithrix jacchus) 
infected with GBV-B experience high 
viremia (108 to 109 genome copies/ml) for a 
period of 40 to 60 days. The infection is 
cleared 60 to 80 days postinfection. A 4 day 
therapy of GBV-B infected marmosets with 
a NS3 protease inhibitor resulted in a 3-log-
fold decrease of viremia (377). 
This shows that tamarins and 
marmosets can be successfully used for the 
evaluation of new antiviral compounds. 
Rodent models for HBV and HCV. 
 
a. Rats. 
The last decades, rats have proven 
their usefulness in several research areas. 
Like mice, these rodents are easily 
maintained, bred and handled at a 
reasonable price in standard animals 
facilities and do not require the special care 
like chimpanzees do. In addition they 
overcome several limitations, like blood 
volume, associated with mouse studies.  
Several attempts were done to 
induce active HBV infection in rats, mostly 
with limited success. Takahashi et al. first 
demonstrated HBV infection in rats by 
direct injection in the liver of a replication 
competent cloned HBV construct (378). 
Three days after transfection viral DNA and 
RNA could be demonstrated inside the liver 
and HBeAg and HBV virions were present 
in the sera of the animals. From then on, the 
amount of virions rapidly declined while 
HBeAg could be detected up to day 7, 
followed by the appearance of HBeAg 
specific antibodies. Transfection with HBV 
genomes of athymic nude rats prolonged 
the presence of HBV virions to up to 21 days 
(378). 
One year later, an alternative rat 
model was presented. Here, high titered 
serum from a chronic HBV patient was 
injected in the portal and caudal veins 
(379). One to 2 months later, the presence 
of HBV DNA and HBsAg could be 
demonstrated inside the liver but neither 
viremia nor antigenemia were detected, 
limiting the usefulness of the model. 
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Wu and colleagues created a novel 
rat model by tolerizing immunocompetent 
rats to human cells by injecting primary 
human hepatocytes through the uterine wall 
into the peritoneal cavity of fetal rats on day 
17 of gestation (380). One day after birth, 
these rats were again transplanted with 
human hepatocytes and one week later HBV 
was administered to the chimeric animals. 
From day three after infection, increasing 
amounts of HBsAg could be detected in 
serum, reaching maximal levels of 0.75 
pg/ml and remaining constant throughout 
the 60 day observation period. About 30% 
of human hepatocytes residing in the liver, 
of which the total amount was not 
mentioned, stained positive for HBsAg. 
Active infection was confirmed by the 
presence of HBV DNA in serum (ranging 
from 5,000 to 50,000 copies per ml) from 1 
to 15 weeks post infection, and by cccDNA 
in liver tissue as well as in serum. Elevations 
of serum alanine aminotransferase levels 
were indicative for a host immune response 
towards the infected hepatocytes (381). 
Since there is certainly no match between 
the human MHC on hepatocytes and the T-
cell receptor on the rat leukocytes, the 
hepatocyte damage is probably the 
consequence of non-specific immune 
mediated toxicity. 
Recently, this model was adapted for 
the study of HCV (382). Immunocompetent 
rats were tolerized and subsequently 
transplanted with Huh-7 hepatoma cells. 
One week later, the transplanted rats were 
inoculated with HCV. Viral infection 
persisted for several weeks but serum levels 
of HCV RNA reached maximum levels of 
only 2x104 copies/ml. Human serum 
albumin levels, indicative for the amount of 
human cells present in this rat chimera, 
ranged from 1 to 10 µg/ml, which is very low 
compared to other chimeric animal models 
(see below). 
It is clear that viral replication can 
be achieved in this rat model, but the low 
levels of hepatocyte engraftment, the use of 
hepatoma cells and the low viremia are 
weaknesses that limit the suitability of this 
model for the study of hepatotropic viral 
infections. The mismatch between human 
and rat MHC molecules definitely prevents 
the study of adaptive immune responses 
towards the infected hepatocytes. In 
addition, the presence of a functional rat 
immune system excludes the 
transplantation of selected human lymphoid 
cells, like HCV-specific T-cell clones. 
 
b. Transgenic mice. 
Transgenic mice are produced by 
embryo microinjection of gene constructs. 
In principle, any gene can be used under the 
control of any specific promoter. This way, 
targeted expression of HBV or HCV genes to 
the liver can be achieved. 
 
HBV transgenic mice. The first 
HBV transgenic mice were created in 1985. 
Two independent groups simultaneously 
published the development of HBsAg 
transgenic mice (383, 384). These mice 
produced subviral HBsAg particles and 
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secreted them in high concentrations into 
the circulation. Remarkably, the transgenic 
mice were tolerant to HBsAg and no liver 
disease was observed. Overexpression of 
large envelope protein resulted in the 
accumulation of the viral envelope proteins 
in the cell (385). Later it became clear that 
this retention had a disastrous effect on the 
physical condition of the hepatocytes (386). 
Long filamentous HBs particles 
accumulated in the dilated endoplasmatic 
reticulum. The hepatocytes became 
enlarged and acquired the characteristics of 
“ground glass” hepatocytes. Subsequently, 
these cells became necrotic and multifocal 
nodular hepatocellular hyperplasia became 
apparent. Ultimately this led to the 
development of hepatocellular carcinomas 
(387). This was the first evidence that 
overexpression of the large envelope protein 
can be directly cytopathic, and could lead to 
the development of HCCs. Ground glass 
hepatocytes can also be found in human 
livers chronically infected with HBV, albeit 
at lower frequencies (388). Transgenic 
expression of the HBV X protein also can 
lead to the development of HCCs, 
suggesting an oncogenic effect of this viral 
protein (389). This probably occurs by  
inactivation of the tumor suppressor p53 
after binding with the X protein (390). 
These results were contradicted in another 
HBV-X transgenic mouse model (391). HBV 
precore and core transgenic mice have also 
been generated (5, 392). 
Although HBV transgenic mice have 
been very useful to study the biochemical 
properties of the viral proteins and their 
interactions with other cellular proteins, 
they cannot be used to study the complete 
replication cycle of the virus. Viral 
replication has been demonstrated in 
several different HBV transgenic mice (393-
396), but the episomal HBV cccDNA has 
never been detected. Viral particles derived 
from transgenic mice were infectious in 
chimpanzees (284). 
The animals can however be used to 
study the immune responses towards the 
viral proteins. Although the transgenic mice 
themselves are immunotolerant to the 
transgenes expressed, selected lymphocytes 
from non-tolerant mice can be adoptively 
transferred to the transgenic mice. After 
transplantation with HBsAg-specific 
cytotoxic T lymphocytes (CTL), the HBsAg 
transgenic mice suffered from CTL-induced 
necroinflammatory liver disease (397). 
While a direct effect of the CTLs can be 
observed, the majority of liver disease is 
caused by an indirect, antigen-nonspecific 
cytotoxic effect of other inflammatory cells 
that are recruited and activated by the CTLs 
(398). Although the liver disease induced is 
only transient and generally mild, retention 
of HBsAg can cause a fulminant hepatitis 
resulting in the death of the animals. 
Antibodies against IFN-γ or inactivation of 
the resident macrophages completely 
abolishes this fulminant hepatitis proving 
their essential role in this process (398). 
Immunodeficient HBV transgenic mice also 
support HBV gene expression and 
replication (399). Plasma from these mice 
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contained between 105 and 107 genome 
equivalents/ml but adoptive transfer of 
unprimed, syngenic splenocytes resulted in 
a chronic hepatitis that persisted for over 9 
months. 
Using HBeAg transgenic mice, the 
tolerogenic capacity of HBeAg was 
demonstrated (5). T-cells from the non-
transgenic progeny of these transgenic mice 
were tolerant to HBeAg and HBcAg, 
probably through thymic deletion of 
nucleocapsid-specific T-cells during 
development. 
 
HCV transgenic mice. Mice 
containing the genomic code for one or 
more HCV proteins have also been 
produced. Koike et al. produced a 
transgenic mouse containing both viral 
envelope proteins E1 and E2 (400). Long-
term follow-up of these mice did not show 
any evidence of hepatocellular damage. 
Several other HCV transgenic mice, 
containing one or both of the envelope 
proteins in combination with the core gene 
under the control of a liver specific 
promotor, also did not suffer from any liver 
disease (401, 402). In contrast, two other 
groups described progressive hepatic 
steatosis in HCV transgenic mice containing 
the genetic code of either the viral core 
protein, the nonstructural proteins or even 
the entire HCV ORF under the control of 
liver specific promotors (403, 404). At later 
age, these animals developed hepatic 
tumors (404, 405). The reasons for these 
 
conflicting data are unknown, but the level 
of gene expression and the different mouse 
strains used in this research may have been 
contributing factors.  
Using a NS5A transgenic mouse, it 
was shown that this viral protein can inhibit 
TNF-mediated hepatic apoptosis by 
interference in the TNF-signal transduction 
pathway (406). 
 
A general major drawback on studies 
conducted with HBV and HCV transgenic 
mice is that the viral proteins a usually 
overexpressed in an uncontrolled fashion. 
The concentration of viral proteins during a 
natural infection may be a lot lower and well 
controlled. Therefore the results must be 
interpreted with caution. Certain qualities 
attributed to these viral proteins might be 
related to this artificial overexpression. 
Another limitation of transgenic 
mice is that viral infection, entry into the 
hepatocyte and viral spread to other 
neighboring cells cannot be studied. 
 
Trimera mice. The first human-
mouse chimera suitable for viral hepatitis 
studies was the Trimera mouse. This mouse 
was originally developed for the 
engraftment of human hematopoietic cells 
and tissues (407, 408). The name ‘Trimera’ 
refers to the three different genetic 
backgrounds of the tissues used to create 
this mouse model. After lethal total body 
irradiation, normal or BNX (beige/nude/X-
linked immunodeficient) mice are rescued 
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with SCID bone marrow and subsequently 
small human liver fragments are 
transplanted under the kidney capsule.  
When HBV infected or ex vivo HBV 
infected human hepatocytes are 
transplanted in these animals, viremia can 
be detected from day 8 on and lasts for 
about one month after transplantation 
(409). The mean viral load ranges from 
7x104 copies/ml to 2.5x105 copies/ml, 
depending on the time point. This model 
was used to evaluate the antiviral activity of 
two reverse transcriptase inhibitors 
(Lamivudine and β-L-5-fluoro-2,3-
dideoxycytidine) and the therapeutic effects 
of human polyclonal anti-HBs antibodies 
(Hepatect) (409) an two monoclonal anti-
HBs antibodies (410). 
A few years later, Ilan and coworkers 
demonstrated that the Trimera mouse could 
also be used for the evaluation of 
compounds with possible anti-HCV activity 
(411). Therefore, human liver fragments, 
infected ex vivo with HCV, were 
transplanted under the kidney capsule. 
Viremia also lasted for about one month 
and viral titers ranged between 104 and 
6x104 HCV RNA copies/ml. In this HCV-
Trimera model, an HCV IRES inhibitor and 
a monoclonal antibody against the HCV E2 
envelope protein were shown to selectively 
reduce the viral load during therapy. 
 
Both the HBV- and HCV-Trimera 
mice are useful instruments to analyze the 
possible antiviral activities of certain 
compounds. However, the low viral titers 
and major histological changes within the 
transplanted tissue, like ischemia, fibrosis, 
loss of lobular architecture and necrosis are 
main drawbacks (409, 411, 412). The 
occurrence of these histologic abnormalities 
is not surprising since the liver fragments 
are transferred to an extrahepatic location. 
Therefore, long-term studies to assess viral 
hepatotoxicity are excluded. 
In addition, it is impossible to use 
this model to study viral entry and 
neutralization since in vivo infection of 
Trimera mice transplanted with healthy 
human hepatocytes has been unsuccessful 
until now. 
 
uPA transgenic mice. Perhaps 
one of the most promising small animal 
models for the study of viral hepatitis is 
based on the Alb-uPA mouse. The Alb-uPA 
mouse is a transgenic mouse carrying the 
murine urokinase-type plasminogen 
activator (uPA) gene linked to the albumin 
enhancer/promoter. This mouse was 
originally developed in 1990 in Ralph 
Brinster’s lab, for the study of plasminogen 
hyperactivation and the treatment of 
bleeding disorders (413). The 
overexpression of the uPA gene in the liver 
resulted in high plasma uPA levels and 
hypofibrinogenemia, ultimately leading to 
severe and sometimes fatal intestinal and 
abdominal bleeding, early after birth. 
Another consequence of the hepatocyte 
specific expression of the uPA-transgene is 
extensive liver toxicity ultimately leading to 
hepatic insufficiency (414). This functional 
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liver deficit provides a chronic, supportive 
niche for liver regeneration by transplanted 
hepatocytes of murine origin (415). 
To allow liver repopulation by 
xenogeneic cells, the Alb-uPA transgene had 
to be backcrossed onto a genetically 
immunodeficient mouse strain. This 
approach allowed that rat hepatocytes could 
almost completely repopulate the diseased 
mouse liver in Swiss athymic (nu/nu) Alb-
uPA mice (416), while woodchuck 
hepatocytes repopulated up to 90% of the 
liver of uPA-RAG2 mice (417, 418). The first 
report of successful transplantation of 
human hepatocytes was announced in 2001 
by Dandri et al. (419). The amount of 
human hepatocytes present in the mouse 
liver (up to 15%) was rather low compared 
to the transplantation efficiencies 
previously reported with rat and woodchuck 
hepatocytes. Apparently the quality and the 
period of ischemia of the human liver 
fragments from which the primary 
hepatocytes were isolated from played a 
major role in that. Later it would become 
clear that also the zygosity of the animals 
was an important contributor to these low 
engraftment levels. Dandri et al. only used 
animals heterozygous for the uPA-
transgene. Early regeneration by mouse 
hepatocytes that have selectively deleted the 
transgene (414), prevented a more 
pronounced and stable engraftment by the 
human hepatocytes. However, the amount 
of liver tissue of human origin was sufficient 
to establish an HBV infection by injecting 
serum from a chronic HBV carrier. HBV 
infection was demonstrated by the presence 
of viral DNA in the serum of the infected 
mice (4.5 to 10x108 genome 
equivalents/ml), and was confirmed by 
immunohistochemical detection of HBcAg 
in liver sections. 
A few months later, a Canadian 
group utilized homozygous uPA+/+-
SCID/Beige mice for the transplantation of 
primary human hepatocytes (420). The 
transplantation of homozygous uPA animals 
is technically more difficult due to the 
narrow transplantation window early after 
birth and the susceptibility to bleeding, but 
the engraftment rate is much higher. 
Histologic analysis showed that more than 
50% of mouse liver parenchyma was 
replaced by hepatocytes of human origin, 
resulting in high serum levels of human 
albumin, sometimes exceeding 1 mg/ml. 
Intraperitoneal injection of HCV containing 
human serum into successfully transplanted 
animals resulted in long-term HCV 
infection. The mouse serum contained viral 
RNA levels ranging from 103 to 106 RNA 
copies/ml; negative strand HCV RNA could 
be detected in the chimeric mouse livers 
and the viral infection could, in some cases, 
be maintained for up to 21 weeks.  
A nice application of the human 
liver-uPA-model was the evaluation of an 
apoptosis-inducing molecule specific for 
HCV infected hepatocytes (421). An 
apoptosis inducing molecule (BID) was 
modified to contain a cleavage site 
specifically recognized by the HCV 
NS3/NS4A protease. Cleavage of the BID 
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precursor molecule by the viral protease 
activated the cell-death pathway, resulting 
in apoptosis of the target cell. The efficacy of 
this approach was evaluated by injecting 
three doses of an adenovirus, expressing 
this modified BID, into six HCV infected 
human liver-uPA mice. This resulted in a 
two to three fold log decrease of viral RNA 
in the mouse serum during treatment, and 
even cleared the infection in animals with 
low viremia at the onset. 
 
It is clear that the uPA-model is a 
very useful instrument for the study of viral 
hepatitis, but it may have numerous 
applications in other fields as well. Tateno 
et al. recently reported that this model could 
also be used for the preclinical evaluation of 
pharmacological responses of human 
hepatocytes to new, candidate drugs (422). 
This is a major step forward compared to 
the current in vitro cultures of human 
hepatocytes. In these cultures, the 
phenotype of the hepatocytes changes 
rapidly due to the artificial culture matrices 
This most likely has a significant influence 
on the function and behavior of the 
hepatocytes. 
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Research objectives. 
 
 
The in vivo study of HBV and HCV 
has been severely hampered by the lack of 
an adequate small animal model. Only 
humans and chimpanzees can acquire a 
‘natural’ HBV or HCV infection. It is clear 
that ethical, practical and financial 
constraints limit the use of humans and 
chimpanzees for such studies. We therefore 
wanted to develop a mouse model that 
could be used for the study of viral hepatitis, 
without the limitations mentioned before. 
 
Our immediate goals are: 
 
1. To back-cross the uPA transgene from 
the B6SJL-TgN(Alb1Plau)144Bri mouse 
onto the SCID background. This way we 
will generate a mouse that suffers from a 
severe liver disease and that has, in 
addition, a non-functional adaptive 
immune system. Both these qualities are 
necessary to allow successful 
repopulation of the diseased mouse liver 
by xenogeneic (human) hepatocytes. 
2. To devise a method to easily and quickly 
discriminate between negative, 
heterozygous and homozygous uPA-
SCID mice. Only the livers of 
homozygous animals can be successfully 
repopulated by human hepatocytes, 
provided that transplantation occurs 
within two weeks after birth. 
 
3. To transplant uPA+/+-SCID mice with 
freshly prepared primary human 
hepatocytes and analyze in detail the 
function, organization and morphology 
of these human hepatocytes in the 
chimeric mouse liver. 
 
4. To establish a chronic HBV and HCV 
infection in the human liver uPA-SCID 
mice, and to evaluate any possible effect 
of HBV and HCV infection on the 
function, organization and morphology 
of the human hepatocytes in the 
chimeric mouse liver. 
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BBRCA simple and rapid method to determine the zygosity
of uPA-transgenic SCID mice
P. Meuleman, P. Vanlandschoot, and G. Leroux-Roels*
Center for Vaccinology, Ghent University, De Pintelaan 185, Ghent 9000, Belgium
Received 7 July 2003Abstract
Successful transplantation of xenogeneic hepatocytes into uPA-transgenic SCID mice depends on the zygosity of the recipient
mice. Normally, the diﬀerence between homozygous and heterozygous animals is determined via a quantitative Southern blot. We
sequenced a part of the mouse genome that is eliminated upon integration of the transgene in the genome. Based on that sequence
we developed a multiplex PCR that allows the unambiguous discrimination of negative, heterozygous, and homozygous uPA-
transgenic SCID mice in a single day procedure. The speed of the procedure is an essential quality because transplantation of
xenogeneic hepatocytes into uPA-SCID mice should be done as soon as possible after birth.
 2003 Elsevier Inc. All rights reserved.
Keywords: uPA; SCID; Transplantation; Hepatocytes; Genotyping; PCR; Animal model; HBV; HCVInfections with the hepatitis B virus (HBV) and the
hepatitis C virus (HCV) are major health problems.
Worldwide chronic infections with HBV and HCV aﬀect
an estimated 350 and 170 million people, respectively,
and are causing over a million deaths annually [1]. In
the past two decades major progress has been made in
the prevention and treatment of these infections but the
search for more eﬃcacious, tolerable, and aﬀordable
treatments for both ailments as well as the quest for a
vaccine for HCV go on. This research is hampered by
the lack of simple in vitro culture systems and reliable
small animal models. Both HBV and HCV have a very
narrow tropism and only man and chimpanzee are
natural hosts of these viruses. Ethical and ﬁnancial
constraints limit the use of chimpanzees for biomedical
research in general and hepatitis-related research in
particular. Therefore a small animal model to study
HBV and HCV is badly needed. Mice or rats are the
prime candidates to create such a model but the strin-
gent tropism of HBV and HCV imposes that hepato-
cytes from man or chimpanzee are transferred in these
rodents. To allow the survival and expansion of xeno-* Corresponding author. Fax : +32-9-240-63-11.
E-mail address: geert.lerouxroels@Ugent.be (G. Leroux-Roels).
0006-291X/$ - see front matter  2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0006-291X(03)01388-3geneic donor hepatocytes in mouse or rat, the recipient
animal must provide an environment that is permissive
for the engraftment and the expansion of the liver cells.
Both criteria are met in an immune deﬁcient animal that
suﬀers from a severe liver disease. An animal with both
ailments is not available but can be created by crossing
the Alb-uPA transgenic mouse with a severely immune
deﬁcient mouse strain such as the nude (nu/nu), the
SCID/beige, or the RAG= mouse [2–4].
The Alb-uPA transgenic mouse, developed in 1990 by
Heckel et al. [5] to study plasminogen hyperactivation
and therapeutic protocols to prevent bleeding, contains
a tandem repeat of four murine uPA genes under the
control of an albumin promoter. The transgene over-
expression results in profound hypoﬁbrinogenemia and
accelerated hepatocyte death. Homozygous animals can
be rescued by transplantation of normal hepatocytes
from mouse [6,7], rat [2], woodchuck [3] or man [4,8]
which undergo rapid proliferation to replace the dying
hepatocytes. Transplants of hepatocytes from species
susceptible to hepatitis viruses can be infected with the
homologous hepatitis virus. This was ﬁrst accomplished
with woodchuck hepatocytes infected with the wood-
chuck hepatitis virus [3] and more recently with human
hepatocytes which could be infected with HVB [8] and
376 P. Meuleman et al. / Biochemical and Biophysical Research Communications 308 (2003) 375–378HCV [4]. Animals heterozygous for the uPA transgene
spontaneously lose the transgene at low frequency and
the ensuing ‘rescued’ mouse hepatocytes then repopulate
the liver [9]. For this reason heterozygous animals are
inferior recipients of xenogeneic hepatocyte grafts
compared to uPA homozygous mice. A rapid and reli-
able screening method to discriminate homozygous
from heterozygous transgenic mice is therefore impor-
tant for successful hepatocyte transplantation.
Initially this analysis of zygosity was performed by
quantitative comparison of the Southern blot signal
produced by probes for an endogenous gene and the
transgenic uPA gene [2]. This method is time consuming
and may generate ambiguous results. Rhim et al. also
noted that the insertion of the uPA transgene into the
mouse genome resulted in the deletion of endogenous
DNA at the integration site. These investigators picked-
up part of this sequence in plasmid p3371C and used this
as a probe to analyze the genotype of the animals. Using
a multiplex PCR based on this deleted endogenous se-
quence we designed a fast and reliable assay that allows
for the unambiguous determination of the zygosity of
the transgenic animals.Fig. 1. Map of plasmid p3371C containing a 2 kb part of the mouse
genome which has been deleted at the uPA transgene integration site.
The grey bar represents a known sequence which was used as the
starting point for the sequencing reactions. All unknown parts are
represented by a black bar. Enzymatic digestion of plasmid p3371C
with BamHI produces a 664 bp fragment which was previously used as
a probe for Southern blotting.Materials and methods
Breeding of the uPA-SCID mice. B6SJL-TgN(Alb1Plau)144Bri
mice were back-crossed on CBySmn.CB17-Prkdcscid mice. Both strains
were purchased from the Jackson Laboratories (Bar Harbor, Maine,
USA). Screening for the SCID background was done with an in-house
mouse IgM sandwich Elisa. Screening for the uPA transgene was done
by PCR, initially using the genotyping protocol described by the
Jackson Laboratories [10] and subsequently by the in-house method
described herein. All mice were bred and handled under speciﬁc
pathogen free (SPF) conditions in the SCID mouse facility of the
Department of Clinical Chemistry, Microbiology and Immunology,
Ghent University.
Ampliﬁcation, isolation, and sequencing of plasmid p3371C. ‘Top 10’
Escherichia coli cells (Invitrogen, Merelbeke, Belgium) were trans-
formed with plasmid p3371C (kindly provided by Dr. R. Palmiter) by
heat shock and grown overnight on LB-plates containing Ampicillin.
Resulting colonies were resuspended in LB-broth containing ampicillin
and incubated overnight at 37 C on a shaking platform. Cells were
centrifuged and plasmid was isolated with a HiSpeed Plasmid puriﬁ-
cation kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol.
Plasmid p3371C was then sequenced with an ABI 310 sequencer
(Applied Biosystems, Lennik, Belgium). Brieﬂy, 500 ng plasmid,
3.2 pmol primer, and 8 ll of the Terminator Ready Reaction Mix
(Applied Biosystems, Lennik, Belgium) were denatured at 90 C for
30 s. Annealing (15 s at 50 C) and polymerization (4min at 60 C) were
repeated for 25 cycles. The resulting product was then puriﬁed using
ethanol/sodium acetate precipitation and analyzed on the sequencer.
Isolation of mouse genomic DNA. Genomic DNA was extracted
from the mouse tail using the Nucleospin Tissue Kit (BD Biosciences
Clontech, Erembodegem, Belgium) according to the manufacturer’s
protocol. Brieﬂy, tissue from the mouse tail was digested with Pro-
teinase K at 56 C for 3 h or until the sample was completely lysed.
After addition of a chaotropic agent the samples were incubated for
10min at 70 C. Then ethanol was added and the sample was loaded on
the Nucleospin columns and centrifuged for 1min at 11,000g. Thecolumn containing the trapped DNA was washed twice to remove any
contaminating proteins and other cellular debris. After contaminants
were spun through the ﬁlter, nucleic acids were eluted in 100 ll of a
Tris-buﬀered solution. All enzymes and buﬀers were provided by the
manufacturer.
PCR. The PCR mix consists of 49 ll of thermophilic DNA poly-
merase buﬀer supplemented with 200 lM dNTPs (Roche Diagnostics,
Vilvoorde, Belgium), 2.5mM MgCl2, 1lM of each primer, and 2.5U
Taq DNA polymerase (Promega, Leiden, The Netherlands). To this
mixture 1 ll of mouse genomic DNA was added. The PCR cycling
proﬁle was as follows: an initial denaturation step of 5min at 94 C was
followed by 30 cycles of 30 s denaturation at 94 C, 30 s primer an-
nealing at 62 C, and 30 s primer extension at 72 C. To promote com-
pletion of partial extension, the samples were held at 72 C for 5min.
The samples were then stored on ice until analysis on a 2.5% agarose gel.Results
Sequencing of plasmid p3371C
Rhim et al. [2] noted that the insertion of the uPA
transgene into the mouse genome resulted in the deletion
of endogenous DNA at the integration site. These in-
vestigators picked up part of this sequence in plasmid
p3371C (Fig. 1) and used the BamHI-fragment of this
region as a probe for detection via Southern blotting.
The sequence of the deleted region was unknown but
part of the plasmid has been sequenced. Starting from
this known sequence we performed serial overlapping
sequence reactions until we completely elucidated the
code of the deleted region. All the known restriction
sites inside p3371C were used as positive markers during
sequencing. The BamHI fragment (underlined in Fig. 1),
previously reported to be approximately 550 bp long,
consisted of the following 664 bp long sequence:
Fig. 2. Multiplex PCR to determine the zygosity of uPA-transgenic
mice. Mouse genomic DNA isolated from an uPA= (lane 2), uPAþ=
(lane 3), and uPAþ=þ (lane 4) SCID mouse was used as a template. The
301 bp product is only present in negative and heterozygous animals.
The ampliﬁcation product from the transgene itself (151 bp) is only
absent in uPA= animals. A control ampliﬁcation product (226 bp)
appears in all samples. All samples were compared to DNA molecular
weight marker XIII (Roche, Vilvoorde, Belgium) run in lane 1.
P. Meuleman et al. / Biochemical and Biophysical Research Communications 308 (2003) 375–378 377GGATCCAGCTCAAGGGAAGGCTCCAAGGCCT
GACACTTACTGATGCTATGGTGAATATTCTCTC
ATTATAAGGGTGACAGAAATAAGAGAAGAAT
TTACATAAAAAGTAAAAGGAACAATGAGTTT
AAAGCAGGGGAGTGTATCCACAGTTGAAATA
ACTACATTTGTCCTTTAAAACGTGGAATTAATC
TTTCTCTTCTCTTGCCCTCTCACATCATTGAATT
TTGCATATTAAGATATTTGCATGTCCAAGAAG
CAGCTGTTTTTGGAAACTGTTATACTTTCTACT
TTTCTCCATTGCTACTCCAATTGCAAAGCACAT
CATCACACAATGTGTGAATGATCCAGAGAGTC
TGATAGCATATCTCCCAAAGGCAGTCATTTCA
AAACTCTAGACAATCACCATCTGCATTGCATG
GGCCAGATTTCAAACAGGAGGCTCAAAGTAG
ACTCTGGAAATTTGCTGCTGTTGGCTGTCTTG
AGGGTCTCAATTGTAGATTCATTTCTCCAAACT
ATTGGAAGAATCTATTAATAGGAAAATTAACT
TAAAAACACAATTGATAATACCTCTCTTTTTTT
TAAAGTGAATTGGACCTTGTGTATTGCACAGA
CAGTAAGTTATGAATTTACCAAGACTTAGAAT
TCCTGCAGCCCGGGGGATCC.
Multiplex PCR
Based on the sequence of the deleted region and the
nature of the transgene cassette we developed a multi-
plex PCR based on three primer pairs.
Primer pair one, ApoA#1: 50-CATCTCGCACCTTT
AGCCAT-30 and ApoA#2: 50-TCTCTGTGCCCAG
GAAGGTA-30, is a control primer pair amplifying a
226 bp region of the mouse Apolipoprotein A1-gene.
This is a control primer pair that should always result in
a positive signal.
Primer pair two, uPA#1: 50-CATCCCTGTGACCC
CTCC-30 and uPA#2: 50-CTCCAAAACCACCCCCC
TC-30, ampliﬁes a 151 bp region within the 30-untrans-
lated region of the human growth hormone which is
present in the transgene cassette. This PCR product
allows us to discriminate between uPA negative and
positive animals.
The ampliﬁcation product of primer pair three,
uPA#3: 50-TTCTCTTCTCTTGCCCTCTCACA-30 and
uPA#4: 50-TTGAGACCCTCAAGACAGCCA-30 (both
underlined in the above shown sequence), is 301 bp large
and is the product of a region within the mouse genome
which was deleted when the transgene had entered.
The combination of the three above-mentioned pri-
mer pairs allowed us to determine unambiguously the
zygosity of the transgenic animals. Fig. 2 clearly shows
that in case of a uPA negative animal (lane 2) two bands
appear (226 and 301 bp). Because the transgene is absent
the 151 bp band is not present. Lane 4 shows the PCR
products of a homozygous uPA animal. Here also only
two bands are visible, the 226 control band and the
151 bp transgene band. There is no ampliﬁcation prod-
uct from primer set uPA#3 and #4 because the trans-gene has been inserted in both copies of the
chromosome. In case of a uPA heterozygous animal
(lane 3) all three bands appear. Heterozygous animals
still have one chromosome left where the endogenous
DNA has not been deleted, explaining the presence of a
301 bp product. This clearly demonstrates the simplicity
and the clarity of this method.Discussion
The need for an aﬀordable, reliable, and ethically
acceptable in vivo model to study HBV and HCV in-
fections is high. The uPA-mouse model ﬁrst described in
1990 represents one of the most promising tools to
create this research tool. uPA-transgenic mice bred on
an immune incompetent background like SCID, SCID/
beige or RAG= allow a repopulation of the sick liver
by allogeneic and xenogeneic hepatocytes. When trans-
planted with human hepatocytes these animals become
susceptible to infections with HBV and HCV [4,8].
However, the outcome of the xenogeneic liver cell graft
in these animals is largely dependent on the zygosity of
the uPA transgene in these animals. Whereas the sur-
vival and expansion of the liver cell graft is poor in
heterozygous mice, an excellent and sustained engraft-
ment is observed in homozygous animals. Since the
success of the transplantation increases when the donor
hepatocytes are introduced early after birth, preferably
at the age of one to two weeks, a fast and unambiguous
method to determine the zygosity of the animals is very
important. We designed a one day method based on the
loss of a small portion of the mouse genome as a con-
sequence of the transgene integration. We have
sequenced this region and used selected fragments from
378 P. Meuleman et al. / Biochemical and Biophysical Research Communications 308 (2003) 375–378it as templates for a PCR. Together with two control
PCRs, one to detect the mouse Apo A1 region and one
to detect the uPA transgene itself, this single tube PCR
method meets the requirements mentioned above.
A search in the mouse genome database revealed
that a region homologous (p ¼ 8, 9E-58) to the deleted
sequence was located on chromosome 10, indicating
that this is the integration site. Finally it must be
stressed that with this method it is impossible to mis-
classify a negative or a heterozygous uPA mouse as a
homozygous animal because the screening method is
based on the absence of a signal. Any possible con-
tamination of uPAþ=þ chromosomal DNA with, e.g.,
wild type DNA will result in a heterozygous result. This
method thus prevents the occurrence of such errors and
as a consequence thereof the waste of very scarce and
valuable hepatocytes in erroneous transplantations.Acknowledgment
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Morphological and Biochemical Characterization of a
Human Liver in a uPA-SCID Mouse Chimera
Philip Meuleman,1 Louis Libbrecht,2 Rita De Vos,2 Bernard de Hemptinne,3 Kris Gevaert,4 Joe¨l Vandekerckhove,4
Tania Roskams,2 and Geert Leroux-Roels1
A small animal model harboring a functional human liver cell xenograft would be a
useful tool to study human liver cell biology, drug metabolism, and infections with
hepatotropic viruses. Here we describe the repopulation, organization, and function of
human hepatocytes in a mouse recipient and the infections with hepatitis B virus (HBV)
and hepatitis C virus (HCV) of the transplanted cells. Homozygous urokinase plasmin-
ogen activator (uPA)-SCID mice underwent transplantation with primary human hepa-
tocytes, and at different times animals were bled and sacriﬁced to analyze plasma and
liver tissue, respectively. The plasma of mice that were successfully transplanted con-
tained albumin and an additional 21 human proteins. Liver histology showed progres-
sive and massive replacement of diseased mouse tissue by human hepatocytes. These cells
were accumulating glycogen but appeared otherwise normal and showed no signs of
damage or death. They formed functional bile canaliculi that connected to mouse canal-
iculi. Besides mature hepatocytes, human hepatic progenitor cells that were differenti-
ating into mature hepatocytes could be identiﬁed within liver parenchyma. Infection of
chimeric mice with HBV or HCV resulted in an active infection that did not alter the
liver function and architecture. Electron microscopy showed the presence of viral and
subviral structures in HBV infected hepatocytes. In conclusion, human hepatocytes
repopulate the uPA/-SCID mouse liver in a very organized fashion with preservation
of normal cell function. The presence of human hepatic progenitor cells in these chi-
meric animals necessitates a critical review of the observations and conclusions made in
experiments with isolated “mature” hepatocytes. Supplementary material for this article
can be found on the HEPATOLOGY website (http://www.interscience.wiley.com/jpages/
0270-9139/suppmat/index.html). (HEPATOLOGY 2005;41:847-856.)
See Editorial on Page 703 Despite decades of research, the processes thatgovern liver development and regeneration areonly partially understood. A good understand-
ing of the mechanisms that play a role in these processes is
important because it may lead to new treatments of
human liver diseases. Several in vivo experimental con-
ditions have been used to study liver regeneration and
repair and the interaction of different cell types in these
processes. These include partial hepatectomy, admin-
istration of toxic compounds, or a combination of
both, and transgenic expression of certain proteins.1,2
In contrast to in vitro experiments, these approaches
raise fewer questions concerning the inﬂuence of arti-
ﬁcial matrices on the function and behavior of hepato-
cytes and other liver cell types.
Although these procedures have generated useful infor-
mation on rodent liver regeneration, stem cell activation,
and other processes, extrapolating these ﬁndings to the
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human situation would be imprudent. Therefore, a suit-
able small animal model to study human liver regenera-
tion is needed.
Successful transplantation of human hepatocytes into
mice or rats requires that the recipient animals do not
reject the graft and provide a “supportive niche” that pro-
motes engraftment and expansion of the liver cells.3 The
former condition can be attained by using recipient ani-
mals that have an inborn (genetic) or acquired (drug-
induced) immune deﬁciency. An environment that favors
hepatocyte engraftment is encountered in animals with
severe, chronic liver disease caused by the overexpression
of a “noxious” protein, as in the urokinase plasminogen
activator (uPA)-transgenic mouse.4
uPA transgenic mice backcrossed with “severe immune
deﬁcient” mice, such as Swiss athymic nude (nu/nu)
mice,5 recombination activation gene 2 (RAG-2) knock-
out mice,6,7 or SCID/beige mice,8 allow the engraftment
and repopulation by xenogeneic hepatocytes.
In 2 of these studies, hepatocytes of human origin were
used that could be infected with hepatitis B virus (HBV)7
or hepatitis C virus (HCV)8 after colonization. These 2
studies provided ample molecular and serological proof of
successful repopulation and infection of human hepato-
cytes. However, they paid less attention to the architec-
ture and organization of the human hepatocytes in this
xenogeneic environment.
We backcrossed the same Alb-uPA mouse on the im-
munodeﬁcient SCID mouse (CBySmn.CB17-Prkdcscid)
and examined with great care the repopulation, organiza-
tion, and functional behavior of the transplanted cells
using immunohistochemical, ultrastructural, and serolog-
ical methods. We infected chimeric animals with HBV
and HCV and examined the infected livers in a similar
fashion.
Materials and Methods
Breeding of the uPA-SCID Mice
B6SJL-TgN(Alb1Plau)144Bri mice were, at least 7
times, back-crossed on CBySmn.CB17-Prkdcscid mice.
Both strains were purchased from The Jackson Laborato-
ries (Bar Harbor, ME). Screening for the SCID
background was done with an in-house mouse immuno-
globulin M (IgM) sandwich ELISA. Genotyping of the
uPA-SCID mice was performed via a multiplex polymer-
ase chain reaction as described before.9 Human hepato-
cytes were transferred only in animals homozygous for the
uPA-transgene. The study protocol was approved by the
Animal Ethics Committee of the Faculty of Medicine of
the Ghent University.
Isolation of Human Hepatocytes and Transfer into
uPA-SCID Mice
Human liver specimens were collected from patients
undergoing a partial hepatectomy for the resection of
metastatic disease. All patients gave written, informed
consent, and all experiments were approved by the Ethical
Committee of the Ghent University Hospital. Hepato-
cytes were isolated from tumor-free sections via a collage-
nase digestion. Brieﬂy, tissue was ﬁrst perfused with Liver
PerfusionMedium (Invitrogen,Merelbeke, Belgium) and
then with Liver Digest Medium (Invitrogen). Subse-
quently, the digested liver was placed inHepatocyteWash
Medium (Invitrogen). The cell suspension released from
the liver was ﬁltered through a 70-m cell strainer (BD
Falcon, Erembodegem, Belgium) and hepatocytes were
separated from non-parenchymal cells via three low-speed
centrifugation steps (5 minutes, 50g). Cell viability, mea-
sured using the Trypan Blue exclusion test, generally ex-
ceeded 90%. One million hepatocytes were injected into
the spleen of 6- to 14-day-old uPA/-SCID mice. At
selected moments, mice were bled, and plasma was stored
at70°C until further analysis.
Quantiﬁcation of Human Albumin
Human albumin in mouse plasma was measured using
an in-house sandwich ELISA. Maxisorp Immunoplates
(Nunc, Roskilde, Denmark) were coated with goat anti-
human albumin antibodies (Bethyl Laboratories, Mont-
gomery, TX). After blocking and washing, diluted
samples or calibrators were added, and human albumin
bound to the plate was detected with a HRP-conjugated
goat-anti-human albumin antibody (Bethyl Laborato-
ries).
HBV andHCV Infection. Five weeks after transplan-
tation, chimeric mice were infected with either HBV or
HCV. As a source of infectious HBV, serum from a pa-
tient suffering from a chronic HBV infection (hepatitis B
surface antigen [HBsAg], hepatitis B e antigen
[HBeAg], and anti-HBs) with a high HBV DNA con-
tent (107 cop/mL) was used. One hundred microliters of
this serum was injected intraperitoneally. To induce an
HCV infection, serum from an acutely infected chimpan-
zee was used (gift from Dr. J. Bukh). Twenty microliters
of this serum (strain J4, 3.16 104 cop/mL) was injected
intraperitoneally.
Detection and Quantiﬁcation of Viral DNA/RNA
and Proteins
HBV DNA and HCV RNA levels were quantiﬁed us-
ing the Cobas AmplicorHBVMonitor test and the Cobas
Amplicor HCV Monitor test v2.0 (Roche Diagnostics,
Mannheim, Germany), respectively. HBsAg and HBeAg
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were determined with the Axsym HBsAg V2 and the Ax-
sym HBe 2.0 system (Abbott, Chicago, IL), respectively.
The antigen levels were expressed as Signal/Noise values.
Detection of Human Proteins in Chimeric Plasma
Fifty microliters unfractionated mouse EDTA plasma
was used for a non-gel proteome analysis. The proteins
were digested with trypsin, and combined fractional diag-
onal chromatography (COFRADIC™) was used to iso-
late the amino terminal peptides out of this complex
peptide mixture.10 The isolated peptides were further an-
alyzed by LC-MS/MS using a Q-TOF1 mass spectrome-
ter (Micromass UK Limited, Cheshire, UK) and the
obtained MS/MS spectra were linked to peptide se-
quences stored in a tailor-made database (http://www-
.proteomics.be/bioinfo/lm/dbtoolkit) containing human
and murine full and sequentially ragged protein sequenc-
es,10 using the MASCOT database search engine (http://
www.matrixscience.com). Peptides identiﬁed by a
MASCOT score that exceeded the identity threshold
score of MASCOT at the 95% conﬁdence level were con-
sidered as positively identiﬁed.
uPA-SCID Mouse Livers Used for Histopathological
Evaluation
The livers of 5 uPA-SCIDmice were used for extensive
histological evaluation. The liver of a 2-week-old non-
transplanted, noninfected uPA-SCID mouse was used as
a reference. Two mice were killed 36 and 78 days after
transplantation, respectively. One HBV- and one HCV-
infected chimeric animal was killed 25 days and 41 days
after infection, respectively.
Histochemistry and Immunohistochemistry
A detailed description of all histochemical procedures
can be consulted online at the HEPATOLOGY website
(http://interscience.wiley.com/jpages/0270-9139/suppmat/
index.html).
Results
Plasma Analysis of Chimeric Mice
The success of human liver cell engraftment and ex-
pansion in the transplanted uPA/ transgenic SCID
mice was evaluated by quantifying human albumin in
mouse plasma at regular intervals. Figure 1 shows that
human albumin concentrations reached a median level of
3 mg/mL by week 4 after transplantation and increased to
7 mg/mL by week 7. Thereafter the albumin levels re-
mained quite constant until at least 14 weeks after trans-
plantation.
To evaluate whether the transplanted human hepato-
cytes were functional and behaved like mature, normal
hepatocytes, we analyzed the human proteome of the
mouse plasma. Seven weeks after transplantation, plasma
from a successfully transplanted mouse was analyzed by
COFRADICTM. We decided to use this particular pro-
teomics method because an a priori in silico study indi-
cated that alike plasma proteins of different origin (mouse
and human) mainly had sequence differences at their N-
Fig. 1. Human albumin concentrations in human hepatocyte uPA-
SCID mice at different times after hepatocyte transplantation. This box-
and-whisker plot represents the median and interquartile ranges of
human albumin levels (mg/mL) in the plasma of 21 uPA-SCID mice
transplanted with human hepatocytes.
Table 1. Proteome Analysis of Chimeric Mouse Plasma
Protein
Accession
Number
1 Afamin precursor P43652
2 Alpha-1 antitrypsin P01009
3 Alpha-1-antichymotrypsin precursor P01011
4 Alpha-2-HS-glycoprotein precursor P02765
5 Apolipoprotein A-II precursor P02652
6 Apolipoprotein E precursor P02649
7 Complement C2 precursor P06681
8 Complement C4b-binding protein alpha chain precursor P04003
9 Complement C3 precursor P01024
10 Complement factor B precursor P00751
11 Chloride channel protein 7 P51798
12 Eukaryotic translation initiation factor 4 gamma Q04637
13 Fibrinogen alpha/alpha-E chain precursor P02671
14 Fibrinogen beta chain precursor P02675
15 Inter-alpha-trypsin inhibitor heavy chain H3 precursor Q06033
16 Kininogen precursor P01042
17 Prostaglandin F2 receptor negative regulator precursor Q9P2B2
18 Protein-tyrosine phosphatase delta precursor P23468
19 RNA-binding protein 5 P52756
20 Serum albumin precursor P02768
21 Synaptobrevin-like protein 1 P51809
22 Zinc ﬁnger protein 70 Q9UC06
NOTE. Overview of the 22 human proteins detected in the plasma of trans-
planted uPA-SCID mice using a mass spectrometric technique. Most of these
proteins are produced exclusively or nonexclusively by hepatocytes. However, in
this context, hepatocytes can be the only source. Some proteins are generally
regarded to have a membrane or nuclear localization and are probably remnants
of dying hepatocytes. Additional information on the above mentioned proteins can
be retrieved via the corresponding SwissProt (http://www.expasy.ch) accession
numbers.
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terminal extremity. We unambiguously identiﬁed 22 dif-
ferent human proteins in this mouse plasma (Table 1).
Besides these 22 proteins of human origin, several other
plasma proteins were detected that were either speciﬁcally
frommurine origin or of which the identiﬁed peptides did
not allow discrimination between a human or murine
origin (data not shown).
Histological Studies of Uninfected Chimeric Livers
Chimeric uPA-SCID Mice 36 and 78 Days After
Transplantation. Massive numbers of mature human
hepatocytes were identiﬁed in the livers of transplanted
mice. These could easily be discriminated from their mu-
rine counterparts by their larger size and the peculiar ap-
pearance of their cytoplasm (Fig. 2A). The human
hepatocytes were somewhat swollen and had a rareﬁed
cytoplasm with wisps and small clumps of eosinophilic
material in an otherwise empty-appearing cytoplasm. The
cell membranes appeared mildly thickened. The empty-
appearing areas of the cytoplasm on hematoxylin and eo-
sin staining corresponded to areas of glycogen storage, as
shown by periodic-acid-Schiff (PAS) staining (Fig. 2B).
The stainings for albumin, mitochondria, pan-cytokera-
tin, and CK18 conﬁrmed the human origin of these hepa-
Fig. 2. Histology of a chimeric liver. (A) Hematoxylin and eosin staining easily allows identiﬁcation of the human hepatocytes (H) within mouse
(M) parenchyma. The cytoplasm of the human hepatocytes has an unusual pale and granular appearance, resembling the morphology of hepatocytes
in glycogen storage diseases. (B) PAS staining shows that, in contrast to the negative mouse hepatocytes, glycogen accumulation is restricted to the
cytoplasm of the human hepatocytes. (C) Staining for human albumin unveils the human origin of these pale hepatocytes. Several ceroid
macrophages (arrows) also can be seen within mouse parenchyma. Despite a low background staining of the lumen of sinusoids and larger blood
vessels (arrowheads), mouse hepatocytes never stain positive for human albumin. Clusters of human hepatocytes can also be visualized with
antibodies speciﬁc for human mitochondria (D), human pan-cytokeratin (E), and human CK18 (F). Human hepatic progenitor cells (black arrows)
and intermediate hepatocyte-like cells (white arrow) were also observed (F). (Original magniﬁcations: A, B, D, and F, 400; C and E, 200)
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tocytes (Fig. 2C-F), and the cytoplasmic staining pattern
was also in wisps and small clumps, indicating that the
organelles were displaced and clumped together by the
excessive glycogen accumulation. The morphological fea-
tures of the hepatocytes are identical to themorphology of
hepatocytes in all glycogen storage diseases, except type
IV.11 This was conﬁrmed by comparing our present ﬁnd-
ings with 4 archival clinical liver biopsy specimens from
patients with glycogenosis and with descriptions of gly-
cogenosis in the literature.11
Apart from this massive glycogen storage, the human
hepatocytes appeared quite “healthy” and showed no
signs of damage or degeneration. This is in sharp contrast
with the extensive damage of mouse liver parenchyma,
where ceroid macrophages formed large clusters (Fig. 3A)
and focal conﬂuent necrosis of mouse hepatocytes was
visible, both indicating moderate to severe hepatocyte
damage and loss. Occasionally, human hepatocytes con-
tained a mitotic ﬁgure, and steatosis was minimal.
In the liver sections of the 44-day-old mouse, also two
red foci were seen. Hepatocytes in red foci were larger
than the surrounding mouse hepatocytes. The red foci
contained no ceroid macrophages and were devoid of oval
cells. The foci were rather sharply demarcated and slightly
compressed surrounding mouse parenchyma. These ﬁnd-
ings indicate that the loss of transgene expression in the
cells of these foci leads to disappearance of cell damage
and to a growth advantage compared with transgene-ex-
pressing parenchyma. Interestingly, most hepatocytes
within the red foci had a cytoplasm that was partly posi-
tive on PAS staining, whereas surrounding, transgene-
expressing hepatocytes were generally PAS negative.
Fig. 4. Human hepatic progenitor cells (HPCs) were identiﬁed in the
livers of chimeric mice at the interface between human (H) and mouse
(M) hepatocytes. (A) HPCs are small cells with scanty cytoplasm and a
relatively large oval nucleus and strongly immunoreactive for pan-cyto-
keratin (black arrows). Intermediate hepatocyte-like cells (white arrows)
could be recognized as polygonal cells with a size and immunophenotype
intermediate between that of HPCs and hepatocytes. Some mature
hepatocytes display a decreased and granular staining pattern, possibly
as a consequence of the glycogen accumulation. (B) Staining with an
anti-CK7 antibody conﬁrms the presence of both these cell types, which
are surrounded by mature hepatocytes that do not stain for CK7. Staining
of the liver of a non-transplanted uPA-SCID mouse with anti–pan-
cytokeratin (C) and anti-CK7 (D) antibodies served as a negative control.
(Original magniﬁcations: A and B, 400; C and D, 100)
Fig. 3. Five weeks after transplantation, approximately one fourth of
liver parenchyma is repopulated by pale human hepatocytes that are
organized in nodules. (A) Ceroid macrophages are restricted to the areas
occupied by diseased mouse hepatocytes, as shown by PAS staining.
(B) Staining with a polyclonal anti-CEA antibody clearly shows connec-
tions between mouse canaliculi (arrows) and canaliculi that are some-
what bigger and that are formed by the surrounding human hepatocytes
(middle). (C) Staining of the liver with an antibody speciﬁc for human
Ki-67 showed that proliferating human hepatocytes were preferentially
localized at the edge of the nodules. The scarce presence of sinusoids
lined by spindle-shaped human endothelial cells was visualized by
staining for human CD34 (D). (Original magniﬁcations: A, 100; B,
400; C and D, 200)
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The transversal section through the liver of the 44-day-
old mouse showed that the human hepatocytes were or-
ganized into approximately 80 nodules, which were well
demarcated with sometimes a singular hepatocyte inﬁl-
trating into the surroundingmouse liver parenchyma. Be-
tween 10 and 90 human hepatocytes were present in the
section through the nodules. Between the nodules, there
were occasionally singular human hepatocytes or small
groups of, maximally, 5 hepatocytes. Overall, 25% of the
liver parenchyma consisted of human cells. In contrast to
mouse liver parenchyma, these nodules rarely contained
ceroid macrophages (Fig. 3A). Only 5 of approximately
80 nodules contained 1 or 2 ceroidmacrophages that were
not located in the center of the nodule, suggesting that
these ceroid macrophages are rather transiting than resi-
dent. There was no preferential localization of the human
hepatocyte nodules in the liver; they were observed as well
periportally as around the centrolobular vein. Areas of
conﬂuent necrosis of mouse liver parenchyma always con-
tained human hepatocyte nodules at their periphery.
As shown in Fig. 3B, human hepatocytes formed nor-
mal canalicular structures that connected to mouse cana-
liculi that were smaller. Ki-67 staining showed that 18%
of human hepatocytes were proliferating, and these cells
were preferentially localized at the edge of the nodules
(Fig. 3C).
In the liver of the 90-day-old mouse, human hepato-
cytes no longer formed nodules but appeared as large areas
separated from each other by small areas of mouse liver
parenchyma. Overall, the human hepatocytes represented
66% of the mouse liver parenchyma. Again, human areas
contained very few ceroidmacrophages; 6% of the human
hepatocytes were Ki-67 positive and showed no preferen-
tial distribution. In both mice, areas consisting of human
hepatocytes contained scarce mouse oval cells, at numbers
that appeared lower than in mouse liver parenchyma. Si-
nusoids lined by human endothelial cells were present but
rare (Fig. 3D).
Fifteen nodules in the 44-day-old mouse contained, in
addition to mature hepatocytes, 1 to 5 human hepatic
progenitor cells (Figs. 2F and 4A-B) that were recognized
on the basis of their morphology and immunohistochem-
ical phenotype.12 Hepatic progenitor cells were present
both in the center and at the edge of the nodules. Reactive
bile ductules containing human cells were not observed.
Occasionally, human intermediate hepatocyte-like cells
were seen neighboring human hepatic progenitor cells
located at the human–mouse parenchymal interface. Sim-
ilarly, singular human hepatic progenitor cells and inter-
mediate hepatocyte-like cells were focally present at the
human–mouse parenchymal interface in the 99-day-old
mouse liver. In this animal, one reactive bile ductule with
a dilated lumen was completely lined by human cells.
We never observed dysplasia or malignant transforma-
tion of human hepatocytes, nor tumor cells of the type for
which the patient underwent liver surgery.
Ultrastructural Analysis. Human hepatocytes had a
normal canalicular and sinusoidal pole and showed no
abnormalities, besides the glycogen accumulation. He-
patic progenitor cells of types I (most undifferentiated
type) and III (having some hepatic features)13,14 were
present in the chimeric liver. Some progenitor cells
showed signs of damage, indicating a mouse origin, and
were forming a chimeric canalicular structure with a hu-
man hepatocyte (Fig. 5A). Healthy type III hepatocyte-
like cells formed part of a canaliculus with adjacent
mature human hepatocytes. The absence of any damage
strongly suggests that these cells were of human origin
(Fig. 5B).
In Vivo HBV Infection
Five weeks after successful transplantation with cells
from 3 different donors, 9 animals were infected with
HBV. Twenty days later, mouse plasma was analyzed for
viral proteins and HBV DNA. All animals showed signs
of infection, but in 3 mice the serum markers were rather
low, namely, an HBsAg level of 52.5 S/N, HBeAg below
the detection limit, and HBV-DNA levels of approxi-
mately 2 105 cop/mL. These values changed very little
until the animals died. In the remaining 6 mice, the HBV
infection was highly replicative, with HBsAg and HBeAg
levels of, on average, 1,130 S/N and 663 S/N, respec-
tively, andHBV-DNA levels exceeding 2 1010 cop/mL.
Twenty-ﬁve days after HBV inoculation, 1 animal was
sacriﬁced for histological analysis of the liver. Human
hepatocytes were loaded with glycogen and formed large
areas occupying 87% of mouse liver parenchyma. No
other signs of damage or cell loss were observed. No hu-
man hepatocytes had a “ground glass” appearance. Al-
most all human hepatocytes had a granular cytoplasmic
staining for HBsAg, and many were also strongly positive
near the cell membrane (Fig. 6A). Figure 6B shows that a
large majority of the human hepatocytes displayed a
strong nuclear and a moderate cytoplasmic staining for
hepatitis B core antigen.
At the interface between red foci and human hepato-
cytes, there was no sharp border, no compression, and the
two cell types appeared to inﬁltrate each other’s areas.
These ﬁndings suggest that the human hepatocytes and
the “transgene-free” mouse hepatocytes proﬁt equally
from the growth stimuli present.
Ultrastructural analysis of the liver of anHBV-infected
mouse showed that the nuclei of numerous hepatocytes
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contained noncoated virus particles with a diameter of 21
to 24 nm corresponding to HBV core particles. In the
cisternae of the endoplasmic reticulum, 1 or 2 longitudi-
nally transsected tubules and cross-sectioned spheres of
HBsAg were present. In some cisternae, core particles
surrounded by a clear halo and a dark ring of approxi-
mately 40 nm in size, corresponding to Dane particles,
were observed (Fig. 6C).
In Vivo HCV Infection
uPA/-SCID mice, untransplanted or successfully
transplanted with human hepatocytes, were infected with
HCV of genotype 1b. In untransplanted but HCV-in-
jected animals, HCV RNA was never detected. Two
weeks after infection, the plasma of transplanted animals
contained  2.35  106 IU/mL HCV RNA. The viral
load increased over time and reached levels of up to 8.1
107 IU/mL by week 10. Plasma from these animals was
used to infect other transplanted mice. Three microliters
infectious mouse plasma (containing approximately 105
IU HCV RNA) sufﬁced to establish a new infection. An-
imals infected in this way also displayed the same massive
increase in viral load. Recalculating all viral titers with
respect to the blood volume of the infected animals, and
taking into account the serial infections, we achieved a
109-fold ampliﬁcation of viral RNA. The in vivo HCV
infection could be maintained for at least 4 months.
Six weeks after infection, one HCV-infected animal
was sacriﬁced for histological examination. Seventy-seven
percent of liver parenchyma consisted of healthy human
glycogen accumulating hepatocytes, which formed large
areas separated from each other by small areas of diseased
Fig. 6. Immunohistochemical and ultrastructural analysis of chimeric
livers infected with HBV (A-C) or HCV (D). HBsAg-speciﬁc staining (A)
shows a granular positivity of the cytoplasm with accentuation near the
membrane, whereas hepatitis B core antigen–speciﬁc staining (B) shows
a strong nuclear and mild cytoplasmic staining. Liver sections from
uninfected chimeric mice were used as controls and were always nega-
tive (insets). Using electron microscopy (C), longitudinally cut HBsAg
tubules (thin arrows) as well as complete Dane particles (thick arrows)
could be observed in the cisternae of the endoplasmic reticulum. Human
hepatocytes infected with HCV could be revealed with antibodies recog-
nizing the HCV E2 protein (D). (Original magniﬁcations: A, B, and insets,
200; C, 77,000; D, 400)
Fig. 5. Ultrastructural analysis of the chimeric mouse liver. (A) Two
hepatic progenitor cells (P) and a small rim of a third progenitor cell are
obvious. Remark the thin basement membrane surrounding the progen-
itor cells (thin arrow). Two progenitor cells present signs of cytoplasmic
damage (arrow), indicating a murine origin. The progenitors form part of
a bile canaliculus (C) with a large mature human hepatocyte (H) showing
unusual glycogen storage (asterisk). The observation of chimeric bile
canaliculi supports our immunohistochemical analysis showing connec-
tions between mouse and human bile canaliculi. A stellate cell (open
arrow) is apparent in the Disse space as well as collagen ﬁbers (cf). (B)
A type III progenitor cell (P) is forming a bile canalicular structure (C) with
two adjacent human hepatocytes (H). The absence of any damage within
the cytoplasm of this progenitor cell suggests a human origin. A small
processus of a stellate cell (open arrow) can be seen in the Disse space.
(Original magniﬁcations: A, 12,000; B, 24,000)
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mouse hepatocytes. Almost all human hepatocytes
showed a granular cytoplasmic staining with the anti-
HCV E2 antibody (Fig. 6D). This granular staining pat-
tern has always been observed in liver biopsy specimens
from chronic HCV patients.15,16 As in the livers of non-
infected and HBV infected mice, singular human hepatic
progenitor cells and intermediate hepatocyte-like cells
were focally present at the human–mouse parenchymal
interface. Moreover, some of the ductular clusters con-
sisted of ductules that were lined by a mixture of bile
ductular cells of mouse and human origin. Despite careful
ultrastructural analysis, no viral particles or viral tubular
structures could be retrieved.
Discussion
Recently, two groups independently created chimeric
mice harboring human hepatocyte grafts and successfully
induced HBV7 and HCV8 infections in these animals.
Both groups provided convincing evidence for solid he-
patocyte engraftment and active viral replication but paid
less attention to the functional integrity and structural
organization of the transplanted hepatocytes in the xeno-
geneic environment. We wanted to ﬁll this gap and
present here a detailed description of the functional and
morphologic characteristics of the chimeric liver before
and during active HBV and HCV infections.
To evaluate the human hepatocyte graft-take and ex-
pansion in uPA/-SCIDmice, the human albumin con-
centration in mouse plasma was monitored at regular
intervals. In successfully transplanted mice, the albumin
level reached a plateau value of approximately 7 mg/mL
(median value) around week 7, and this level remained
unchanged in the weeks that followed. Although the hu-
man albumin level is a reliable marker of the integrity and
functional status of the human hepatocytes, we per-
formed a proteomic analysis10 of the mouse plasma and
demonstrated the presence of 21 additional and less abun-
dant human proteins. Most of these proteins are known
plasma proteins synthesized by the liver. Apart from these
“classical” human plasma proteins, some human proteins
with a membrane or nuclear localization could also be
detected. Their presence in the plasma may be due to
membrane turnover or release from dying hepatocytes.
The presence of these atypical plasma proteins in our
chimeric mouse plasma is not unexpected because such
proteins are also found in the plasma of healthy blood
donors.17,18
The integrity and spatial organization of the human
hepatocytes in the chimeric liver was also examined by
histology. Early after engraftment, the human hepato-
cytes appeared as sharp nodules that expanded and be-
came blurred as time went on and occupied up to 87% of
liver parenchyma. Although the human hepatocytes re-
sided in a xenogeneic environment, they showed no signs
of damage or degeneration and appeared to have remod-
eled the diseased mouse liver in a progressive and orga-
nized fashion. We also demonstrated connections
between human and mouse canaliculi. These chimeric
ducts must be open and functional, because no signs of
cholestasis were found.
The only, but striking, abnormality of the transplanted
liver cells was the abundant accumulation of glycogen.
The cause of this aberrant polysaccharide accumulation
remains unclear, but this phenomenon is most likely at-
tributable to inappropriate recognition of murine signals
(e.g., hormones) by human hepatocytes. This feature is
independent of HBV or HCV infection, and it is proba-
bly not just a compensation for the absence of glycogen in
the diseased mouse hepatocytes because mouse hepato-
cytes in red foci have a normal appearance and normal
intracellular glycogen content. The overall appearance of
the chimeric mouse and the aspect of the liver cells in
histology studies suggest that this metabolic disturbance
has a negative effect on the animal as a whole and the
grafted hepatocytes in particular. This is conﬁrmed by the
fact that uPA/ mice transplanted with human hepato-
cytes never looked as healthy as their uPA/ -SCID lit-
termates that were “rescued” with a murine hepatocyte
graft. Although the latter developed normally and after a
fewweeks could not be discriminated from uPA/ SCID
mice (P. Meuleman, unpublished data, 2004), the former
survived but suffered from severe growth retardation and
failure to thrive. This can be a result of the observed
glycogenosis, but it is plausible that also other biochemi-
cal pathways may not function optimally, possibly be-
cause of communication failure betweenmouse ligands or
receptors and their human counterparts. The inconsis-
tency between the albumin levels (approximately 20% of
normal values) and tissue analysis (repopulation up to
87%), again indicates suboptimal communication be-
tween human cells and the mouse environment. These
observations deserve further study considering the grow-
ing interest in transplantation of xenogeneic liver tissue or
hepatocytes to treat hepatic failure in humans.
Once human hepatocytes had stably engrafted in the
uPA/ -SCID host, these animals could indeed easily be
infected with hepatotropic viruses. After an infection with
HBV, we could detect high levels of HBsAg, HBeAg, and
HBV DNA in the mouse plasma. The concentrations of
HBsAg and HBV DNA observed in our experiments
largely exceeded those reported by Dandri et al.,7 and
these investigators were unable to ﬁnd HBeAg. This may
be linked to the inferior hepatocyte engraftment (5%-
15%) obtained in heterozygous uPA animals. The immu-
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nohistochemical staining pattern of the infected mouse
liver corresponds very well to that observed in chronic
hepatitis B patients during the viral tolerance/replication
phase.19 However, the proportion of HBV-positive hepa-
tocytes seen in our mouse model is considerably higher
than routinely observed in biopsy specimens of such pa-
tients.19 This result correlates well with the extremely
high amounts of HBV DNA values found in the infected
mouse plasma.20,21 We were also able to visualize subviral
HBV particles and infectious Dane particles inside the
human hepatocytes of our chimeric mice.
Infections of chimeric mice with HCVwere as success-
ful as theHBV infections. Viral RNA could be detected in
the plasma of all infected mice (n  7), and HCV RNA
levels were much higher than those routinely observed
during chronic HCV infections in humans. High viremia
of this magnitude can be observed, however, when HCV-
infected patients are undergoing immune suppressive
therapy after transplantation.22-24 Histological analysis of
the liver of an HCV-infected mouse showed that most
human hepatocytes were infected. Despite careful elec-
tron microscopic analysis, no viral or subviral particles
could be identiﬁed in human hepatocytes. This is not
surprising, because these structures are also rarely seen in
biopsy specimens of chronically infected patients.13 How-
ever, sequential infections proved the presence and de
novo production of infectious HCV particles.
Although most human hepatocytes were infected with
either HBV or HCV and although the viral replication
was high, these viruses had no negative effects on the
function, survival, or proliferation of the infected hepato-
cytes. This ﬁnding is in agreement with the current view
that hepatocyte damage in patients with active chronic
viral hepatitis is induced by the immune system rather
than the virus itself.25 Whether long-term infections with
HBV or HCV have any negative or cytopathic effect on
the transplanted human hepatocytes is currently being
explored.
A ﬁnal, but very important, observation is the fact that
the chimeric mouse liver contained human hepatic pro-
genitor cells in addition to mature human hepatocytes. In
close association with the human progenitor cells we no-
ticed human intermediate hepatocyte-like cells, which
suggests that the progenitor cells are differentiating to-
ward mature hepatocytes through this intermediate stage.
Occasionally, human hepatic progenitors were observed
within murine ductular structures, illustrating the bipo-
tential characteristics of these cells. The presence of pro-
genitors in all the analyzed hosts indicates that these cells
must have been present in the injected cell suspensions.
This report suggests the presence of progenitor cells in a
cell suspension obtained via a widely used technique for
the isolation of hepatocytes. This observation is impor-
tant because certain qualities attributed to mature hepa-
tocytes, such as the capacity to trans-differentiate into
biliary cells26,27 and the extensive potential to repopulate
damaged liver,28,29 might be related to the presence of
these progenitor cells. Data obtained in previous studies
using so-called hepatocyte suspensions should at least be
critically reviewed. The number of progenitor cells in the
hepatocyte graft and their role in the repopulation of the
diseased liver is being examined.
In conclusion, the uPA/ -SCIDmouse easily accepts
human hepatocyte grafts, and the chimeric animals thus
created represent a successful small animal model to study
HBV and HCV infections and new therapeutic com-
pounds to treat these infections. In addition, this model
also may prove useful for the study of metabolic aspects of
xenogeneic transplantation and the hepatic engraftment,
maturation, and differentiation of stem cells of different
origins.
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Additional Materials and Methods. 
(http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.html) 
 
 
Preparation of tissues for histological study. 
A part of each fresh mouse liver was snap-frozen in 
liquid nitrogen-cooled isopenthane and stored at -70˚ 
C until further use. Another small part of the fresh 
liver was fixed overnight in 2.5% glutaraldehyde, 0.1 
M phosphate buffer followed by a 1 hour 
postfixation in 1% osmiumtetroxide, 0.1 M 
phosphate buffer for standard ultrastructural 
evaluation. After fixation, the samples were 
dehydrated in graded series of alcohol and embedded 
in epoxy resins. Ultrathin sections were cut, stained 
with uranyl acetate and lead citrate and examined 
using a Zeiss EM 10 electron microscope. The 
remainder of the liver and the spleen was fixed in 
B5-fixative for approximately 3 hours. In some 
cases, a part of the liver was fixed in 6% formalin. 
After fixation, the tissue was embedded in paraffin. 
 
Histology. 
Four µm-thick sections from paraffin-embedded 
liver tissue were stained with hematoxylin and eosin 
(H&E) for overall histopathological evaluation, 
periodic-acid-Schiff (PAS) to assess cellular 
polysaccharide deposits, PAS after predigestion with 
amylase (PASα) to detect ceroid macrophages, 
Sirius red for fibrosis and Hall-Van Gieson to detect 
bilirubinostasis (1-3). Five µm-thick sections from 
frozen liver tissue were fixed in acetone for 10 min 
after overnight drying, followed by an oil red O 
(ORO) staining for the evaluation of steatosis (2). 
Frozen tissue was used for assessment of fat (3). 
 
Immunohistochemistry. 
Four µm-thick sections were deparaffinized and 
rehydrated. For most stainings, the sections were 
heated in a microwave oven in citrate buffer, pH 6.0 
for 5 min at 500 Watt, followed by 20 min at 
‘defrost’ setting and the slides were then cooled at 
room temperature for 15 min. This antigen retrieval 
method was used before the incubation with most of 
the primary antibodies, except for those against 
albumin, mitochondria, carcinoembryonic antigen 
(CEA) and hepatitis B surface and core antigen 
(HBsAg and HBcAg), since we always obtain 
adequate staining without antigen retrieval when 
performing immunohistochemistry with these 
antibodies on routine clinical liver biopsies 
processed in an identical fashion as the samples in 
the present study. 
Incubation with the primary antibodies was 
performed at room temperature for 30 min, followed 
by three washes with PBS. The different human cell 
types within the mouse livers were studied with a 
polyclonal rabbit anti-human antibody against 
albumin (dilution 1/200, Dako, Denmark) and 
monoclonal mouse anti-human antibodies against 
mitochondria (clone 113-1, dilution 1/100, 
Chemicon, USA), pan-cytokeratin (clone KL1, 
dilution 1/50, Immunotech, USA), cytokeratin 8 
(CK8) (clone 35betah11, dilution 1/100, Dako), 
CK18 (clone CD10, dilution 1/10, Dako), CK7 
(clone OV-TL12/30, dilution 1/50, Dako), CK19 
(clone RCK108, dilution 1/20, Dako), vimentin 
(clone V9, dilution 1/30, Dako), and CD34 (clone 
My10, dilution 1/10, Becton Dickinson, USA) and 
Ki67 (clone Mib-1, dilution 1/100, Dako). Albumin 
is a well-established marker of hepatocytes while 
vimentin is a marker of all mesenchymal liver cells 
(i.e. (myo)fibroblasts, hepatic stellate cells and 
endothelial cells (4), while CD34 only stains 
endothelial cells (5). The different anti-keratin 
antibodies were used to detect all human epithelial 
cells. Their staining intensity and pattern and the 
morphology of the positive cells makes it possible to 
recognize mature hepatocytes, bile duct epithelial 
cells and cells of the progenitor cell compartment 
(i.e. hepatic progenitor cells, intermediate 
hepatocyte-like cell and reactive ductular cells) (6). 
The monoclonal mouse anti-human antibody Ki67 
(clone Mib-1, dilution 1/100, Dako) was used to 
assess the proliferative status of human hepatocytes, 
since it stains all nuclei that are not in the G0-phase 
(7). Expression of viral proteins was assessed using a 
polyclonal rabbit antibody against HBcAg (dilution 
1/200, Dako) and monoclonal mouse antibodies 
against HBsAg (clone H1, dilution 1/80, ForLab, 
Belgium) and HCV E2 (clone IG222, 1/50, 
Innogenetics, Belgium). Immunohistochemical 
analysis of liver tissue with the antibody IG222 is a 
specific and sensitive method to detect HCV 
infection (8). To evaluate both human and mouse 
cells, polyclonal rabbit anti-human antibodies against 
CEA (dilution 1/300, Dako) were used. The 
polyclonal antibody against carcinoembryonic 
antigen (pCEA) is a marker for canaliculi (9). For all 
mouse monoclonal antibodies, the secondary 
antibody was undiluted anti-mouse Envision (Dako). 
The secondary antibody was applied for 30 min, 
  
followed by a wash in three changes of phosphate-
buffered saline (PBS) for 5 min. A second step was 
not used for the anti-albumin antibody, since this 
antibody is peroxidase-labeled while the others are 
unlabeled. For the rabbit polyclonal antibodies 
against CEA and HBcAg, the second and third step 
consisted of swine anti-rabbit immunoglobulins and 
rabbit peroxidase-antiperoxidase (both from Dako) 
diluted in phosphate-buffered saline (PBS), pH 7.2, 
containing 10% normal human serum. The 
incubations were carried out for 30 min at room 
temperature and each incubation step was followed 
by a wash in three changes of PBS for 5 min. For all 
stainings, the brown reaction product was developed 
with the use of 3,3-diaminobenzidine 
tetrahydrochloride and H2O2. The sections were 
counterstained with hematoxylin. 
Sections wherein the incubation with the first and/or 
secondary/tertiary antibodies were omitted and fully-
processed sections of liver tissue from 
untransplanted animals served as controls. Positive 
controls consisted of selected liver biopsies from the 
clinical routine that were stained with these 
antibodies. 
 
Quantitative assessment of the different human 
liver cell types present in uPA-SCID liver. 
To measure the fraction of liver parenchyma 
represented by human hepatocytes, digital pictures 
(totally 7 to 8 pictures per liver) were taken with a 5x 
objective. Using Adobe Photoshop 7.0, the amount 
of pixels within the total liver parenchyma 
(excluding large portal veins, areas of calcifications, 
red foci and areas without tissue) was determined 
and compared to the amount of pixels within 
delineated human hepatocyte areas. To quantify 
proliferating hepatocytes the number of Ki67 nuclei 
positive hepatocytes was counted in random fields of 
at least 300 human hepatocytes. 
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It is generally accepted that the host’s immune response rather than the virus itself is causing the hepatocellular
damage seen in acute and chronic hepatitis B virus (HBV) infections. However, in situations of severe immune
suppression, chronic HBV patients may develop a considerable degree of liver disease. To examine whether HBV has
direct cytopathic effects in severely immune compromised hosts, we have infected severe combined immune deficient
mice (uPA-SCID), harboring human liver cells, with HBV. Serologic analysis of the plasma of HBV-infected
animals revealed the presence of extremely high amounts of viral genomes and proteins. Histological analysis
of the livers of uPA-SCID chimeras infected with HBV for more than 2 months showed that the majority of
human hepatocytes had a ground-glass appearance, stained intensely for viral proteins, and showed signs of
considerable damage and cell death. This histopathologic pattern closely resembles the picture observed in the
livers of immunosuppressed HBV patients. These lesions were not observed in animals infected with HBV for
less than 1 month. Ultrastructural analysis of long-term-infected hepatocytes showed a highly increased
presence of cylindrical HBsAg structures, core particles, and Dane particles compared to short-term-infected
hepatocytes. These long-term-infected hepatocytes also contained elevated amounts of HBV cccDNA. In con-
clusion, HBV causes dramatic intracellular changes and hepatocellular damage in the human hepatocytes that
reside in a severely immune deficient mouse. These lesions show much resemblance to the ones encountered
in immunosuppressed chronic HBV patients. Our observations indicate that HBV may be directly cytopathic
in conditions of severe immune suppression.
Hepatitis B virus (HBV) is considered to be a noncytopathic
virus, and the hepatocellular damage observed during acute
and chronic HBV infections is thought to be mediated by the
host’s immune response to the virus (6). More than 90% of
immune competent adults who become infected with HBV
display a vigorous, polyclonal, and multispecific antiviral im-
mune response that results in a rapid reduction of the viral
load and a long-lasting, protective immunity. About 5% of
infected immune competent adults and a large proportion of
neonates (up to 90%) and young children are unable to mount
an immune response of sufficient magnitude and complexity to
clear the virus and develop a chronic infection with various
degrees of necro-inflammatory liver disease. Self-limiting and
chronic HBV infections represent different stages of a dynamic
equilibrium between the immune response of the host and the
replicative capacity of the virus.
Suppression of the immune system by immunosuppressive
agents or by progressive immune failure in the context of
acquired immune deficiencies (e.g., human immunodeficiency
virus/AIDS) may lead to reactivation of seemingly recovered
or “silent” HBV infections (1). This generally presents as a
reappearance of “classic” HBV markers such as HBsAg,
HBeAg, and HBV DNA, in the absence of overt liver disease
and/or elevated levels of transaminases. In addition, chronic
HBV carriers who undergo an immunosuppressive therapy for
an autoimmune disorder (62) or after liver (3, 11, 32), renal (5,
27), or bone marrow (43) transplantation or who are treated
with chemotherapy for non-Hodgkin lymphoma (39) experi-
ence increased viremia accompanied by intensified viral pro-
tein expression in the infected hepatocytes. In a minority of
these immunosuppressed patients, this liver disease may evolve
toward fibrosing cholestatic hepatitis (FCH), an aggressive and
mostly fatal form of viral hepatitis. FCH is associated with
increased viral replication (42) and is characterized histologi-
cally by high intrahepatic expression of viral proteins, diffuse
hepatocyte ballooning, the presence of ground-glass hepato-
cytes, prominent cholestasis, and periportal fibrosis (3, 5, 11,
27, 32, 42).
To examine whether this particular disease course is related
to the severe immunosuppression encountered in these pa-
tients, we have studied the evolution of an experimental HBV
infection in the human liver-uPA-SCID model (46). This
model is based on the successful transplantation of uPA mice
(24, 51, 52), backcrossed on the immune deficient SCID
mouse, with primary human hepatocytes. We have recently
shown that, after transplantation, up to 85% of the liver of
these chimeric animals is repopulated by well-organized hu-
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man hepatocytes that retain their normal cell functions and
characteristics (46).
In addition, we compared the changes induced by HBV in
this animal model with immunohistochemical and ultrastruc-
tural observations made in liver biopsies of an immunosup-
pressed patient with HBV-induced FCH and with literature
data on this syndrome.
We show that HBV infection of human hepatocytes in im-
mune deficient uPA mice induces a clinicopathological syn-
drome that closely resembles the picture in severely immu-
nodepressed chronic HBV patients, which indicates that the
hepatocellular damage in these HBV patients is caused by
endogenous cytopathic effects of the virus itself.
MATERIALS AND METHODS
Patient with HBV-induced FCH. In the present study, we have examined
histologically a needle liver biopsy and fragments from the explant liver of a
patient with HBV-induced FCH. The patient was a 54-year-old female chronic
hepatitis B carrier who developed hemolytic-uremic syndrome, possibly induced
by a severe, acute gastroenteritis. She was treated with plasmaferesis, hemo-
dialysis, and corticosteroids and intermittently with vincristine and cyclosporine.
The immunosuppressive treatment elicited a FCH, which was confirmed by
needle liver biopsy. Treatment with lamivudine could not prevent the develop-
ment of subacute liver failure, and the patient underwent a liver transplantation.
Production of human liver-uPA-SCID mice and infection with HBV. Human
hepatocytes were isolated via a standard collagenase digestion (46) from tumor-
free liver fragments, collected from three patients undergoing a partial hepatec-
tomy. All patients gave written, informed consent, and the study protocol was
approved by the Ethical Committee of the Ghent University Hospital. Within 2
weeks after birth, nine homozygous uPA-SCID mice (47) were transplanted with
one million human hepatocytes (three mice with donor 1 hepatocytes, four mice
with donor 2 hepatocytes, and two mice with donor 3 hepatocytes). At selected
moments, plasma was taken and stored at80°C until analysis. To evaluate graft
take and survival, human albumin was determined by using an in-house enzyme-
linked immunosorbent assay (46).
Five weeks after the transfer of hepatocytes and the demonstration of suc-
cessful engraftment, these nine chimeric mice were infected with HBV via an
intraperitoneal injection of 100 l of serum from a patient that was suffering
from a mild chronic hepatitis B infection for at least 17 years. This serum
contained 107 copies of HBV DNA/ml and was positive for HBsAg and HBeAg
and negative for anti-HBs and antibodies against HCV, HDV, and human
immunodeficiency virus.
Detection and quantification of viral DNA, HBsAg, and HBeAg. HBV DNA
levels in mouse EDTA plasma were quantified by using the Cobas Amplicor
HBV Monitor test (Roche Diagnostics, Mannheim, Germany). HBsAg and
HBeAg levels were measured with a modified protocol of the Axsym HBsAg V2
and the Axsym HBe 2.0 system (Abbott, Chicago, Ill.), respectively. Internal
calibration panels, standardized to the NIBSC HBsAg standard (international
units [IU]/ml) and to the Paul Ehrlich Institute standard for HBeAg (Paul
Ehrlich Institute units [PEIU]/ml), were serially diluted to generate two calibra-
tion curves of fluorescence rate versus concentration. The concentrations of
HBsAg and HBeAg in plasma samples were determined by interpolation of the
fluorescence rate on 5-point and 7-point calibration curves, respectively.
UPA-SCID mice livers used for histopathological evaluation. The livers of
seven uPA-SCID mice were used for extensive histopathological evaluation. Two
HBV-infected animals were sacrificed 21 and 25 days after inoculation and are
referred to here as “short-term infected,” whereas two other infected animals
were sacrificed 73 and 88 days after infection. These animals are referred to as
“long-term infected.” The liver pathology in these livers was compared to that in
a 2-week-old untransplanted, uninfected uPA-SCID mouse and that in two
chimeric mice 36 and 78 days after transplantation with human hepatocytes. The
latter animals were not inoculated with HBV.
Preparation of tissues for histological study. The largest fragment of each
mouse liver was fixed in either B5-fixative or 6% formalin and then embedded in
paraffin. A small part of each fresh liver was fixed in 2.5% glutaraldehyde–0.1 M
phosphate buffer and prepared for standard electron microscopy. The remainder
was snap-frozen in liquid nitrogen-cooled isopentane and stored at 80°C until
further use.
The largest part of the needle biopsy of an FCH patient was fixed in B5 fixative
and embedded in paraffin. Small fragments were snap-frozen or fixed in glutar-
aldehyde for electron microscopy. Five large biopsies were randomly taken from
the explant liver and embedded in paraffin after fixation in 6% formalin. Small
fragments were snap-frozen or fixed in glutaraldehyde for electron microscopy.
Histology. Four-micrometer-thick sections from paraffin-embedded liver tis-
sue were stained with hematoxylin and eosin (H&E) for overall histopathological
evaluation, periodic-acid-Schiff (PAS) to assess cellular polysaccharide deposits,
PAS after predigestion with amylase (PAS) to detect ceroid macrophages,
Sirius red for fibrosis, and Hall-Van Gieson to detect bilirubinostasis (2, 40, 41).
Five-micrometer-thick sections from frozen liver tissue were fixed in acetone for
10 min after overnight drying, followed by an oil red O (ORO) staining to
visualize steatosis (2).
Immunohistochemistry. Four-micrometer-thick sections from paraffin-em-
bedded tissue were deparaffinized and rehydrated. Incubation with the primary
antibodies was performed at room temperature for 30 min, followed by a wash
in three changes of phosphate-buffered saline for 5 min. The primary antibodies
used to detect and study the different cell types of human liver within the mouse
livers were as follows: a polyclonal rabbit antibody to human albumin (dilution
1/200; Dako, Denmark) and monoclonal mouse antibodies to human hepatocytes
(hepatocyte paraffin 1 or Heppar-1, dilution 1/50; Dako), mitochondria (clone
113-1, dilution 1/100; Chemicon), pan-cytokeratin (clone KL1, dilution 1/50;
Immunotech), cytokeratin 8 (CK8; clone 35betah11, dilution 1/100; Dako), CK18
(clone CD10, dilution 1/10; Dako), CK7 (clone OV-TL12/30, dilution 1/50;
Dako), and CK19 (clone RCK108, dilution 1/20; Dako). The antibodies to
albumin and Heppar-1 are well-established markers of hepatocytes (59). The
different anti-keratin antibodies were used to detect all human epithelial cells.
Their staining intensity and pattern and the morphology of the positive cells
makes it possible to recognize mature hepatocytes, bile duct epithelial cells, and
cells of the progenitor cell compartment (i.e., hepatic progenitor cells, interme-
diate hepatocyte-like cell and reactive ductular cells) (37). Expression of viral
proteins was assessed by using a polyclonal rabbit antibody to HBcAg (dilution
1/200; Dako) and monoclonal mouse anti-human antibodies to HBsAg (clone
H1, dilution 1/80; ForLab, Belgium). The monoclonal mouse anti-human anti-
body Ki67 (clone Mib-1, dilution 1/100; Dako) was used to assess the prolifer-
ative status of human hepatocytes (20). To evaluate both human and mouse cells,
polyclonal rabbit antibodies against human cytokeratins (dilution 1/20; Dako)
and CEA (dilution 1/300; Dako) were used (15, 36). The polyclonal antibody to
CEA is a marker for canaliculi (33). For all mouse monoclonal antibodies and
the rabbit polyclonal anti-cytokeratin antibody, the secondary antibodies were
undiluted anti-mouse and anti-rabbit Envision (Dako), respectively. Sections
wherein the incubation with the first and/or secondary/tertiary antibodies were
omitted, and fully processed sections of liver tissue from untransplanted animals
served as controls. Positive controls consisted of selected liver biopsies from the
clinical routine that were stained with these antibodies.
Quantitative assessment of the different human liver cell types present in
uPA-SCID liver. To measure the fraction of liver parenchyma represented by
human hepatocytes, digital pictures (total of seven to eight pictures per liver)
were taken with a 5 objective lens. Using Adobe Photoshop 7.0, the number of
pixels within the total liver parenchyma (excluding large portal veins, areas of
calcifications, red foci, and areas without tissue) was determined and compared
to the number of pixels within delineated human hepatocyte areas. To quantify
proliferating hepatocytes, the number of Ki67 nucleus-positive hepatocytes was
counted in random fields containing at least 300 human hepatocytes.
HBV genotyping and sequencing. Total DNA from the infecting inoculum and
from mouse plasma was extracted by using the QIAamp DNA Minikit (QIAGEN
GmbH, Hilden, Germany) according to the manufacturer’s instructions. The
HBV isolates were genotyped by using the method of Lindh et al. (38). Primers
P7 and P8 were used to amplify nucleotides (nt) 256 to 796 of the S region. The
amplicon was then cleaved by using restriction enzymes HinfI and Tsp509I, in
separate reactions to give the characteristic restriction fragment length polymor-
phism patterns for the different genotypes.
The full sequence of the HBV strains was obtained by amplifying overlapping
regions of the genome as follows: (i) with a single-round PCR with the primer
pairs P7 and P8 (nt 230 to 796) (38), 455() and 1800() (29), and 2408() and
1327() (49); (ii) with a nested PCR with primer pairs 1689() and 2498() for
the first round (I) and 1898() and 2396()for the second round (II) (49),
1689() and 685() (I) and 2267() and 2858() (II), and 1730() and
2043() (I) and 1763() and 1966() (II) (49). The amplicons were prepared
for direct sequencing by using the BigDye Terminator v3.0 Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, Calif.) and sequenced on
a Spectrumedix SCE2410 (SpectruMedix LLC, Pennsylvania). In addition to the
primers used for amplification, HBV-specific primers [112(), 970(), 1373(),
2807(), 472(), 1009(), 1920() (5-ATT TGG AGC TAC TGT GGA G-3),
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and 2352() (5-TCT AAC AAC AGT ATT CTC-3)] were used for sequencing.
All sequences were analyzed in both the forward and reverse directions. Com-
plete HBV genome sequences were compared to corresponding sequences of
HBV from GenBank.
HBV RNA detection in the liver. Frozen liver tissues were dissolved in guani-
dine-isothiocyanate solution, and RNA was extracted by the acid-guanidinium
phenol-chloroform method (8). Total RNA (10 g) was analyzed by Northern
blotting and probing for HBV and GAPDH exactly as described previously (21).
HBV DNA detection in the liver. Total liver DNA was extracted from frozen
liver biopsy samples as described previously (22), and the levels of HBV DNA
replicative intermediates were determined by quantitative real-time PCR using a
Bio-Rad iCycler system exactly as described previously (56).
HBV cccDNA quantification in the liver. Covalently closed circular DNA
(cccDNA) was isolated from frozen liver biopsies and analyzed by Southern
blotting and by quantitative real-time PCR for quantification exactly as described
previously (60). For quantification of mitochondrial DNA derived from the
human hepatocytes, the following primers specific for human mitochondrial
DNA were used: HsMito3362U, 5-TCCTAATGCTTACCGAACGA-3; and
HsMito3442L, 5-GCGTCAGCGAAGGGTTGTAG-3. The number of human
hepatocytes represented in the total DNA samples was determined by quantita-
tive real-time PCR of total liver DNA for the cellular gene IMAP1 (30) using
primers specific for the human IMAP gene: hIMAP3652U, 5-TTTTCAGCT
CCCAAGTGTCC-3; and hIMAP3703L, 5-GCCGAGAGCAGGTAGCAGT-3,
and human genome copy numbers were obtained by comparing the IMAP PCR
results with a dilution series of purified genomic human DNA (Clontech, Moun-
tain View, CA) under the assumption that 6-pg genomic DNA represent one
hepatocyte.
Statistics. Statistical analysis was performed by using GraphPad Prism v4.
Before regression analysis, the normality of distribution of HBsAg, HBeAg,
HBV DNA, and albumin was assessed by the Kolmogorov-Smirnov test. Survival
curves were created by using Kaplan-Meier analysis.
RESULTS
Hepatocyte transplantation and engraftment. Nine uPA-
SCID mice, successfully transplanted with primary human
hepatocytes, were infected with 106 HBV genome copies. Sev-
enteen days later, EDTA plasma was analyzed for the presence
of HBsAg, HBeAg, and HBV DNA. Eight of the nine animals
were positive for these viral markers. The one negative animal
showed signs of infection 2 weeks later, when HBsAg, HBeAg,
and HBV DNA appeared in the plasma.
Kinetic study of HBV markers. To study the progression of
the HBV infections in uPA-SCID mice, we quantified the viral
proteins and DNA in the mouse plasma. Figure 1A shows the
evolution of the virologic parameters, together with the human
albumin levels, obtained in six mice and shows that 2.5 weeks
after injection of HBV the mean HBV DNA titer was 1.4 
1010 copies/ml, while HBeAg and HBsAg reached levels of 107
PEIU/ml and 788 IU/ml, respectively. Serologic HBV param-
eters peaked between 4 and 5 weeks after infection and
reached a mean HBV DNA level of 5 1010 copies/ml, a mean
HBeAg level of 602 PEIU/ml, and a mean HBsAg level of
14,398 IU/ml. From then on three animals appeared clinically
sick and died within 2 weeks. One month later, the surviving
animals had either equal or lower HBeAg and HBsAg levels,
and all had lower HBV DNA levels in their plasma. The
clinical condition of two animals rapidly deteriorated, and they
died 4 days later. Only one mouse survived beyond 12.5 weeks
after infection. In all animals, clinical deterioration coincided
with a dramatic drop of human albumin levels in plasma. The
median life span of the HBV-infected animals was 50 days
after infection or 85 days after transplantation. This is signifi-
cantly shorter (P  0.0001) than the survival of uninfected
mice (Fig. 1B), which survived for at least 220 days after trans-
plantation and maintained a human albumin concentration in
their plasma ranging between 4 and 6 mg/ml.
Correlation between HBV DNA and viral proteins. When
HBsAg levels were compared to the levels of HBeAg in the
plasma of the infected animals, a strong and linear correlation was
observed (r 	 0.9808, P  0.0001) (Fig. 2A). Figure 2B shows a
linear correlation between HBV DNA and both HBsAg (r 	
FIG. 1. (A) Overview of plasma analysis of 6 HBV-infected human liver-uPA-SCID mice. The concentration of human albumin (Hu-Alb) and
HBsAg can be deduced from the left axis, while HBeAg and HBV DNA concentrations can be derived from the right axis. In general, all HBV
markers (HBsAg, HBeAg, and HBV DNA) increased up to 5 weeks after infection. Later on, the concentrations of viral proteins dropped
impressively and coincided with a drastic decrease in secreted human albumin. The drop in viral proteins is also accompanied with a reduction in
produced virions. (B) Kaplan-Meier graph illustrating the survival of human liver-uPA-SCID mice. HBV-infected animals show a significantly
shorter life span compared to uninfected counterparts.
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0.8710, P  0.0001) and HBeAg (r 	 0.9344, P  0.0001). The
absence of any correlation between the human albumin levels
and the HBV markers (Fig. 2C) indicates that the correlations
highlighted before are specific for viral protein expression and
replication.
Sequence analysis of HBV. The HBV strains amplified from
the infecting inoculum and from the mouse plasma (88 days
after inoculation) both belonged to genotype E, serological
subtype ayw4. The complete genomes of the two HBV iso-
lates were sequenced and compared by phylogenetic analysis
to the 17 complete sequences of genotype E in the GenBank
database (AB091255, AB091256, AB032431, X75657, X75664,
AB106564, AY738144, AY739675, and DQ060822 to
DQ060830 (A. Kramvis et al., submitted for publication, and
data not shown). Both isolates had a genome length of 3,212 nt
characteristic of genotype E, and their sequences were identi-
cal (GenBank accession no. AY935700).
The pre-S1 sequence was completely conserved, whereas a
single missense mutation relative to other genotype E se-
quences was found in the pre-S2: T53C (Phe22Leu). The poly-
merase open reading frame (ORF) was well conserved relative
to other genotype E sequences except for an amino acid sub-
stitution within the reverse transcriptase rtSer212Thr as a re-
sult of the T766A missense mutation. The following missense
mutations were detected in the X ORF overlapping the basic
core promoter: T1753C (Ile127Thr), A1762U (Lys130Met),
and G1764A (Val131Ile). The core region contained four mis-
sense mutations: A2092T (Glu64Asp), C2093G (Leu65Val),
A2099T (Thr67Ser), and A2159G (Ser87Gly).
Histology. The histological findings of the livers from unin-
fected, short-term HBV-infected and long-term HBV-infected
animals are hereafter described in this order. However, we
present the figures of short-term and long-term-infected ani-
mals side to side to illustrate the differences between both
conditions in the best way. For this reason, the order of figures
does not always follow the flow of the text.
Histologic analysis of the livers of transplanted, uninfected
uPA-SCID mice. At 36 and 78 days after transplantation, the
livers of two uninfected animals were examined. Mature hu-
man hepatocytes could easily be recognized because they are
larger in size than their murine counterparts and, in addition,
they stained positive for Heppar-1, human albumin, mitochon-
dria, and CK8/18. All of these markers were negative on tissue
derived from untransplanted control animals. We recently
found (46) that the human hepatocytes tend to accumulate
glycogen in the cytoplasm, which results in the typical “plant-
like” morphology that is also seen in all glycogen storage dis-
eases, except in type IV. Steatosis of human hepatocytes was
minimal. At 25 days after transplantation, one-quarter of the
liver parenchyma was occupied by nodules of human hepato-
cytes. Ki67 staining showed that 18% of human cells were
proliferating. In contrast to the sick mouse liver parenchyma,
the regions occupied by human hepatocytes contained almost
no ceroid macrophages. At 73 days after transplantation, 66%
of the liver parenchyma was of human origin. Only 6% of
human cells were still proliferating, and ceroid macrophages
were still rare within the human zones. Except for glycogen
storage, human hepatocytes showed no abnormalities. Besides
mature hepatocytes, the host liver also contained human he-
patic progenitor cells, which were recognized on the basis of
their characteristic morphology and immunohistochemical
phenotype (37).
Histologic and ultrastructural analysis of the liver of short-
term-infected animals. Two uPA-SCID mice, transplanted
with human hepatocytes and subsequently infected with HBV,
were sacrificed 21 and 25 days after infection. Figure 3A shows
that also in this animal and in no way different from the livers
of noninfected mice, human hepatocytes were excessively
loaded with glycogen and formed large areas occupying 34 and
87% of mouse liver parenchyma, respectively. Apart from the
glycogen storage, no other signs of damage or cell loss were
seen. The human hepatocytes stained strongly for human al-
bumin (Fig. 3B), and ceroid macrophages were confined to the
mouse areas (Fig. 3C). Hepatocytes staining for Ki67 were scat-
tered over the liver and accounted for 10% of all human hepato-
cytes. There were no human hepatocytes with a “ground-glass”
aspect of the cytoplasm.
Figure 4A shows that 25 days after infection almost all hu-
man hepatocytes stained for HBcAg, displaying a strong signal
in the nucleus and a moderate one in the cytoplasm. At 21 days
after infection, 50% of the human hepatocytes stained positive
(not shown). The cytoplasm of the human hepatocytes almost
always had a granular staining for HBsAg, frequently with an
accentuation near the cell membrane (Fig. 4B). Whereas al-
most all human hepatocytes stained positive for HBsAg 25
days after inoculation, only 10% stained positive 21 days after
infection. The staining patterns and intensities are similar to
those observed in liver biopsies of patients with chronic HBV
in the viral replicative phase. The number of positive hepato-
cytes is usually lower in human liver biopsies (14).
In addition to human hepatocytes and diseased mouse hepato-
cytes, seven red foci (mouse regenerative nodules that have
FIG. 2. (A and B) Plasma analysis of HBV-infected animals revealed linear correlations between HBsAg and HBeAg (r 	 0.9808, P  0.0001)
(A) and between HBV DNA and HBsAg (r	 0.8710, P 0.0001) and HBeAg (r	 0.9344, P 0.0001) (B). (C) In contrast, no correlation between
any viral marker and human albumin (HBV DNA and human albumin, r 	 0.244, P 	 0.4006) could be demonstrated.
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deleted the uPA transgene) were also present in the liver of
one short-term-infected animal. These consisted of 21 to 88
hepatocytes that were partly or completely surrounded by
areas of human hepatocytes. The interface between red foci
and human areas was neither sharply delineated nor com-
pressed, and the two cell types seemed to infiltrate each other’s
“territories.” These findings suggest that the human hepato-
cytes and the transgene-free mouse hepatocytes are respond-
ing equally well to the available growth stimuli. As in nonin-
fected mouse livers, human hepatic progenitor cells and
intermediate hepatocyte-like cells were focally present at the
human-mouse parenchymal interface.
Using electron microscopy, noncoated viral particles with a
diameter of 21 to 24 nm, corresponding to HBV core particles,
could be observed dispersed in the nuclei of several human
hepatocytes. In the cisternae of the endoplasmic reticulum,
one or two longitudinally transected tubules and cross-sec-
tioned spheres of HBsAg were present. In some cisternae, core
particles, surrounded by a clear halo and a dark ring approx-
imately 40 nm in size, corresponding to Dane particles were
observed. In addition to the presence of viral and subviral
particles, no ultrastructural alterations could be observed in
these hepatocytes compared to those of noninfected animals.
Histologic and ultrastructural analysis of the livers of long-
term-infected animals. The clinical condition of the HBV-in-
fected animals deteriorated over time, and some animals died
spontaneously. Two mice that looked clinically “terminal” (in-
fected for 73 and 88 days) were sacrificed to examine their livers.
In these mice, the cytoplasm of most human hepatocytes had a
“ground-glass” appearance (Fig. 3D) and no longer showed the
excessive accumulation of glycogen, observed in uninfected or
short-term-infected mice. The stainings for CK8, CK18, pan-cyto-
keratin, albumin, Heppar-1, and mitochondria were diffusely
positive in most human hepatocytes. The intensity of the stain-
ing for albumin was much weaker compared to the four other
markers (Fig. 3E). This was not the case in the short-term-
infected livers (Fig. 3B). Small areas of diseased mouse liver
parenchyma were separated from each other by large areas of
human hepatocytes that occupied 70% (73 days postinfection)
and 50% (88 days postinfection) of the liver parenchyma.
Within the human parenchyma, scattered ceroid macrophages
were seen that sometimes formed small clusters (Fig. 3F),
indicating considerable loss and damage of human hepato-
cytes. Occasionally, degenerative and apoptotic hepatocytes
were observed, but never signs of bilirubinostasis. In a com-
plete section, only five human hepatocytes were Ki67 positive,
FIG. 3. Comparison of liver architecture of short-term (A, B, and C) and long-term (D, E, and F) HBV-infected human liver-uPA-SCID mice.
Human hepatocytes (H) in short-term-infected animals have a pale appearance on H&E staining (A) due to the accumulation of glycogen as shown
by PAS staining (inset). Diseased mouse hepatocytes (M) are devoid of glycogen. (B) Staining for human albumin shows that short-term infection
does not compromise the functionality of the human hepatocytes. (C) PAS staining on the same livers shows that ceroid macrophages, an
indication of cell loss, are confined to the diseased mouse regions. (D) The majority of long-term HBV-infected human hepatocytes have a
ground-glass appearance on H&E staining, whereas these were absent in uninfected and short-term-infected livers. The insert shows a magnifi-
cation of human ground-glass hepatocytes. (E) Long-term HBV infection results in an overall deterioration of the condition of the cells as shown
by the decreased albumin production. (F) Large amounts of ceroid macrophages are now also present in the regions occupied by human
hepatocytes, indicating that long-term infection causes the death of human hepatocytes. Original magnifications: A, C, D, and F, 200; insets, B,
and E, 400.
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which is much less than in the uninfected and short-term HBV-
infected livers containing a comparable amount of human cells.
The liver sections also revealed seven red foci consisting of 16 to
43 hepatocytes. In contrast to the picture seen in short-term
infection, these red foci were sharply delineated and mildly com-
pressed the surrounding human parenchyma, which indicates that
the hepatocytes in these red foci have a growth advantage over
the long-term-infected human hepatocytes.
The immunohistochemical staining for HBcAg (Fig. 4C)
showed a very intense staining of hepatocyte nuclei and a less
intense, but still pronounced staining of cytoplasm and cell
surface membranes. The staining for HBsAg (Fig. 4D) showed
that the cytoplasm of most hepatocytes contained high
amounts of this viral protein. In some hepatocytes with a less
intense staining of the cytoplasm, membranous staining be-
came apparent. Overall, the staining intensities were much
higher than in the livers of the short-term-infected mice.
Several human hepatic progenitor cells and intermediate
hepatocyte-like cells were present not only at the human-
mouse parenchymal interface but also within the human pa-
renchymal areas (Fig. 5). This leads to higher numbers of
human progenitor and intermediate cells in long-term-infected
animals than in short-term or noninfected animals.
Ultrastructural analysis showed that long-term HBV-in-
FIG. 4. Immunohistochemical staining for HBcAg (A, C, and E) and HBsAg (B, D, and F) on liver sections of short-term (upper panel) and
long-term (middle panel) HBV-infected human liver-uPA-SCID mice and biopsies from a patient suffering from FCH (lower panel). We can
clearly observe a highly increased presence and difference in the distribution of both viral proteins in long-term-infected tussue compared to
short-term-infected tissue. The amount and pattern of HBcAg and HBsAg staining on the long-term-infected liver corresponds very well to the
one observed in liver tissue derived from the FCH patient. Original magnifications, 200.
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fected hepatocytes were swollen, ballooned, and considerably
damaged. This was never observed in the livers of the short-
term-infected mice. The nuclei of most human hepatocytes
were completely filled with noncoated round HBV core parti-
cles with diameters of 21 to 24 nm. In the cytoplasm of these
hepatocytes, nearly all of the cisternae of the endoplasmic
reticulum displayed cystic dilations that contained numerous
HBsAg tubules and spheres and complete Dane particles
(Fig. 6A). Unlike the livers of the short-term-infected and
noninfected mice, glycogen granules were scarce in these bal-
looned human hepatocytes loaded with virus. Human hepato-
cytes that contained fewer viral particles and showed less cell
damage were scarce.
Dysplasia or malignant transformation of human hepato-
cytes, or tumor cells of the type for which the patient under-
went liver surgery were never seen.
Histologic and ultrastructural analysis of liver tissue from a
patient with HBV-induced FCH. The needle biopsy and the
fragments of the explant liver showed periportal fibrosis with
occasional formation of a septum, vague nodularity of the
parenchyma, and perisinusoidal fibrosis. The periportal area
contained an impressive ductular reaction that extended into
FIG. 5. Immunohistochemistry for human cytokeratin 7 on a
liver section from a chimeric mouse long-term infected with HBV.
Hepatic progenitor cells (arrows), as well as cells with a phenotype
intermediate between progenitors and mature hepatocytes (arrow-
heads), are not only located at the interface between human
(H) and mouse (M) hepatocytes but also within human paren-
chyma. Staining with anti-cytokeratin 19 confirms the presence of
human hepatic progenitor cells (inset). Original magnifications:
main image, 200; inset, 400.
FIG. 6. Electron micrograph of a human hepatocyte in the liver from a long-term-infected chimeric mouse (left) and in the liver of a patient
with HBV-induced FCH (right). (A and B) Numerous amounts of HBV core particles (open arrows) are obvious inside the nucleus, whereas
complete Dane particles (arrow) are present in the cisternae of the endoplasmic reticulum. (C and D) These cisternae are dilated and contain large
amounts of HBV surface tubules. Original magnification: 77,000.
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the lobular parenchyma. Singular hepatic progenitor cells and
intermediate hepatocyte-like cells were scattered throughout
the parenchyma. The parenchyma showed several signs of con-
siderable cell damage and loss: (i) some hepatocytes showed
ballooning, (ii) there were numerous ceroid macrophages that
sometimes formed clusters, and (iii) a few areas of confluent
necrosis were present. The cytoplasm of a considerable pro-
portion of hepatocytes had a “ground-glass” aspect. There was
also prominent bilirubinostasis. Bilirubin droplets were present
in hepatocytes, bile canaliculi, and frequently in bile ductules
with dilated lumina and damaged epithelium. The parenchy-
mal inflammatory infiltrate was only mildly increased.
The immunohistochemical staining for HBcAg (Fig. 4E)
showed a very intense staining of nearly all hepatocyte nuclei
and a less intense, but still marked, staining of cytoplasm and
membrane. The cytoplasm of almost all hepatocytes stained
intensely positive for HBsAg (Fig. 4F). Remarkably, some cells
from reactive bile ducts were also positive for HBsAg and
HBcAg, a feature that has been described previously in chronic
HBV infection (13). Striking similarities between the livers of
the long-term HBV-infected mice and the human liver with
HBV-induced FCH were the presence of extensive hepatocyte
damage and loss, the pattern and intensity of immunohisto-
chemical HBV stainings, and the presence of only a mild in-
flammatory infiltrate.
Ultrastructural evaluation of the small biopsies fixed in glutar-
aldehyde showed findings almost identical to those seen in the
long-term-infected animals (Fig. 6). Many hepatocytes contained
nuclei filled with HBV core particles, while the cytoplasmic en-
doplasmic reticulum cisternae were dilated and packed with
HBsAg tubules and spheres and complete Dane particles.
Determination of HBV cccDNA, DNA, and RNA. The livers
of one short-term-infected and one long-term-infected animal
were also analyzed for the presence of HBV cccDNA, repli-
cative intermediates, and RNA transcripts. Using Southern
blotting, cccDNA could easily be identified in both chimeric
livers (Fig. 7A). After EcoRI digestion, the cccDNA molecules
were linearized and comigrated with the linear HBV DNA
present in the total DNA isolated from the same tissue.
cccDNA could also be detected in liver biopsies from a chron-
ically infected chimpanzee and the FCH patient, but was ab-
sent in DNA extracts from HBV transgenic mice. HBV DNA
replicative intermediates were detected in all liver samples
except in the noninfected chimeric mouse (Fig. 7B). The
cccDNA copy number per infected hepatocyte was quantified
by using quantitative real-time PCR. In the liver of a short-
term-infected animal we detected 1.4 cccDNA molecules per
HBcAg human hepatocyte. In contrast, in the long-term-
infected animal the amount of cccDNA molecules per HBV-
infected human hepatocyte increased to 65.7 copies/cell. The
liver of the FCH patient contained 6.8 cccDNA molecules per
hepatocyte.
Northern blot analysis showed very high HBV gene expres-
sion in the long-term mouse liver but only low expression in the
chimeric mouse liver after 21 days (Fig. 8). The preS1 mRNA
was visible only in the liver extracts of the long-term-infected
chimeric uPA-mouse and in the HBV transgenic mouse.
DISCUSSION
The hepatic injury during acute and chronic HBV infections
is thought to be caused by the host’s immune response against
the infected hepatocytes (6). However, in some severely im-
munosuppressed chronic HBV patients, excessive viremia and
a very severe, sometimes fatal hepatic disease, known as FCH
may occur. This suggests that severe liver pathology may arise
in the absence of a functional immune system (5, 27, 39, 43).
To examine the pathology induced by HBV in an immune
deficient host, we have infected chimeric human liver-uPA-
SCID mice with HBV.
FIG. 7. Southern blot analysis of HBV cccDNA (lanes 2 to 13) and replicative intermediates (lanes 15 to 19) isolated from the livers of a
noninfected chimeric mouse (lanes 2, 3, and 15), short-term (lanes 4, 5, and 16) and long-term (lanes 6, 7, and 17) HBV-infected uPA-SCID mice,
a patient with HBV-induced FCH (lanes 8, 9, and 18), a chronically HBV-infected chimpanzee (lanes 10 and 11), and an HBV-infected transgenic
mouse (lanes 12, 13, and 19). A 3.182-kb molecular weight marker is also included (lanes 1 and 14). After EcoRI digestion, the cccDNA molecules
linearized to a double-stranded, linear (DS-l) form (lanes 3, 5, 7, 9, 11, and 13). As expected, cccDNA is not detectable in the HBV transgenic
(Tg) mouse extracts. The relative amounts of cccDNA between the different samples cannot be compared because of the varying sizes of the
starting material. Replicative intermediates can be easily visualized in the long-term mouse liver but are hardly detectable in the short-term-
infected chimeric mouse.
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At several moments after infection, the concentrations of
HBsAg, HBeAg, and HBV DNA in mouse plasma were de-
termined. In agreement with Degushi et al. (12) and previous
observations of our lab (54), very strong linear correlations
between HBsAg and HBeAg and HBV DNA were observed.
Also, a linear correlation between the amount of HBeAg and
HBV DNA was seen. Two groups that independently analyzed
serum from chronic HBV patients were unable to find such a
relationship before the start of antiviral treatment (4, 25).
However, during antiviral treatment, these researchers found a
correlation between HBeAg and HBV DNA levels and con-
cluded that quantification of HBeAg in serum or plasma may
be a valuable alternative to HBV DNA measurements to mon-
itor the success of antiviral treatment.
Compared to noninfected human liver-uPA-SCID mice,
HBV-infected animals have a decreased life expectancy and
their premature death is caused by the progressive deteriora-
tion of the liver structure and function. Several observations
are indicative of a direct cytopathic effect of the hepatitis B
virus in our model. A large proportion of human hepatocytes
in long-term-infected animals acquired a ground-glass appear-
ance. This was not seen in noninfected or short-term-infected
mice. These ground-glass hepatocytes stained extremely posi-
tive for both HBsAg and HBcAg, whereas the staining pattern
of short-term-infected hepatocytes was less pronounced. Elec-
tron microscopic analysis revealed several signs of structural
damage within the infected human hepatocytes. Large num-
bers of clustering ceroid macrophages were only observed in
the human areas of the livers of long-term-infected animals.
This is a hallmark of ongoing cell death and the ensuing re-
moval of cellular remnants. The physical condition and func-
tional integrity of the long-term-infected hepatocytes were ir-
reversibly compromised, since these cells produced less
albumin and were literally pushed aside by regenerative mouse
“red nodules.” These regenerative mouse red nodules do not
cause the death of the human hepatocytes by themsleves.
Sandgren et al. showed that somatic deletion of the uPA-
transgene results in a restoration of the normal liver architec-
ture (53). If these nodules were just replacing the human
hepatocytes then the clinical condition of our infected mice
would ameliorate and the animals would be rescued. However,
this is not happening. The overwhelming infection and repli-
cation of HBV in human hepatocytes causes massive dysfunc-
tion of these cells that cannot be compensated for sufficiently
by the “healthy” mouse hepatocytes in the red nodules. This
process ultimately leads to liver failure and death of the ani-
mals. Only one animal survived the HBV infection and showed
signs of clinical improvement. In the liver of this animal lower
amounts of human hepatocytes were present, whereas large
amounts of healthy, regenerative mouse hepatocytes were ob-
served. These red nodules most likely rescued this animal.
Dandri et al. (9) were the first to successfully infect chimeric
immune deficient uPA mice with HBV. These researchers did
not report HBV-induced hepatocellular toxicity in two infected
animals. Some important differences in the experimental de-
sign may explain this. The human hepatocytes were trans-
planted into heterozygous uPA/ mice and not in homozy-
gous uPA/ animals like we did. The transfer of hepatocytes
in heterozygous mice results in a repopulation grade with hu-
man cells of only 2 to 10%, meaning that most of the liver
parenchyma is occupied by healthy mouse hepatocytes derived
from uPA/ revertants. A lethal effect of HBV infection
cannot be observed since these mice even survive without a
hepatocyte graft. In addition, the infected animals were sacri-
ficed 8 weeks after transplantation, which may have been to
soon to observe the cytopathic effects we report here. At that
moment, the animals had high levels of HBV DNA and HBV
proteins in their plasma and a strong nuclear expression of the
HBV core protein in the liver, phenomena we also observed at
a similar time point. Levels of circulating HBV DNA with
values exceeding 109 copies/ml are also common in immuno-
suppressed HBV patients (1, 28).
Tsuge et al. recently described long-term HBV infection in
uPA-SCID mice (57). Several weeks after infection, the con-
centration of human albumin decreased in these animals, al-
beit less dramatically than what we observed. It is not clear
whether this is due to the HBV infection or to a spontaneous
loss of chimerism. Obvious signs of a cytopathic effect were not
reported, and a lethal effect is less likely in this setup because
the low levels of human albumin suggest the presence of high
amounts of regenerative red nodules. These would rescue the
animals in case of graft failure.
uPA/ RAG2/ mice transplanted with tupaia hepato-
cytes have also been infected with HBV (10). In these animals
the HBV infection persisted for 6 months, the experimental
endpoint, and no signs of hepatocellular damage were re-
ported. The main differences with the human liver-uPA model
are that the onset of viremia was considerably delayed and that
the plasma levels of HBV DNA were significantly lower. This
may be due to the nature of the tupaia hepatocytes.
Similarly, hepatocytes from a woodchuck infected with the
woodchuck hepatitis virus were transplanted in uPA-RAG2
mice. These animals experienced high viremia for more than
10 months without obvious lesions in the liver. It might be that
the woodchuck hepatitis virus is less cytopathic than HBV.
FIG. 8. Northern blot analysis of total RNA extracts of the livers of
an HBV-transgenic mouse (lane 1), a patient with HBV-induced FCH
(lane 2), a noninfected chimeric mouse (lane 3), a short-term HBV-
infected mouse (lane 4), and a long-term HBV-infected mouse (lane
5). From each sample 10 g of total RNA was loaded. The Pre-S1
transcript can be easily seen in the long-term-infected chimeric mouse.
The lower hGAPDH signal in the short-term-infected mouse reflects a
lower amount of human hepatocytes present in the chimeric liver.
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Alternatively, this difference may also be related to the differ-
ent nature of the woodchuck hepatocytes.
Our observations closely resemble those made by Lenhoff et
al. in a model for the study of the duck hepatitis B virus (34).
Three-day-old ducklings were infected with a duck hepatitis B
virus strain that contained a mutation in the Pre-S region. This
mutation induced elevated levels of viral cccDNA and viral
capsid protein in the nucleus of the infected hepatocytes. In
addition to high intracellular viral protein expression, we also
observed a 47-fold increase in cccDNA copy number per in-
fected hepatocyte when we compared the short- and long-
term-infected animals.
The infected ducklings also displayed high viremia and hepato-
cellular damage. Like in our model, this cell damage elicited an
increase of mononuclear cells and regenerating bile ductule-
like cells in the liver parenchyma. In biopsies of patients with
chronic viral hepatitis, the number of hepatic progenitor cells
is also correlated with the severity of hepatocyte damage and
loss (18). As a consequence of the cytopathic effect, the duck-
lings experienced a marked growth retardation. In contrast to
our study, this cytopathic effect lasted for only 23 days, and the
recovery was associated with the appearance of a noncyto-
pathic revertant virus (35). We did not observe any sequence
variability during the 88-day infection period.
The mechanisms underlying the cytopathic effect of the virus
have not yet been defined. Several in vitro and in vivo studies
showed that the accumulation of the L protein leads to the
appearance of ground-glass hepatocytes (7, 17) and can induce
stress in the endoplasmic reticulum (58), as well as oxidative
DNA damage and mutagenesis (26). The virus isolate we used
here lacked the mutations in the pre-S region that have been
shown to lead to the development of ground-glass hepatocytes
in chronic carriers (16, 45, 61). It can be argued that the
cytopathic effect seen in the present study is the result of the
human hepatocytes being infected with an isolate that has
mutations in the basic core promoter. However, these muta-
tions have also be found in asymptomatic carriers, in patients
experiencing only a mild form of chronic HBV infection (19,
31, 48, 55), and in immune compromised HBV patients with no
or mild liver disease (23, 44, 50).
In the context of the present study, an ultrastructural anal-
ysis on biopsies from a FCH liver has been performed for the
first time. This evaluation revealed massive amounts of viral
and subviral particles inside ballooned and damaged hepato-
cytes. Electron micrographs of human hepatocytes in the long-
term-infected mice could not be distinguished from those of
the FCH liver. We did not detect a significant increase in
cccDNA copy number in the FCH patient, indicating that the
cause of the cytopathic effect might be different at the molec-
ular level.
Our data and the clinicopathological observations made in
other patients with FCH suggest that, in the absence of a
functioning immune system as it occurs in SCID mice and
severely immunosuppressed patients, HBV can replicate and
express its proteins in an unrestrained fashion. This leads to
excessive accumulation of viral proteins, cell damage, and ul-
timately cell death. Our mouse model can be useful for study-
ing new therapies and strategies to control the viral replication
during immunosuppression after organ transplantation in pa-
tients with chronic hepatitis B infection. It may also be useful
for the evaluation and prediction of the pathogenic effect of
the various genotypes of HBV and certain HBV mutants.
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Background: Chronic hepatitis B (HBV) and hepatitis C (HCV) patients have elevated plasma levels of soluble CD14 (sCD14). We
examined whether human hepatocytes produce sCD14 in vivo, and whether HBV or HCV infections influence this production.
Methods: uPA-SCID mice were transplanted with primary human hepatocytes and some animals were subsequently infected with HBV or
HCV. Plasma from these mice was analyzed for the presence of human sCD14. The liver was examined via immunohistochemistry.
Results: A soluble form of human CD14 could be detected in the plasma from successfully transplanted mice, while it was completely absent
in non-transplanted control animals. The isoform of this human sCD14 corresponded with the most abundant isoform found in human
plasma. CD14 levels in circulation were not significantly different between non-infected, HBV infected and HCV infected animals.
Conclusions: Our data indicate that human hepatocytes produce sCD14 in vivo, and that liver cells might be the major source of sCD14 in
normal human plasma. In addition we demonstrate that HBV and HCV infections have no direct influence on the production of sCD14 by
human hepatocytes in this chimeric model.
D 2005 Elsevier B.V. All rights reserved.Keywords: Hepatitis B; Hepatitis C; Endotoxemia; CD14; uPA-SCID; Human hepatocyte1. Introduction
CD14 is a differentiation marker expressed on the surface
of monocytes, macrophages and granulocytes [1]. Mem-
brane bound CD14 (mCD14) has a molecular weight of 56
kDa and is attached to the cell surface via a glycosyl-
phosphatidylinositol (GPI) anchor [2]. Binding of microbial
lipopolysaccharide (LPS) to CD14 leads to activation of the
cell via the co-receptor Toll-like receptor 4 (TLR-4), and the
subsequent production of the cytokines interleukin-1 (IL-1),
interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a)
[3]. In addition to its function in LPS signal transduction,0009-8981/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.cca.2005.09.022
* Corresponding author. Tel.: +32 9 240 34 22; fax: +32 9 240 63 11.
E-mail address: geert.lerouxroels@ugent.be (G. Leroux-Roels).CD14 also recognizes apoptotic cells [4], mediates phago-
cytosis of Gram-negative bacteria [5], interacts with TLR-2
[6,7], is involved in monocyte–endothelial cell interactions
[8] and binds recombinant hepatitis B surface antigen
(HBsAg) [9].
Studies in mice and rats suggest that CD14 can also be
expressed by hepatocytes. Fearns et al. injected LPS in mice
and observed a peak of CD14 mRNA expression in the liver
after 8 to 16 h [10]. In situ hybridization showed that this
CD14 mRNA was localized inside the hepatocytes. Admin-
istration of LPS to rats also induced expression of CD14
mRNA and protein in hepatocytes [11–13].
CD14 not only occurs on the membrane of certain cell
types, but can also be found in a soluble form in human
plasma. While normal mouse plasma is devoid of solublex (2005) xxx – xxx
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[10]. sCD14 is thought to originate from myeloid cells that
express CD14 and release it via either a protease-dependent
shedding (48–53 kDa) [14] or a protease-independent
release from intracellular compartments (56 kDa) [15].
Observations in mouse and rat indicate that hepatocytes
might also be a source of sCD14. However, observations
made in rodents cannot simply be extrapolated to the human
situation and there is at present no direct evidence showing
that human hepatocytes also express CD14 in vivo and
release sCD14 into the plasma. In vitro studies of human
hepatoma cells and primary human hepatocytes showed that
these cells are able to produce sCD14 [16–18].
sCD14 is involved in LPS-induced responses by cells
that do not express CD14 on their surface, like epithelial
[19], endothelial [19,20] and smooth muscle cells [21]. It
can act as a competitor to prevent LPS-induced responses by
CD14-expressing cells [22] and forms a protein pair with
LPS-binding protein (LBP) that can exchange and transport
phospholipids [23].
Elevated sCD14 concentrations have been found in the
plasma of patients suffering from HIV [24,25], alcoholic
liver disease [26–28], chronic HCV [29,30] and chronic
HBV [30]. In the latter we recently observed an inverse
correlation between sCD14 and HBsAg concentrations [30].
The uPA-SCID mouse suffers from a severe, chronic liver
disease due to the transgenic overexpression of urokinase
plasminogen activator (uPA) [31,32]. Introduction of the
uPA transgene into the SCID background results in immune
deficient uPA-SCID mice that accept human hepatocyte
grafts. The human liver cells repopulate the diseased mouse
liver and can subsequently be infected with HBV and HCV
[33–35]. Here we use this chimeric uPA-SCID mouse to
investigate in vivo whether human hepatocytes express
CD14 and release sCD14 in circulation. We further
examined whether HBVor HCV infections of these animals
have an impact on the plasma levels of sCD14.2. Materials and methods
2.1. Isolation of human hepatocytes
Human hepatocytes were isolated from liver fragments
obtained from patients that underwent a partial hepatectomy
to remove metastases of colorectal carcinomas. All patients
gave informed consent and all experiments were approved
by the Ethical Committee of the Ghent University Hospital.
Hepatocytes were isolated from tumor free sections via a
collagenase digestion in which tissue was first perfused with
Liver Perfusion Medium (Invitrogen, Merelbeke, Belgium)
and then with Liver Digest Medium (Invitrogen). Subse-
quently, the digested liver was placed in Hepatocyte Wash
Medium (Invitrogen). The cell suspension released from the
liver was filtered through a 70 Am cell strainer (BD Falcon,
Erembodegem, Belgium) and hepatocytes were separatedfrom non-parenchymal cells via three low-speed centrifu-
gation steps (5 min, 50 g). Cell viability was measured using
the Trypan Blue exclusion test and exceeded 90%.
2.2. Breeding and transplantation of uPA-SCID mice
uPA-SCID mice were generated by backcrossing B6SJL-
TgN(Alb1Plau)144Bri mice (The Jackson Laboratories, Bar
Harbor, Maine, USA) at least seven times on a SCID
(CBySmn.CB17-Prkdcscid) background. The offspring were
screened for the SCID phenotype based on the absence of
mouse immunoglobulins, using an in-house Elisa. The uPA
zygosity was determined by multiplex PCR as previously
described [36]. Within two weeks after birth, homozygous
uPA-SCID mice were transplanted with one million human
hepatocytes via an intrasplenic injection. Five weeks after
transplantation, some animals were infected with HBV or
HCV by an intraperitoneal injection of plasma from patients
infected with HBV or HCV, respectively.
All animals were bred and handled under specific
pathogen free (SPF) conditions in the SCID mouse facility
of the Department of Clinical Chemistry, Microbiology and
Immunology, Ghent University.
2.3. Transplantation of NOD/SCID mice
NOD/SCID mice (NOD.CB17-Prkdcscid/J), originally
purchased from The Jackson Laboratories, were bred and
maintained in our animal facility. One day before cell
transfer, all animals received a total body irradiation of 100
rad and were injected with 0.5 mg TM-h1 [37]. The next
day, human PBMC were isolated from a buffy coat (BTC
Oost-Vlaanderen, Gent, Belgium) via Ficoll-Hypaque
(Nycomed Pharma, Oslo, Norway) density gradient cen-
trifugation. Ten million PBMC were injected in the
peritoneal cavity of the pretreated NOD/SCID mice. Three
and 7 days after cell injection, plasma was taken and stored
at 80 -C until further analysis. Some NOD/SCID mice
were transplanted with one million human hepatocytes via
intrasplenic injection.
2.4. Quantification of human albumin
The concentration of human albumin in chimeric mouse
plasma was determined via a sandwich Elisa. Maxisorp
Immunoplates (Nunc, Roskilde, Denmark) were coated with
a goat-anti-human albumin antibody (Bethyl Laboratories
Inc., Montgomery, TX, USA). After blocking, diluted
samples were added and after incubation and washing,
bound human albumin was revealed with a HRP conjugated
goat-anti-human albumin antibody (Bethyl Lab.).
2.5. Detection and quantification of viral DNA/RNA
HBVDNA and HCV RNA levels in mouse EDTA plasma
were quantified using the Cobas Amplicor HBVMonitor test
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Diagnostics, Mannheim, Germany), respectively.
2.6. Quantification of sCD14
Human soluble CD14 levels in mouse plasma were
determined using the sCD-14 EASIA kit (Biosource,
Camarillo, CA, USA), according to the manufacturer’s
instructions. This Elisa is specific for human sCD14 and is
not cross-reactive to mouse sCD14.
2.7. Detection and quantification of HBsAg
HBs antigen levels in mouse plasma were quantified with
a modified protocol [38] of the Axsym HBsAg V2 system
(Abbott, Chicago, Illinois, USA). To determine the concen-
tration of HBsAg, a curve containing six calibrators (5.867,
2.933, 1.467, 0.733, 0.367 and 0 IU/ml), standardized to the
NIBSC HBsAg standard, was generated. The fluorescence
rate of the unknown samples was compared to the
calibration curve to calculate the actual HBsAg content.
2.8. Western blot analysis
Human and mouse EDTA plasma was diluted 1 /100 in
PBS. Ten microliters of sample was diluted in 2 loading
buffer (Sigma-Aldrich, St. Louis, MO, USA) and loaded on
an 8% SDS-PAGE after denaturation. Affinity purified
human recombinant sCD14 (25 ng/lane) produced in CHO-
cells [39] was used as a positive control. After separation,
the samples were transferred to a nitrocellulose membrane
(Schleicher and Schull, Dassel, Germany) that was then
blocked with TBS–Tween 20 (0.1%) containing 5% Skim
Milk (BD Difco, Franklin Lakes, NJ, USA). sCD14 was
detected using a rabbit anti-CD14 antibody (dilution 1 /
5000; Biometec, Greifswald, Germany) in combination with
a goat-anti-rabbit HRP labeled antibody (dilution 1 /10,000;
Dako, Denmark), both diluted in blocking buffer. After
incubation for 1 h at room temperature, extensive washing
and treatment with the ECL Advance Western Blotting
Detection System (Amersham Biosciences, Freiburg, Ger-
many) the signal was visualized on autoradiography film
(Pierce, Rockford, IL, USA).
2.9. Immunohistochemistry
A part of each fresh mouse liver was snap-frozen in
liquid nitrogen-cooled isopenthane and stored at 80 -C
until further use. The spleen and the remainder of the liver
was fixed in B5-fixative or in 6% formalin. After fixation,
the tissue was embedded in paraffin.
Four micrometer-thick sections from paraffin-embedded
tissue were deparaffinized, rehydrated and incubated with
the primary antibodies for 30 min at room temperature. The
primary antibodies used to detect and study the different
human cell types within the chimeric mouse were apolyclonal rabbit anti-human antibody against human
albumin (dilution 1 /200, Dako, Denmark), and mouse
monoclonal antibodies against human cytokeratin 8 (CK8)
(clone 35hH11, dilution 1 /100, Dako), CD14 (Biometec,
Greifswald, Germany; Novocastra Laboratories Ltd., New-
castle, UK), CD45 (clone 2B11+PD7/26, dilution 1 /50,
Dako) and CD68 (clone KP1, dilution 1 /75, Dako). CD45
is present on the surface of all leukocytes, while CD68 is a
highly glycosylated lysosomal membrane protein that is
strongly expressed in cytoplasmic granules, and weakly on
the surface of macrophages, monocytes, neutrophils, baso-
phils and NK-cells.
For all mouse monoclonal antibodies and the rabbit
polyclonal anti-cytokeratin antibody, the secondary anti-
body was undiluted anti-mouse and anti-rabbit Envision
(Dako), respectively. Sections wherein the incubation with
the first and/or secondary antibodies were omitted and fully
processed sections of liver tissue from untransplanted
animals served as negative controls, while liver biopsies
from the clinical routine served as positive controls.
2.10. Statistics
Statistical analysis was performed using GraphPad Prism
v4. Before regression analysis, the normality of distribution
of sCD14, HBsAg and albumin was assessed by the
Kolmogorov–Smirnov test. Normalized sCD14 concentra-
tions in non-infected, HBV infected and HCV infected uPA-
SCID mice were compared using the Mann–WhitneyU-test.3. Results
3.1. Identification and quantification of sCD14 in chimeric
uPA-SCID mouse plasma
Plasma from successfully transplanted uPA-SCID mice
(n =23) was analyzed for the presence of human albumin
and sCD14. The concentration of human albumin, which is
a marker of hepatocyte graft take and survival, ranged from
1.1 to 8.5 mg/ml (median value=2.60 mg/ml). All samples
were also positive for sCD14 and ranged from 0.82 to 4.56
Ag/ml (median value=1.70 Ag/ml). A linear correlation
between the concentrations of human albumin and sCD14
was observed (r2=0.7395, P <0.0001; Fig. 1). The plasma
of untransplanted control animals contained neither human
albumin nor human sCD14.
To determine the isoform of the sCD14 produced by the
human hepatocytes in the chimeric mice, plasma from a
transplanted mouse was analyzed by electrophoresis and
western blotting and this resulting pattern was compared
with that of plasma from an untransplanted mouse, a human
plasma sample and a specimen containing recombinant
sCD14. Plasma from a successfully transplanted mouse
contained human sCD14 (Fig. 2). The plasma from an
untransplanted control animal was devoid of sCD14, which
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Fig. 2. Western blotting analysis to detect human soluble CD14 (sCD14).
Plasma from a non-transplanted mouse (lane 1), chimeric mouse plasma
(lane 2) and normal human plasma (lane 4) was separated on an 8% SDS-
PAGE and subsequently transferred to a nitrocellulose membrane.
Recombinant human sCD14 was used as a positive control (lane 3). While
plasma from a non-transplanted mouse was devoid of human sCD14,
sCD14 (arrow) was perceived in plasma originating from a mouse
transplanted with human hepatocytes. The size of sCD14 detected in
chimeric plasma corresponded very well with the size of the sCD14 isoform
mainly found in human plasma. Two forms of a recombinant sCD14 can be
visualized with a size slightly different from what is found in human
plasma, probably due to different glycosylation patterns. Several aspecific
bands with a size higher than 75 kDa are also visible in all samples.
Fig. 1. Correlation between the concentration of human albumin and
sCD14. Human albumin and sCD14 were quantified in chimeric mouse
plasma. A linear correlation between both plasma proteins could be
observed (r2=0.7395, P <0.0001).
P. Meuleman et al. / Clinica Chimica Acta xx (2005) xxx–xxx4confirms the Elisa results. The electrophoretic mobility of
sCD14 in mouse plasma corresponded exactly to that of the
most abundant isoform present in normal human plasma.
The specimen with recombinant sCD14 contained two
bands which differed slightly from the one found in the
human and chimeric mouse plasma. Since this recombinant
sCD14 was produced in CHO cells, a difference in
glycosylation may be responsible for the different electro-
phoretic migration pattern [40].
3.2. Human hepatocyte-exclusive production of sCD14
To exclude the possibility that the sCD14 found in the
human liver-uPA-SCID mice was originating from mono-
cytes, macrophages or other cells that could have been
transferred with the ‘‘liver cell’’ suspension, we performed
the following experiments.
Three NOD/SCID mice were injected with a ‘‘liver cell’’
suspension. Four weeks later the plasma of these animals
was analyzed and neither human albumin nor sCD14 could
be found. This is not surprising since hepatocytes do not
survive in NOD/SCID mice. These mice are severely
immune deficient but do not suffer from a chronic liver
disease which is an essential requirement for the survival
and expansion of the transplanted hepatocytes.
To examine whether passenger leukocytes in the ‘‘liver
cell’’ graft could be the source of the sCD14 we next
measured sCD14 in the plasma of NOD/SCID mice that
were transplanted with 107 human PBMC. This cell number
largely exceeds any possible leukocyte contamination of the
liver cell graft. The plasma of the 5 transplanted mice was
analyzed 3 and 7 days after PBMC transfer, but neither
human albumin nor sCD14 could be detected.
Immunohistochemical analyses of the liver and spleen of
successfully transplanted uPA-SCID mice unambiguously
showed the presence of human hepatocytes in the liver,
while lymphocytes, macrophages and other leukocytes
could never be observed in the liver, or in the spleen (data
not shown). These morphological data make it very unlikelythat apart from the hepatocytes there is another cellular
source of human sCD14 in our chimeric uPA-SCID mice.
3.3. Quantification of sCD14 in HBV and HCV infected
chimeric mice
Since we previously observed that chronic HBV and
HCV infections induced a rise in sCD14 levels in patients
and since human hepatocytes were most likely the only
source of the sCD14 in this animal model, we wanted to
investigate whether HBV or HCV infections had a direct
influence on the plasma levels of human sCD14 in the
chimeric mice. Plasma from HBV infected animals con-
tained at least 108 viral copies/ml, while in HCV-infected
animals viral RNA levels exceeded 2.106 IU/ml. Histologic
analysis of the liver confirmed these infections [35].
The linear correlation between the concentration of
human albumin and sCD14 seen before (Fig. 1), suggested
that both analytes are markers for the number and functional
integrity of the human hepatocytes present in the chimeric
animal. To demonstrate any effect of HBVor HCV infection
on the production of sCD14 by human hepatocytes, the
sCD14 values had to be normalized for the amount of
human hepatocytes present in the chimeric liver. To this end
a Fnormalized_ sCD14 concentration was calculated by
dividing the sCD14 concentration by the human albumin
concentration in each plasma sample. The Fnormalized_
sCD14 levels in the plasma of uninfected (n =23), HBV-
infected (n =18) and HCV-infected (n =11) chimeric ani-
mals (Fig. 3a) were then compared and no differences
between the three groups of mice (uninfected vs. HBV
infected mice: P=0.6839; uninfected vs. HCV infected
mice: P=0.7966; and HBV vs. HCV infected mice:
P=0.7360) were observed.
In addition, the amount of HBsAg, HBeAg and HBV
DNA in the plasma of the HBV infected chimeric uPA-
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Fig. 3. Soluble CD14 (sCD14) levels in HBV and HCV infected animals. (a) Box-and-whisker plot representing the Fnormalized_ concentrations of sCD14 in
chimeric plasma. Normalization was preformed to compensate for differences in liver repopulation grade in distinct animals. Comparison of these normalized
sCD14 levels did not show any statistically acceptable divergence between non-infected, HBV infected and HCV infected uPA-SCID mice (uninfected vs.
HBV infected mice: P=0.6839; uninfected vs. HCV infected mice: P=0.7966; and HBV vs. HCV infected mice: P=0.7360). In HBV infected animals we
could not demonstrate a correlation between sCD14 and (b) HBsAg (r2=0.05289, P=0.4096), (c) HBeAg (r2=0.09787, P=0.2562) and (d) HBV DNA levels
(r2=0.1388, P=0.1715), respectively.
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the Fnormalized_ concentration of sCD14. Here as well no
correlation could be found (Fig. 3b–d).4. Discussion
Soluble CD14 found in human plasma is thought to
originate from monocytes/macrophages. Recent studies in
transgenic mice showed that also hepatocytes can produce
sCD14 [18,41]. Administration of LPS to normal mice and
rats induces the secretion of CD14 by hepatocytes
[10,11,13]. Additionally, in vitro studies with HepG2
hepatoma cells [17,18] and primary hepatocytes [16]
showed that human hepatocytes are able to secrete a soluble
form of CD14. However, tumor cells may not be the best
model cells to demonstrate the Fnatural_ production of a
protein and the release of sCD14 by primary hepatocytes in
vitro may be a tissue culture artifact.
Here we investigated the in vivo production of sCD14 by
human hepatocytes in chimeric uPA-SCID mice [35] at
several time points following transplantation of human
hepatocytes. The plasma of these chimeric mice contained
human sCD14 concentrations comparable to those found in
healthy humans [42]. A direct correlation was found
between plasma sCD14 levels and the amounts of human
albumin in the mouse plasma. Since the concentration of
human albumin in chimeric mouse plasma is an excellentmarker of the engraftment and function of the human
hepatocytes, the significant correlation between albumin
and sCD14 levels is highly suggestive for a hepatocytic
origin of sCD14.
To exclude the possibility that other, non-hepatocytic,
human cells present in the ‘‘liver cell’’ graft were
contributing to the sCD14 production, we transplanted
NOD/SCID mice with human peripheral blood mononuclear
cells (PBMC). Although more than 10% of these cells
express CD14, no sCD14 could be detected in the plasma of
these transplanted mice. Since our ‘‘liver cell’’ suspension
contained only a fraction of contaminating cells capable of
producing sCD14, it is most unlikely that these contami-
nants are responsible for or contribute to the sCD14
production in the chimeric uPA-SCID mice. Despite careful
microscopic analysis we could never detect human mono-
cytes, macrophages or other leukocytes in the chimeric
mice. Transplantation of NOD/SCID mice with a ‘‘liver
cell’’ suspension did not lead to detectable human albumin
or sCD14 secretion in the mouse plasma. This is not
surprising since hepatocytes do not survive in NOD/SCID
mice, which do not provide the environment that favors
hepatocyte engraftment. The absence of sCD14 observed in
the latter experiment is yet another indication that the human
hepatocytes are the origin of the CD14 in the circulation of
the chimeric uPA-SCID mice.
Despite the use of two different anti-CD14 antibody
clones, we could not visualize CD14 protein inside the
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anticipated since we (unpublished data) and others have
shown that in rat and human liver biopsies only Kupffer
cells stain for CD14 [43,44]. Intracellular CD14 protein has
only been detected inside hepatoma cells [17] and in
cultured human hepatocytes [16]. This suggests that the
intracellular CD14 expression is low and that, once
synthesized, the protein is quickly secreted into the
circulation.
Depending on the production pathway, two forms of
sCD14 with different molecular masses can be identified
[14,15]. The size of the human sCD14 found in the mouse
plasma corresponded exactly to that of the isoform which is
most abundant in normal human plasma [40,45] and in
human milk [45]. This isoform is the result from a direct
secretion from intracellular compartments into the plasma,
while the smaller form originates from membrane-bound
CD14 that is released after proteolytic cleavage [15].
We recently observed increased sCD14 concentrations in
the plasma of patients suffering form chronic HBV and
HCV infections in comparison with healthy subjects [30]. In
the chimeric mouse model, infections with HBV or HCV
had no effect on the plasma sCD14 levels. This suggests that
infections of human hepatocytes with HBVor HCV have no
direct effect on the production of sCD14 by these cells. The
increased sCD14 concentration in the plasma of chronically
infected patients could be due to an increased production by
activated monocytes. It is known that the plasma of patients
suffering from chronic liver diseases contains more lipo-
polysaccharide (LPS) than healthy controls [46]. This was
also observed by Sozinov et al. in patients with chronic viral
hepatitis [47]. This peripheral endotoxemia in chronic liver
disease may be the result of a decreased detoxification of
endotoxin-rich portal blood by the diseased liver, an
increased intestinal permeability for bacterial toxins [48],
or a combination of both. This endotoxemia may activate
monocytes and increase the production of sCD14.
We previously observed that sCD14 concentrations in
plasma of patients with chronic HBV infections were
inversely correlated with the amounts of circulating
HBsAg [30]. Therefore we quantified HBsAg in the
plasma of our HBV-infected chimeric uPA-SCID mice
and compared these values with the concentrations of
sCD14. No correlation could be found. This may be due to
the absence of human macrophages in our model and the
possible role of these cells in the production of sCD14
during liver disease.
Here we show for the first time in vivo that human
hepatocytes are able to secrete sCD14 into the circulation.
Since the transplanted human hepatocytes are the only
human cells that survive for extended periods in the
recipient mice, we can be certain that hepatocytes are the
sole source of the human sCD14. We dare to suggest that a
still undefined, but possibly large fraction of the sCD14 in
human plasma originates from the liver. This is not
surprising since the liver produces a series of acute-phaseproteins in response to inflammation. The production of
sCD14 by the liver may be a powerful mechanism to rapidly
clear the blood from LPS and another mechanism of host
defense and control of systemic inflammation. The hepatic
production of sCD14 may also play a role in the transport
and transfer of phospholipids [23]. Finally, we have
demonstrated that HBV and HCV infections have no direct
influence on the production of sCD14 by hepatocytes. The
elevated sCD14 levels observed in chronic HBV and HCV
patients are therefore most likely of non-hepatic origin.Acknowledgments
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Chapter 6: Conclusions, general discussion and future 
 perspectives. 
 
 
A small animal model that is suitable 
for the study of HBV and HCV infections 
would greatly promote our understanding of 
these infections and the development of 
preventative and therapeutic strategies. 
Until now, these viruses have been 
primarily studied in chimpanzees but the 
use of these animals is not only very 
expensive but also increasingly questionable 
for ethical and ecological reasons. In 
addition, the natural course of chronic HBV 
and HCV infections in chimpanzees differs 
significantly from that observed in humans. 
Because mouse hepatocytes are not 
permissive for HBV or HCV infections a 
mouse must harbor human hepatocytes 
before it can be infected with HBV or HCV. 
The development of a mouse model for HBV 
and HCV therefore necessitates the 
transplantation of human hepatocytes. Two 
major obstacles impede the successful 
transplantation of human hepatocytes in 
any recipient mouse: 1) xenogeneic 
hepatocytes transplanted into immune 
competent mice will be rejected and 2) 
xenogeneic hepatocytes will not thrive and 
expand in a “healthy” mouse liver due to 
lack of “space” and absence of appropriate 
“growth support”. A mouse that will accept 
a human hepatocyte graft and support its 
survival and expansion therefore needs to 
have the following qualities: 1) be immune 
deficient and not reject xenografts and 2) 
suffer from a severe and chronic liver 
disease that provides the “supportive niche” 
for the transplanted, healthy, human 
hepatocytes. An animal with these qualities 
does not exist as such but can be created by 
combining, through cross-breeding, the 
qualities of two existing mouse strains. The 
severe combined immunodeficient mouse 
(SCID, CBySmn.CB17-Prkdcscid/J) (1, 2) 
brings in the immune deficiency and thus 
the “acceptance” of the xenograft. The 
urokinase-type plasminogen activator (uPA) 
transgenic mouse (B6SJL-
TgN(Alb1Plau)144Bri) (3) suffers from a 
severe and chronic liver disease through the 
liver specific overexpression of uPA and 
thereby provides the required “niche” for 
healthy donor hepatocytes.  
 
In 2000 we started breeding SCID 
mice (available in the lab) with uPA+/- 
transgenic mice (obtained from The 
Jackson Laboratories) and kept crossing the 
uPA+ offspring with “pure” SCID mice. After 
seven generations more than 99% of the 
mouse background is expected to be of the 
SCID genotype. For this backcrossing 
program it sufficed to distinguish uPA+ 
from uPA- animals. However as we started 
transplanting human hepatocytes in the 
uPA-SCID mouse recipients we realized the 
need to discriminate uPA+/+ (homozygous) 
from uPA+/- (heterozygous) mice. This 
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distinction is very important since 
heterozygous animals only allow limited 
and transient repopulation due to 
spontaneous deletion of the uPA transgene 
and consequent regeneration of the 
diseased liver by “revertant, healthy” mouse 
hepatocytes (3). Existing screening methods 
were based on a semi-quantitative analysis 
of the copy number of the uPA transgene 
using Southern blotting (4). However, this 
methodology has some weaknesses: it is 
time consuming and the results are 
sometimes difficult to interpret. 
Therefore we designed a method 
that would allow for the discrimination 
between heterozygous and homozygous 
uPA-SCID mice in a rapid, robust and 
unambiguous manner. We took advantage 
of the fact that the introduction of the uPA-
transgene cassette in the mouse genome 
had induced a small deletion of the target 
chromosome (5). This region was picked-up 
in a plasmid that we have sequenced. We 
then selected a combination of three PCR 
primer pairs that unambiguously allowed 
for the identification of homozygous uPA-
SCID mice within a working day (6). The 
speed of the method is of the utmost 
importance since homozygous uPA-SCID 
mice should ideally be transplanted within 
two weeks after birth. Our screening 
method is currently being used by the two 
other groups that use the uPA mouse for 
human liver cell transplantation (7) 
(Kneteman N., personal communication). 
Additionally, we also needed an 
easy, sensitive and non-invasive method to 
assess the success of our transplantation 
experiments. We chose for an Elisa based 
method using antibodies that detect human 
albumin, a protein of hepatic origin, in a 
sensitive and specific manner. The 
concentration of human albumin in the 
mouse plasma is a reliable “in vivo” marker 
of the extent and functionality of the human 
liver cells graft. 
 
Once we had developed these crucial 
instruments to select homozygous uPA-
SCID mice and to measure human albumin 
in a mouse matrix, we transplanted uPA+/+-
SCID mice with fresh human hepatocytes. 
These cells were injected in the spleen from 
where they migrated to the liver via the 
splenic and portal veins. This injection 
route is superior to direct injection into the 
liver since the latter is more traumatic and 
would only result in a focal localization of 
the injected hepatocytes. In contrast, 
intrasplenic injection results in a more 
dispersed distribution of the injected cells. 
At different time points after 
transplantation, we evaluated the integrity 
and morphology of the human hepatocytes 
in our mice (8). Plasma analysis showed 
that the human hepatocytes secreted at least 
22 human proteins. Most of these proteins 
are classical human plasma proteins, but 
others are known to be localized in the 
membrane or in the nucleus of the cell. This 
is not surprising since the applied proteome 
method is very sensitive and able to pick up 
less abundant proteins (9). Using 
comparable methods, such atypical plasma 
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proteins can also be found in plasma from 
healthy human blood donors (10, 11). Other 
groups that have developed chimeric human 
liver mouse models have not performed 
such a systematic analysis of the human 
proteome in the chimeric mouse. A 
Japanese group has reported the expression 
and induction of human cytochromes P450 
enzymes in the chimeric liver (12-14). These 
data are an additional proof that the human 
hepatocytes retain their normal functional 
characteristics also in a xenogeneic 
environment. 
Histological analysis of our chimeric 
mouse livers showed that up to 87% of the 
liver parenchyma can be repopulated by 
healthy human hepatocytes. The 
repopulation process occurs in a gradual 
and organized fashion. The human 
hepatocytes clearly communicate with the 
mouse environment, as illustrated by the 
connections made by bile canaliculi formed 
by human hepatocytes with canaliculi of 
mouse origin and even functional chimeric 
bile canaliculi can be observed. 
Although the general appearance of 
the human hepatocytes closely resembles 
that in human liver, there are some minor 
differences. The human hepatocytes tend to 
accumulate glycogen, comparable to what is 
seen in glycogen storage diseases (15). Since 
the chimeric mice are hypoglycemic 
(Meuleman et al., unpublished data) it is 
very likely, but not yet proven, that certain 
mouse signals (not yet determined) fail to 
interact adequately with their receptors on 
the human hepatocytes. The chimeric 
animals are relatively small (10 to 12 g) in 
comparison to healthy SCID mice of the 
same age (20 to 25 g). Homozygous animals 
transplanted with mouse hepatocytes do not 
experience this pronounced failure to thrive 
and 6 to 8 weeks after liver cell transfer 
these cannot be distinguished form their 
healthy SCID counterparts. This growth 
retardation is likely the result of the 
glycogen accumulation, but other types of 
“dysmetabolism” can also be involved. It is 
intriguing that although up to 87% of liver 
parenchyma is occupied by human 
hepatocytes, plasma human albumin levels 
are only 20% of normal values. These 
phenomena deserve further investigation 
since similar abnormalities may arise when 
whole livers of xenogeneic origin (e.g. pig or 
baboon) will be transplanted in humans, an 
approach that is being considered. Other 
investigators working with similar chimeric 
animal models have not described the 
glycogen storage. The glycogenosis is 
however also present in the human 
hepatocytes of their chimeric mice, but they 
have overlooked this phenomenon because 
they have not enjoyed the same 
anatomopathological support and expertise 
as we did (Kneteman N., personal 
communication). 
A remarkable finding was the fact 
that not only mature hepatocytes were 
involved in the repopulation process, but 
that also hepatic progenitor cell (HPCs) 
participated in this process. 
Immunohistochemical analysis revealed 
HPCs that were differentiating towards 
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mature hepatocytes via intermediate 
hepatocyte-like cells. These HPCs were 
generally observed at the interface between 
human and mouse regions in the chimeric 
liver, This observation has a major impact 
and may shed a new light on certain 
qualities attributed to hepatocytes. Using 
liver cell suspensions comparable to ours, 
other investigators have observed that these 
may give rise to biliary epithelial cells and 
concluded from this that “mature 
hepatocytes” were able to transdifferentiate 
towards cholangiocytes (16, 17). Other 
groups used such cell suspensions to prove 
that mature hepatocytes have an extensive 
repopulative capacity (18, 19). The presence 
of HPCs in the suspensions used represents 
an alternative explanation for these 
phenomena. 
 
Successfully transplanted animals 
could be easily infected with HBV and HCV. 
In both infections the viremia was 
considerably higher than what is routinely 
observed in chronically infected humans 
(20-22). On retrospect this is not so 
surprising. After all, the chimeric animals 
are severely immune suppressed and the 
viremia in these animals should not be 
compared with that observed in immune 
competent “chronic patients” but rather 
with that observed in chronically infected 
patients undergoing immune suppressive 
therapy after organ transplantation (23-25). 
Using electron microscopy, complete HBV 
particles (Dane particles) and subviral 
particles (spheres and rods) could be easily 
visualized in the HBV-infected hepatocytes. 
This was not the case for HCV-infected 
chimeric livers in which no HCV could be 
observed despite very careful examination. 
HCV particles are also hard to identify 
inside HCV infected human liver biopsies 
(26). Considering the size of a human 
hepatocyte (25 - 30 µm), the ultra-thin 
sections used for EM analysis (50 nm), the 
size of a HCV virion (56 - 60 nm) and the 
fact that hepatocytes only produce between 
10 and 100 complete virions per day (27), 
this is not unexpected. An indirect proof of 
HCV replication and the production of 
intact, infectious HCV particles is given by 
the fact that HCV infection can be 
transferred from an infected chimeric 
animal to an uninfected one with minute 
(<5 µl) amounts of infected mouse plasma. 
This procedure resulted in a 109-fold 
amplification of the virus. 
While we did not observe any 
obvious effect of the infection on the 
morphology of the HCV-infected 
hepatocytes, infection of chimeric mice with 
HBV resulted in severe hepatocellular 
damage and cell death, which ultimately led 
to the death of the animals. High plasma 
concentrations of HBV virions and viral 
proteins could be detected up to 5 weeks 
after infection. Thereafter all viral markers 
(HBsAg, HBeAg and HBV-DNA) as well as 
the human albumin levels rapidly 
decreased. This decrease coincided with the 
clinical deterioration and these animals 
survived the infection on average for only 
50 days. Histologic and electron 
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microscopic analysis of the livers of 
clinically terminal mice revealed several 
signs of hepatocyte malfunction and 
degeneration. The infected human 
hepatocytes were completely filled with viral 
and subviral particles. Molecular analysis 
showed very high replication in these long-
term infected human hepatocytes. Like in 
patients with chronic HBV (28) and in a 
model for the study of duck hepatitis B virus 
(DHBV) (29), we also observed an 
activation of the hepatic progenitor cell 
compartment which is another indirect sign 
of hepatocellular damage. Sequence 
analysis of the HBV inoculum employed for 
these experiments did not reveal any 
mutations that were known to be 
cytopathic. Therefore, the only possible 
explanation is that HBV has endogenous 
cytopathic capacities that only prevail under 
conditions of severe immune suppression. 
This is in contrast to the generally accepted 
opinion that HBV is a non-cytopathic virus 
and that the hepatocellular damage in 
chronic HBV patients is caused by the host’s 
immune response towards the infected 
hepatocytes (30). On the other hand, a 
condition known as fibrosing cholestatic 
hepatitis (FCH) can occur in chronic HBV 
patients whose immune system is severely 
suppressed (31-35). The serology and the 
liver histology in this, often fatal, syndrome 
closely resembles those observed in our 
chimeric animals. These observations 
support our theory that also in chronic HBV 
patients the immune system, despite its 
inability to completely eradicate the viral 
infection, plays a role in the control of the 
infection by preventing the massive viral 
replication and protein expression that 
leads to the destruction of the infected cell. 
Nowadays, FCH is rather uncommon in 
HBV infected transplant patients due to 
more effective antiviral treatment and 
passive administration of anti-HBsAg 
immunoglobulins (36-38). 
 
We (39) and others (40) have 
described that chronic HBV and HCV 
patients have elevated soluble CD14 
(sCD14) levels in their plasma. sCD14 is 
involved in LPS-induced responses by cells 
that do not express CD14 on their surface 
(41-43), but can also prevent activation of 
CD14 bearing cells by LPS (44). In addition, 
sCD14 forms a protein pair with 
lipopolysaccharide (LPS) binding protein 
(LPB) that is involved in the transport and 
exchange of phospholipids (45). Using our 
animal model we investigated whether this 
increase in sCD14 was directly caused by the 
virus. The unique nature of our model 
allowed us to prove that human hepatocytes 
are able to produce and secrete sCD14 in 
vivo (46). Monocytes, another important 
source of sCD14 in humans, are completely 
absent in our chimeric animals. The levels 
of sCD14 found in our animals were 
comparable to those measured in healthy 
humans, indicating that hepatocytes may be 
a major source of sCD14. Infections of 
chimeric mice with HBV or HCV did not 
induce significant changes in the sCD14 
levels measured in the plasma of the mice. 
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This finding suggests that HBV or HCV 
infections have no direct effect on sCD14 
production by the hepatocytes (46). The 
elevated sCD14 levels observed in patients 
suffering from chronic viral hepatitis can be 
explained by the fact that patients with 
(viral) liver diseases also have elevated 
levels of LPS in their plasma (47, 48). These 
higher than normal levels of LPS might in 
turn activate monocytes to secrete sCD14. 
In addition, chronically infected livers are 
also known to be less efficient in clearing 
numerous serum constituents, amongst 
which endogenous proteins. 
 
The development of the uPA-SCID model is 
a major breakthrough in the study of viral 
hepatitis, but the model has some 
drawbacks that deserve to be discussed. 
First of all, large numbers of uPA-SCID 
breeding pairs are needed to generate a 
constant and sufficient output of 
homozygous animals suitable for 
transplantation. Secondly, the 
transplantation of these homozygous 
animals is a complex and difficult task. Due 
to the high uPA expression and consequent 
bleeding disorder, perioperative 
complications are not uncommon even in 
skilled hands. A third and probably the 
most important limitation is the availability 
of human hepatocytes of excellent quality. 
These cells are instrumental for success and 
due to the short window in which the 
animals need to be transplanted, a good 
liaison with liver surgeons is of utmost 
importance. Cryopreserved human 
hepatocytes are an alternative but the 
possible use of frozen cells needs to be 
further studied. We have shortly explored 
the usefulness of these cells, however with 
limited success (unpublished data). Finally, 
since the chimeric human liver in uPA-SCID 
mice are devoid of an immune system, these 
animals cannot be used to study the “host” 
immune response towards HBV or HCV. 
The direct evaluation of new prophylactic or 
therapeutic vaccines is therefore impossible 
in the present model. However, the 
neutralizing capacity of polyclonal or 
monoclonal antibodies against these viruses 
can be examined by passive administration 
to the chimera prior to the injection of the 
viral inoculum. The “perfect” model that 
would allow the study of innate and 
adaptive antiviral immune responses 
against HBV or HCV requires the presence 
of an intact and functional human immune 
system in addition to the successful human 
hepatocytes graft in the uPA-SCID mouse. 
The model could be adapted by several ways 
to achieve this goal. First, the infected 
chimeric animals can be transplanted with 
lymphocytes derived from the same donor 
from whom the hepatocytes were isolated. 
Alternatively, lymphocytes from an HLA-
matched donor could be used. In both set-
ups a method has to be devised to overcome 
the occurrence of a graft-versus-host 
reaction which will lead to the premature 
death (2 to 4 weeks after cell 
transplantation) of the chimeric animals. 
Second, the chimeric animals could be 
transplanted with selected cell populations, 
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like T-cell clones, NK-cells, etc. A third 
method could be the transplantation of 
human cord blood cells or other 
haematopoietic stem cells. However, to 
generate a functional immune system, here 
again the HLA restriction must not be 
overlooked. 
 
Despite these concerns which are 
essentially of a logistic and technical nature, 
the human liver uPA-SCID mouse remains 
the best available alternative for the 
chimpanzee. We will use this model for the 
in vivo evaluation of neutralizing anti-HCV 
antibodies. Several reports already 
described the neutralizing activity of 
monoclonal and polyclonal antibodies 
against HCV in the HCV pseudo-particle 
system (49-51). However, it remains to be 
determined whether these antibodies will 
demonstrate neutralization in vivo where 
the properties of authentic virus and target 
cells may be different from the in vitro 
systems. The advantage of our small animal 
model is that much lower quantities of 
antibodies are required than in 
chimpanzees. Recently, successful HCV 
infection and replication were established in 
vitro (52-54). This in vitro culture system 
resembles the real situation more closely 
than the pseudo-particle system, but does 
not match an in vivo challenge. The market 
for antibodies that are able to neutralize a 
HCV infection in vivo must be huge. 
Indeed, chronic HCV infections and their 
complications represent the major 
indication for liver transplantation in 
Western countries. Infection of the 
transplanted liver with HCV is an almost 
certain event that cannot be prevented, nor 
treated (55). Even worse, because of the 
immune suppression the allograft recipient 
is undergoing, this infection evolves more 
rapidly towards end-stage liver disease than 
the original one. The effectiveness of passive 
immunization to prevent infection of the 
liver graft following transplantation has 
been established in HBV-infected patients 
(36-38). This clinical experience suggests 
that passive immunization may equally be 
the best approach for transplanted HCV 
patients. 
In collaboration with other groups, 
we will also use our chimeric mouse model 
for the evaluation of novel antiviral drugs 
against HBV and HCV. Candidate antiviral 
compounds are now only evaluated in the 
subgenomic replicon system (56) before 
human trials can commence. If the chimeric 
mouse proves to be a good system to 
evaluate antivirals, regulatory agencies will 
certainly require its use before a compound 
will be allowed to go into clinical testing. 
Although such a measure seems to make the 
procedure of drug development heavier it 
will be most useful in preventing the loss of 
time and money required for clinical tests 
(phase I and II). 
Besides its use as an animal model 
for the study of HBV and HCV, the human 
liver uPA-SCID mouse has also potential in 
other research areas. Any microorganism 
that targets the liver or needs human 
hepatocytes at a specific stage of its life 
 122
cycle can be studied in this model. One such 
example is malaria, where the sporozoites of 
the Plasmodium falciparum mature inside 
the hepatocyte before they move into the 
red blood cells (57). 
Applications of the uPA-SCID model 
reach far beyond the limits of microbiology. 
The model is not only useful to examine 
biotransformation of drugs by human 
hepatocytes in vivo but may also be 
employed to study the potential liver 
toxicity of new compounds (12-14). 
Finally, the uPA-SCID mouse can be 
used for basic research on stem cells and 
liver regeneration. We have already shown 
that human HPCs are involved in the liver 
repopulation process (8). To what extent 
progenitor cells and mature hepatocytes 
each contribute to the liver repair is 
currently unknown. Transplantation of  
selected immature subpopulations and 
purified mature liver cells may help 
elucidate this question. In addition, the 
potential of other stem cells of different 
origin to (trans)differentiate towards 
hepatocytes can also be evaluated in this 
model (58, 59). The disease state of the 
uPA-SCID liver mimics the situation of 
chronic liver disease more closely than the 
currently used in vitro systems which 
employ all different kinds of artificial 
matrices in combination with a cocktail of 
growth factors. We have already evaluated 
the capacity of different stem cells from 
haematopoietic origin to repopulate the sick 
livers of our uPA-SCID mice. None of these 
“pluripotent” stem cells were able to engraft 
and expand in the uPA-SCID liver, despite 
their promising and multipotential qualities 
in vitro (unpublished data). 
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